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ABSTRACT OF THE DISSERTATION
Identification of Candidate Microbial Biomarkers of Disease, and Design of Engineered
Microbial Therapeutics for the Gut Microbiome
by
Aura L. Ferreiro
Doctor of Philosophy in Biomedical Engineering
McKelvey School of Engineering
Washington University in St. Louis, 2021
Professor Gautam Dantas, Chair
The human gut microbiome is a compositionally and functionally diverse community of
microorganisms that profoundly influences the health of the host. Deep characterization of gut
microbiomes via high-throughput sequencing has identified associations between the gut
microbiome and disease states, and spurred development of engineered microbial therapeutics.
Successful translation of these research efforts to the clinic will involve i) consideration of how
engineered microbes behave and adapt in the gut, towards the implementation of biosafety
mechanisms, and ii) identification and validation of microbial biomarkers of disease. This
dissertation describes both investigative (Chapter 2) and engineering (Chapters 3 and 4)
approaches to improving the safety and efficacy of microbial therapies, using the commensal
Escherichia coli Nissle 1917 (EcN) as a model chassis. This work further investigates the gut
microbiome as an early predictor of preclinical Alzheimer Disease (Chapter 5), with corresponding
identification of candidate microbial biomarkers.
Unlike traditional therapeutics, engineered microbes are subject to selection potentially at
the cost of their intended function. In Chapter 2, gnotobiotic and conventional mouse models of
colonization were used to identify the major selective forces acting on EcN in the dysbiotic

ix

mammalian gut. Functional metagenomic selections and isolate whole-genome sequencing
identified access to preferred carbon sources as the main selective pressure on EcN in the lowdiversity gut. In functional metagenomic selections, EcN populations encoding heterologous
glycosyl hydrolases enabling consumption of dietary polysaccharides were strongly enriched. In
the absence of this repertoire of heterologous functions, wild-type EcN mutated to better consume
host mucins. In addition, EcN was observed to be a reservoir of aminoglycoside resistanceconferring mutations subsequent to a single antibiotic exposure. These findings carry clinical
implications for the administration of engineered probiotics in low-diversity, dysbiotic guts.
As such, biocontainment of engineered functions and microbes in situ is an important
design consideration, with the goal of mitigating potential for pathology and environmental
contamination. In Chapter 3, a transcript-barcoding approach enabling measurement of activity of
many synthetic constructs in parallel was developed and validated in mice. The relative activities
of 30 pooled EcN strains, each harboring a distinct synthetic construct, were ranked in multiple
gut sites; this work informed the development of EcN strains engineered for the treatment of
phenylketonuria, the efficacy of which were validated in a murine model of the disease (Chapter
2). This transcript barcoding method will facilitate the design and testing of bio-sensing synthetic
constructs in vivo, towards the restriction of engineered functions to target sites of interest.
In Chapter 4, a CRISPR-based approach to microbial biocontainment was developed and
tested in mice. The kill switch design enabled selective removal of EcN from the guts of mice upon
chemical induction; inclusion of temperature-responsive element further enabled kill switch
induction upon excretion from the gut. Due to the stringent selective pressure imposed by kill
switches, such designs are prone to mutational inactivation. Genetic stability was achieved using
parallel approaches of engineering and environmental control, the first by inclusion of functional
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redundancies, a plasmid retention system, and knockouts of SOS response genes, and the latter by
the innovative leveraging of inter-strain exclusion behaviors observed in the gut. Specifically, coadministration of kill switch-encoding EcN with a control EcN strain, in tandem with kill switch
induction, enabled virtually complete eradication of the kill switch population from the guts of
mice. This approach is attractive when the goal is to remove an engineered subpopulation of
engineered microbes, and not a probiotic species itself, from the gut.
In Chapter 5, the gut microbiome was instead considered as source of candidate microbial
biomarkers of preclinical Alzheimer Disease (AD). Identification of microbiome correlates at the
preclinical stage has the potential for clinical significance in that canonical biomarkers of
preclinical AD require access to PET-CT scanners, or invasive CSF lumbar puncture, whereas
stool is a cheaply acquired analyte. Gut microbiome features were correlated with amyloid
biomarkers, but not markers of tau or neurodegeneration, highlighting the potential utility of gut
microbiome correlates in early screening as abnormal amyloid levels are considered the most
antecedent in disease progression. Further, addition of microbiome features to machine learning
classifiers for preclinical status improved sensitivity, predominantly when metagenome-assembled
genomes were included as features, rather than taxa identified through clade-specific marker
sequences. This suggests taxonomic associations with AD status may be strain-specific, and
encourages the pursuit of strain-level resolution in microbiome-wide association studies.
As we work to translate observations about the gut microbiome to actionable clinical
interventions, we must consider the interactions of engineered microbial therapeutics and recipient
microbiomes, as well as the resolution necessary to validate gut microbiome-derived biomarkers
of disease. This thesis work represents efforts to that end, and will ultimately inform the design of
novel gut-directed therapies.
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Chapter 1 : Introduction (Evolutionary Dynamics of HostAssociated Microbiomes)
Abstract
The composite members of the microbiota face a range of selective pressures, and must
adapt to persist in the host. We highlight recent work characterizing the evolution and transfer of
genetic information across nested scales of host-associated microbiota, which enable resilience to
biotic and abiotic perturbations. At the strain level, we consider the preservation and diversification
of adaptive information in progeny lineages. At the community level, we consider genetic
exchange between distinct microbes in the ecosystem. Finally, we frame microbiomes as open
systems subject to acquisition of novel information from foreign ecosystems through invasion by
outsider microbes.
Introduction
The human body is colonized by a diverse community of microbes, collectively referred to
as the microbiota, which outnumbers the human body in both cells and genetic content [1]. In
recent decades, understanding of the role that these microbes play in human health and disease has
increased, which has in turn fueled interest in microbiota-directed or derived therapeutics. Studies
leveraging metagenomic and gnotobiotic technologies have illuminated the critical and often
causal roles that the microbiota plays in nutrient absorption, vitamin biosynthesis, immune system
maturation, pathogen colonization resistance, and other critical physiological processes [2, 3].
Healthy human microbiomes can be considered as pseudo-steady states in microbial
community composition and function, that lie in minima of an ecological stability landscape (Box
1) and as such are resilient to perturbations [4]. Much work has been done to describe the

community-level changes that the microbiome undergoes under varied selective pressures using
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metagenomic techniques [5-7], but it is important also to understand how individual microbial
populations evolve in such systems. While development of bioinformatics tools for strain tracking
in metagenomic data is ongoing [8-10], it remains challenging to assign gene variants or mobile
genetic elements to individual microbial lineages (Box 1) using metagenomic techniques. Recent
studies have used single-isolate whole-genome sequencing (Box 2) to gain high-resolution insights
to the fates of single microbial lineages [11-14].
Box 1: Common Terms in Population Genetics

2

Box 2: Techniques for Understanding Genetic Change in Microbes

Due to their short generation time, microbes evolve rapidly. Furthermore, bacterial
evolution can consist of substantial vertical (i.e. transgenerational) as well as horizontal (i.e.
intragenerational) components. While extensive and elegant work on the evolution of microbes in
vitro has demonstrated that microbial evolution is characterized by both rapid adaptation and
clonal interference (Box 1) [15-17], the literature examining the evolution of host-associated
microbes in situ and in the context of communities is sparser.
So it bears consideration, to what extent do microbial communities evolve in a host-specific
fashion? Many factors, including exposure to xenobiotics and host diet are likely to make any
individual human their own habitat with unique selective pressures manifested in mutational
signatures specific to each individual. Indeed, two recent studies have demonstrated that human
microbial communities on the skin [18] and in the gut [19] are highly individual-specific at the
3

strain level. This variation may be due to host-specific accumulation of mutations over time, or
due to host-specific selection on which environmental microbes colonize (i.e. a bottleneck). The
studies we describe provide compelling evidence in support of both of these selective modes.

(A) Scale 1: evolution via single-nucleotide polymorphisms,
rearrangements, and transposon-mediated insertions. (B) Scale 2: evolution within a microbiome,
encompassing HGT mediated by transduction, conjugation, and transformation. (C) Scale 3: evolution
between microbial communities is mediated by organismal transfer.
Figure 1.1: Scales of Microbial Evolution.

In this review, we examine the evolution of human-associated microbes occurring across
three scales (Figure 1.1). The first scale of genetic change entails evolution at the gene level, in
which single nucleotide polymorphisms (SNPs), copy number variation, and transposition events,
within individual microbial genomes in both coding and noncoding regions are selected if they
4

confer an adaptive advantage. The second scale is change that occurs at the microbial community
level. At this scale, evolution occurs across multiple bacterial strains within the community
via horizontal gene transfer (HGT), through transformation, conjugation, or phage transduction
[13]. The third scale is cross-ecosystem exchange, wherein microbiomes can acquire new genetic
content encoding beneficial or detrimental functions from other habitats. This can manifest in the
form of foreign organisms and their metagenomes, hailing from environments outside the host and
potentially facilitated by human activity such as food consumption or travel. Importantly, we show
that genetic change often occurs over multiple scales simultaneously. We use this multi-scale
framing of microbial evolution to discuss recent work on patterns of host-associated microbial
adaptation in vivo.
In vivo evolutionary responses to xenobiotics
The human microbiota is exposed to a plethora of foreign small molecules, the most
obvious of which are antibiotics and antifungals. Other compounds such as heavy metals also place
unique selective pressures on commensal and pathogenic microbes in addition to their effects on
host physiology. Exciting recent work is uncovering the evolutionary effects of such xenobiotics
on the human microbiota.
Evolution and transfer of antibiotic resistance
Resistance to antimicrobials via point mutation has been studied for decades in the wellmixed, nutrient rich, axenic environment of culture broth. These studies have provided valuable
insight into the evolutionary mechanisms contributing to drug resistance, and have been
excellently reviewed elsewhere [20, 21]. There are relatively few studies examining microbial
evolution occurring in human or animal hosts, where tradeoffs between antibiotic resistance and
competitive fitness (Box 1) in a complex environment may be more pronounced. In a recent study,
a natural isolate of Escherichia coli was passaged for over one year in the gut of streptomycin5

treated mice [11]. Interestingly, this strain exhibited a lower rate of evolution in vivo than in vitro,
potentially reflective of being passaged in its native habitat. Nonetheless, deletions were recovered
in two genes involved in ribosomal maturation: rluD and gidB. Inactivation of these genes
contributed to increased streptomycin resistance in this natural isolate. Notably, the authors did
not recover a mutation in the global regulator rpoB, which is a common target in in vitro selections
for antibiotic resistance. This suggests that such a mutation could be detrimental for overall fitness
in the gut, and that to gain an accurate picture of antibiotic evolutionary trajectories, selection
experiments should be performed in an environment which closely mimics the body site of interest.
Most in vivo studies on evolution towards antibiotic resistance have focused on the second
scale of genetic change, that is, on horizontal transfer of antibiotic resistance between gut microbes
as the gut is the highest density microbial community on the human body and therefore represents
a hotspot for horizontal gene transfer. Recently, whole-genome sequencing has illuminated
resistance gene sharing between gut bacteria over the course of medical treatment. Sequencing of
E. coli isolates from an infant administered amoxicillin, ampicillin, and trimethoprim revealed
interstrain transfer via conjugation of an antibiotic resistance gene (ARG) containing plasmid from
a resistant strain to a susceptible strain over the course of treatment [12, 22]. Exposure of the
resistant strain to antibiotics also selected for a mutation in the promoter driving the betalactamase, leading to increased expression of the resistance gene and a higher level of resistance
[12]. Enabled by expanding plasmid assembly tools, plasmids have also been recently shown to
exhibit high plasticity in vivo [23], as exemplified in a study involving patients harboring
carbapenemase-containing Klebsiella pneumoniae over the course of several years. In one patient,
a major lineage contained plasmids which underwent complex rearrangements to form several
hybrid plasmids. In another patient, multiple co-dominant lineages, each with different sets of
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plasmids (sometimes overlapping) were present. It is unclear whether plasmid rearrangements
require the presence of other microbes in the gut, or whether they can occur within a strain.
In a separate study, Pseudomonas moraviensis carrying an antibiotic resistance plasmid
was evolved for 1000 generations under antibiotic selection. Acquisition of a toxin-antitoxin
system by the plasmid via transposition from a co-residing native plasmid expanded its persistence
and host range [24]. While not an instance of HGT per se, this example of intracellular genetic
transfer between plasmids resulting in greater plasmid fitness frames our understanding of HGT
as co-evolution between bacteria and the plasmids they harbor, particularly if the plasmids carry
genes beneficial to the host.
Similarly, the acquisition of new genetic material in the form of prophages via transduction
has been shown to contribute to improved fitness. It was recently demonstrated in Staphylococcus
aureus that phage particles can capture genomic DNA, including antibiotic resistance genes at low
frequency, enabling their transduction to other cells [25]. Phage-mediated transduction of
antibiotic resistance genes has also been reported in strains of E. coli and Salmonella spp., although
the extent to which this contributes to ARG dissemination outside the laboratory is unclear [26].
Phages can also contribute to antibiotic resistance indirectly, such as in the enhancement of biofilm
formation in some lysogenic species when the prophages are induced [27, 28].
Due to the high prevalence of ARG exchange in microbial communities, and the potential
for microbes to transfer between communities, it is natural to ask which habitats are likely to serve
as “reservoirs” of resistance genes likely to transfer to humans and pose a health threat. The
application of metagenomic analysis, both of existing and novel datasets, has revealed the
widespread nature and origins of mobilizable resistance [29, 30]. Analysis of sequenced genomes
showed that food and agriculture-associated organisms are a major participant in HGT of ARGs
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with gut commensals [31]. Recently, functional characterization of resistomes (Box 1) from lowincome rural and peri-urban settings revealed chicken coops and sewage treatment plants serve as
hotspots for ARG enrichment and transmission between human and environmental microbiomes.
The authors also identified key ARGs which are likely to occur in multiple genetic contexts and
are at high risk for mobilization [32]. Also of note for its potential role in nosocomial infections is
the hospital microbiome, which has been shown to be a reservoir of resistance genes [33, 34].
Together, these analyses indicate a pressing need for a comprehensive measurement of the rates
and types of ARG transfer between human commensal, environmental, and pathogen-dominated
microbiomes across the globe, to enable improved molecular surveillance of ARG dissemination.
These studies indicate the necessity for high-resolution sampling and optimization of
bioinformatics tools to elucidate the sequence of genetic events leading to resistance gene transfer
between strains. Additionally, current shotgun approaches to metagenomics are ill equipped to
reveal genetic changes associated with particular microbial lineages, and technical, computational,
and conceptual advancements are needed to be able to answer such questions in the context of
microbial communities. Future studies could further characterize adaptations that occur at the
chromosomal level in response to acquisition of a drug resistance plasmid with or without
antibiotic exposure.
Evolution and horizontal gene transfer in response to antifungals
While bacteria have received the majority of attention in in vivo evolutionary studies,
commensal and pathogenic fungi also play an important role in the gut and undoubtedly evolve in
response to selective pressures in that context. Indeed, it has been shown that Candida albicans
accumulates a diverse array of mutations during fluconazole treatment [35]. The divergent
genomic structure, including multiple linear chromosomes and polyploidy, of fungi reveal
additional evolutionary modes. Loss-of-heterozygosity events are a major player in acquiring
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resistance to fluconazole, a mechanism which would not be observed in bacteria. Additionally,
polyploidy has been shown to buffer organisms against deleterious mutations and as a consequence
enable evolutionary exploration of a wider swath of sequence space, potentially contributing to the
large number of SNPs observed in this study. Finally, aneuploidy (loss and addition of large
chromosomal segments) also contributes to fluconazole resistance, a mechanism analogous to
large-scale gene deletion or duplication events in bacteria. Fungi have recently been shown to
participate in HGT, both to other fungi [36] and from bacteria [37], though the mechanisms
operating in vivo have not been fully elucidated. Mating may also play a role, as yeast sporulation
has been shown to be enhanced in the guts of wasps [38]. Together, these processes indicate that
gut fungi may be an important player in horizontal gene transmission and cross-ecosystem gene
exchange, the 2nd and 3rd scales of evolution, in addition to bacteria.
Evolution in response to heavy metal exposure
Heavy metal exposure can pose significant selective pressure against commensal bacteria.
Recently, it has been shown that copper supplementation, a technique for growth promotion in
cattle, selects for an increased prevalence of copper resistance in Enterococcus faecium in the cattle
gut [39]. While this fact alone is not surprising, it was also found that the copper resistance gene
(tcrB) is carried on a plasmid with resistance genes for macrolide and tetracycline resistance. The
authors subsequently showed that these multidrug and copper-resistance phenotypes are cotransferred during conjugation assays. The co-occurrence of metal and antibiotic resistance on
single plasmids has been observed in other gut settings [40-42], and indicate that for organisms
which transit between ecosystems (e.g. through agricultural and food consumption networks)
selective pressures experienced in one habitat may result in the presence and transmission of colocalized but distinct genetic material across habitats, a combination of genetic change at both the
second and third scales.
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In vivo evolutionary responses to host diet
Many microbes, particularly in the gastrointestinal tract, utilize host dietary material as a
nutrient source. Therefore, it comes as no surprise that host-associated microbes adapt to the
unique dietary conditions of their host. Many studies examining strain abundance changes in
response to dietary intervention have been undertaken [43-46], but few have investigated
mutations or genomic rearrangements that occur during exposure in vivo. This may be because the
selective pressure imposed by diet is both weaker and imposed over longer timescales than
selective pressures imposed by xenobiotics. Nonetheless, several exciting retrospective analyses
of microbiota diversity across populations have indicated historical transfers of genetic
information that adapt the human gut microbiota to a specialized diet. A landmark study
demonstrated transfer of a porphyranase (an enzyme which degrades porphyrin, a carbohydrate
found in red algae such as seaweed) from a marine Bacteroides to a gut Bacteroides species in the
gut microbiome of Japanese individuals, for whom seaweed is a major dietary component [47].
Such enzymes were not observed in the gut microbiomes of Western subjects. This addition of a
new function to the gut microbiome exemplifies a combination of genetic change across the second
and third scales, with a cross-ecosystem introduction of new functions in the form of a foreign
organism and subsequent transfer to a native commensal via horizontal gene transfer. In another
study, mobilizable glycosyl hydrolases present in the guts of Fijian individuals were distinct from
those present in Americans, supporting the notion that the gut microbiome may share and evolve
genes in response to locale-specific dietary pressures [48]. Interestingly, diet has been shown to
affect the mobilization rate of certain plasmids in rats with a high fat diet reducing the rate of
plasmid transfer relative to a more conventional rat chow diet [49]. Fermented foods have also
been shown to affect the density of transconjugants in germ-free mice, though it’s unknown
whether this effect is due to an increase in the growth rate of the transconjugants or an increase in
10

the mobilization rate itself [50]. The capacity for horizontal gene transfer may also be explored
synthetically in “forced HGT” experiments, where genes from one microbe are transferred en
masse on cloning vectors to another, and selecting for more fit transformants via passage through
the mouse gut. Using such a strategy, it was recently shown that acquisition of carbohydrate
utilization enzymes from Bacteroides thetaiotaomicron confers a fitness advantage to a lab strain
of E. coli in the germ-free mouse gut [51]. It would be interesting to determine which functions
confer a selective advantage to E. coli (as well as other gut microbes) in more realistic gut contexts
when the entire gut metagenome can be sampled [52], as this would provide a broader riskassessment for HGT in the gut.
Evolutionary response to competition in microbial communities
Human-associated microbes contend with a range of selective pressures differing between
body sites and in the context of host health or disease (Figure 1.2). These challenging and
spatiotemporally dynamic environments lead to microbial competition and support ongoing
transitions in the allelic composition of the microbiome, such that even an ecologically stable
bacterial community may not be evolutionarily stable. Examples of this property include metabolic
adaptations in one subpopulation that lead to new niche creation that other subpopulations can
evolve to occupy [53]. High densities of bacteria in the gut lead to extensive cross-feeding on
metabolites produced by co-localized species; the ability to utilize these metabolites provides a
selective advantage such that the metabolic profile of each bacterial species can be driven by those
in the rest of the community [54].
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The selective pressures governing microbial
evolution are often dictated by unique features of the habitat in which it occurs, including its nutrient
sources, microbial density, dilution rate, and spatial arrangement.
Figure 1.2: Features of the Human Body Impacting Microbial Evolution.

In an extreme case described by the Black Queen Hypothesis (Box 1), the metabolic
benefit of ‘cheating’ by utilizing necessary secreted molecules, such as proteases or iron-chelating
siderophores, produced by other bacteria can result in loss of the ability to produce these public
goods by all but one member of a community, requiring that member to continue producing to
avoid its own extinction despite the disparate benefit to its competitors [55]. Conversely, some
microbes may evolve to privatize their secreted public goods. For example, Pseudomonas
aeruginosa has been shown to reduce siderophore production and increase production of an
12

alternative compound for increasing iron availability when evolved in the presence of ‘cheater’
strains. A conceptual example of ongoing transitions in allelic compositions of competitive
communities is illustrated in Figure 1.3a, where a killer species able to produce a compound lethal
to a sensitive strain rises in abundance, measured by the frequency of detection of its killer gene.
Concomitantly, the sensitive species falls in abundance while mutation events give rise to a
resistant lineage, or even a lineage able to degrade the killer compound. As these lineages rise in
abundance, the fitness advantage of producing the killer compound decreases until outweighed by
its metabolic cost. Eventually, mutational events may give rise to an evolved killer lineage that has
overcome the resistance or degrader phenotypes of the once-sensitive lineages. As stated by the
Red Queen Hypothesis (Box 1), classically applied to parasitic relationships but also applicable to
competitive ones, adaptation in one species leading to a fitness advantage can require adaptation
in a competing species, resulting in an evolutionary arms race.
Bacterial relationships are dynamic not only between species but also within species, as
lineages continue to competitively co-evolve. Theoretical and controlled in vitro experiments have
supported clonal interference as a major factor in the adaptive dynamics of large asexual
populations (Figure 1.3b) [53, 56, 57]. For example, experimental evolution of E. coli during
exposure to macrophages in vitro resulted in functional parallelism (Box 1), especially in genes
related to the electron-transport chain [58]. These adapted clones had a fitness advantage inside
macrophages and had increased aminoglycoside resistance with increased collateral sensitivity to
other antibiotics like tetracycline, likely mediated by reduced proton-motive force across the inner
membrane on which many efflux pumps depend. Thus experimental evolution experiments can
reveal the traits important for within-host fitness at a genetic level and detail the adaptive dynamics
exhibited by bacterial populations under stress.
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(A) An example of adaptive dynamics
involving antibiotic-producing, sensitive, resistant, or degrader microbial phenotypes. Dynamics of a coevolutionary arms race between lineages or species with inhibitory interactions is driven by cycles of
fitness advantage and fitness cost and by the emergence of new lineages with evolved phenotypes. (B)
Left: the classical dominant-lineage model of evolution. Neutral variation accumulates until a bottleneck
event leads to a hard sweep, resulting in allelic fixation. A new dominant lineage is established (black
lines), and less fit lineages fall to extinction (gray lines). The background colors denote relative abundances
of specific lineages. Right: the clonal interference model of evolution. Adaptive and polymorphic
mutations arise in parallel, and lineages compete and co-exist over prolonged periods.
Figure 1.3: Evolutionary Dynamics of Co-localized and Competing Lineages.

Recent studies, however, have emphasized the importance of describing lineage dynamics
in vivo. For example, in a study demonstrating plasmid transfer among 3 lineages of E. coli
sampled from the feces of a healthy infant [13], mutants enriched in vivo exhibited a fitness cost
in vitro. Thus genetic information is fluid even in the absence of obvious perturbation, and intraspecies competition in vitro alone cannot account for the relative abundances of different lineages
of the same species in vivo. This underscores the need to characterize the adaptation and lineage
14

progression of human-associated microbes, including commensals and probiotics, in
physiologically relevant environments [59-61].
Evolution in gut bacterial populations
In a study of adaptation of E. coli in the mouse gut, YFP and CFP tagged E. coli gavaged
into streptomycin-treated mice and collected over 24 days displayed evolutionary dynamics
diagnostic of clonal interference with rapid soft sweeps (Box 1) of adaptive mutations related to
carbohydrate metabolism with large effect with a mean of 15% and reaching as high as 30% fitness
advantage [14]. Whole genome sequencing of isolated clones displayed parallelism of evolution
at the operon and gene levels with all clones exhibiting inactivating mutations in the gat operon
(gat-negative phenotype), involved in galactitol metabolism, which is inhibitory to E. coli and
likely to be often encountered in the mouse gut. Multiple clones had mutations in the srIR repressor
that likely improved their ability to metabolize sorbitol, in dcuB and focA, transmembrane
transporters involved in anaerobic respiration, and in asnA which catalyzes the conversion of
aspartate to asparagine. Interestingly, triple mutants occurred at a low rate (6%), all of which were
gat-negative with additional mutations in srIR and dcuB or srIR and focA, but never dcuB and focA
together. Because dcuB and focA carry out similar functions, this suggests a role for epistasis (Box
1) in adaptation. The initial adaptive steps of E. coli were characterized by insertion elements that

led to gene inactivation or modulation, half of which occurred in regulatory regions, and a high
degree of parallelism and clonal interference. The time scales of fixation (Box 1) of the gat-negative
phenotype (though not necessarily of fixation of the neutral marker) was as little as two days post
gavage. The authors found no evidence of mutation limitation with polymorphism remaining high
throughout the experiment, no emergence of hypermutator (Box 1) strains, and found the
improved fitness of adapted isolates to be independent of their initial frequencies in competition
experiments, suggesting no role for frequency dependent selection (Box 1) in this case.
15

Similar signatures of selection were seen in the yearlong in vivo evolution study (~6500
generations) of E. coli in streptomycin-treated mice described above [11]. A strong selection for
gene inactivation and parallelism of adaptation between lineages both at the gene and pathway
levels was reported (eg. galactonate operon, ribosomal maturation genes). 56% of mutations were
shared by at least two lineages of E. coli. The authors also reported epistasis between two genes
involved in ribosomal maturation. In these controlled evolution experiments using a single
bacterial species, adaptation was dominated by the type encompassed by the 1st scale:
polymorphisms at the gene and operon levels that are vertically transmitted through bacterial
replication.
Evolution in skin bacterial populations
Fewer studies have described within-host evolution of members of the skin microbiome at
such resolution, likely due to difficulties in sampling low abundance environments although
technical improvements in metagenomic sequencing are helping. In one study, 131 Staphylococcus
aureus isolates from the nasal passages of 13 asymptomatic carriers were sequenced. Greater
genetic variability was found between hosts than within hosts, as well as coexisting within-host
lineages with evidence to suggest host-associated populations were each derived from a single
colonization event [62]. Importantly, no strain variation was detected in the multilocus sequence
typing loci used in conventional sequence typing, underscoring the importance of using whole
genome sequencing approaches in lineage tracking. While gut-focused studies have reported a
preponderance of adaptive evolution, in this skin study it was concluded that adaptive evolution in
skin commensals is rare. It was detected only in genes encoding a surface anchored protein and
an enterotoxin, which may be attributable to a unique population dynamic characterized by huge
fluctuations in absolute size, indicating periods of clearance and re-expansion. Another study
examined a panel of skin sites longitudinally and found evidence for long-term stability of
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individual-associated SNP signatures in polyallelic Propionibacterium acnes and Staphylococcus
epidermidis populations.

The study used KEGG annotations to identify greater functional

variation in S. epidermidis populations than P. acnes ones, which may be due to the broader niche
range exhibited by the former [18, 63]. The skin microbiome is an exciting field for future studies
of within-host evolution, due to large differences in local selective pressures, low biodiversity,
compartmentalization of subpopulations, ease of sampling (despite low abundance), and uniquely
direct interfaces with the outside world.
Pathogen evolution during infection
Observational studies of pathogenic adaptation in vivo are dominated by interrogations of
chronic infections, which allow for longitudinal comparisons of clonally related isolates. These
are ideal examples of the third scale of genetic change, which includes addition of new genetic
information to a perturbed microbiome via colonization by foreign microbes. Further, the invading
microbes themselves adapt to their new environment at the first scale of genetic change. Whole
genome sequencing of hundreds of Burkholderia dolosa isolates from five patients with cystic
fibrosis revealed a high degree of polymorphism and parallelism as seen with the studies exploring
adaptation of nonpathogenic strains, [64]. Multiple lineages were detected within the patients, but
those lineages shared an enrichment of nonsynonymous polymorphisms in genes determined to be
under adaptive evolution, including genes involved in outer-membrane synthesis, quinolone
resistance, iron scavenging, and lipopolysaccharide transport. These data support the existence of
clonal interference and persistent within-host genomic diversity, and reject the dominant-lineage
model of infection. Further, the data demonstrate the utility of single-clone sequencing as it
provides a record of the selective pressures experienced by the pathogen in vivo [64]. The
emergence of a hypermutator isolate, which has been associated with development of antibiotic
resistance and persister phenotypes (Box 1), is reported here unlike in the studies of in vivo
17

adaptation of non-pathogens [65, 66]. In a separate study, 91 Stenotrophomonas maltophilia
isolates from 10 CF patients were sequenced identifying 20 different sequence types across three
major lineages as well as persistent polymorphic heterogeneity within lineages [67]. Virulent
isolates showed a significant trend towards an increased mutation rate, and these strong mutators
were significantly associated with greater antibiotic resistance.
In another study, serial isolates from cerebrospinal fluid of 18 South African patients with
recurring fungal (Cryptococcus spp.) infections, where relapse only occurs in a subset of the
population, were analyzed to investigate whether adaptive mutations exist that are determinants
for relapse [68]. 89% of the relapse infections were caused by isolates of the same genotypes as
the initial infections, indicating persister phenotypes. Two thirds of the 29 SNPs detected in the C.
neoformans var. grubii coding regions were nonsynonymous mutations distributed across 19
genes, and of patients with second relapse samples only 50% of SNPs were retained between first
and second relapse isolates indicating that a large proportion of alleles remain unfixed during
infection. Genes that were under positive selection (Box 1) included those involved in virulence
and fluconazole resistance. The authors argue the importance of microevolution of Cryptococcus
to the human central nervous system in determining disease outcomes.
Exchange of microbiomes across habitats
As sub-genomic regions of DNA are shared between individual microbes, whole genomes
or collections of genomes can be shared between microbiomes, characteristic of the third scale of
genetic change. While pathogenicity and colonization are well-known examples of single genomes
exploiting a new host niche, the rules and processes governing multi-genome transfer are just
beginning to be elucidated.
Some of the clearest examples of microbiome transfer have been provided through cohoused gnotobiotic mice harboring distinguishable microbial communities. Co-housing mice
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containing the microbiomes of either malnourished or healthy Malawian children revealed that the
microbes from healthy individuals reproducibly transferred to the mice containing the “unhealthy”
microbiome, but not the other way around, and that this transfer ameliorated the stunting caused
by the “unhealthy” microbiome [69]. Studies using co-housed mice containing either an “obese”
or “lean” microbiome have shown that members of the “lean” microbiome expand to mice
containing the “obese” microbiome and reduce weight gain, but only when these mice are fed a
low-fat, high fruit/vegetable diet. When the mice are fed a high-fat, low fruit/vegetable diet, this
colonization pattern is reversed [70], indicating that “obese” and “lean” microbiomes are adapted
to their originating diet.
As a counterexample to the idea that metagenomes are the “most fit” in their originating
context, it has also been shown using co-housing experiments that soil bacteria can dominate the
mouse gut, even when bacteria from other gut environments are present [71]. These studies reveal
that the determinants of microbial colonization are still largely unknown, and a fruitful area of
future investigation.
Perhaps the most clinically-relevant example of microbiome transfer involves Clostridium
difficile infection (CDI), usually acquired nosocomially, which is estimated to cause ~500,000
infections yearly of which more than 15% are recurrent [72]. Fecal microbiota transplantations
(FMTs) are a promising therapy for recurrent CDI, with the goal of restoring the microbiome’s
colonization resistance. A randomized controlled trial demonstrated resolution of recurring CDI
in 94% of patients that received one or two FMTs from a healthy donor [73], and other studies
have shown similar success [74-77]. The post-FMT microbiome can be considered better adapted,
since it displaces C. difficile and, unlike recurring CDI, its long-term colonization of the host is
sustainable. Because the gut microbiomes of recipients switch to match the profile of the donor
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with high fidelity, it appears that, despite high levels of interpersonal variation, there does exist a
core profile of selective pressures that characterize the human gut ecosystem. Quantitative
characterization of these selective pressures will be a critical future task for the field of
microbiome-directed and derived therapies.
Conclusions and Future Perspectives
In summary, bacterial colonization of diverse human body sites is characterized by
sustained clonal interference within populations with rare allele fixation, and adaptive parallelism
between lineages at the gene and operon level. These adaptations appear to be enriched in genes
related to carbon source utilization for commensal microbes, or in virulence genes for pathogens,
and while hypermutator phenotypes are often identified in pathogens they are not in commensals
(perhaps in response to antibiotic treatment). Often, these adaptations provide a temporal record
of the selective pressures encountered within-host by the microbe in question. While pathogens
hold obvious clinical relevance, further studies could elucidate the adaptation of other members of
the microbiome in response to infection, which could inform chronic inflammatory disease
outcomes. In addition, most lineage-tracking studies lack analysis of adaptation in genomic
regulatory regions and of what the effects may be.

In the future, these studies could be

complemented by transcriptional analyses.
As we engineer probiotics for the delivery of biologics and modulation of the microbiome,
more work needs to be done to assess risk in the evolution of probiotics in the gut in the context
of health or disease. Similarly, because transfer of intact or partial microbiomes shows therapeutic
promise, the evolutionary response of naïve microbiomes to disease states in their new hosts should
be explored. Current technical challenges include discrimination between the evolution of a
resident strain and invasion of a related strain, and the resolution of closely related strains in hostassociated microbial communities. Recent technical and computational improvements bring us
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closer to addressing these challenges, and have been reviewed elsewhere [8, 9, 78]. In particular,
assembly of genomes directly from metagenomes is a promising method that facilitates
identification of strain-level variation using short-read sequencing (Figure 1.4a) [10]. A number of
recent tools have improved metagenomic assembly capability [79-85].

A fundamental challenge in
studying the evolution of individual microbes within communities remains the ability to associate
polymorphism with a specific lineage over time. Three approaches to overcoming this barrier that have
been subject to great recent advances are metagenomic assembly (A), next-generation culturing (B), and
single-cell sequencing (C).
Figure 1.4: Future Directions in Studying Evolution of Host-Associated Microbes In Situ.

Additionally, advancements in culturing techniques which pair multiple culture conditions
with mass spectrometry or sequencing based identification are allowing isolation of traditionally
inaccessible members of the microbiota (Figure 1.4b) [86-88]. Lastly, single-cell sequencing
circumvents the limitations imposed by culture and provides the resolution necessary to identify
microbial adaptation within communities (Figure 1.4c) [89]. An exciting future prospect is
improved correlation of strain-level variation in the context of disease to patient outcomes, which
may enable more personalized treatment strategies. This requires greater investment in
understanding the complex evolutionary dynamics of determinant microbes within the host.
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Chapter 2 : Adaptive Strategies of the Candidate Probiotic E. coli
Nissle in the Mammalian Gut
Abstract
Probiotics are living microorganisms that are increasingly used as gastrointestinal
therapeutics by virtue of their innate or engineered genetic function. Unlike abiotic therapeutics,
probiotics can replicate in their intended site, subjecting their genomes and therapeutic properties
to natural selection. We exposed the candidate probiotic E. coli Nissle (EcN) to the mouse
gastrointestinal tract over several weeks, systematically altering diet and background microbiota
complexity. In-transit EcN accumulates genetic mutations that modulate carbohydrate utilization,
stress response, and adhesion to gain competitive fitness, while previous exposure to antibiotics
reveals an acquisition of resistance. We leveraged these insights to generate an EcN strain that
shows therapeutic efficacy in a mouse model of phenylketonuria and found that it was genetically
stable over one week, validating EcN’s utility as a chassis for engineering. Collectively, we
demonstrate a generalizable pipeline which can be applied to other probiotics to better understand
their safety and engineering potential.
Introduction
Probiotics are live microorganisms that provide health benefits when consumed, including
enhancement of gut epithelial barrier function, blocking of pathogen binding, and vitamin
synthesis [1]. There has been increasing success in expanding the therapeutic scope and efficacy
of probiotics through genetic engineering, with prior work demonstrating preclinical efficacy
against infectious and metabolic diseases [2-5]. Engineered probiotics are exciting platforms for
in situ drug synthesis and delivery, provided they maintain appropriate abundance and activity at
their target site. Unlike conventional (abiotic) therapeutics, wild type or engineered probiotics
replicate in the gut and are therefore subject to natural selection, potentially to the detriment of
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their intended therapeutic effect and safety profile. Indeed, both commensal and pathogenic
microbes adapt in a host-specific manner during gut passage [6, 7]. In addition, probiotic efficacy
and colonization of the gut is highly variable between subjects, and some of this variability can be
attributed to person-specific gut microbiome features prior to treatment such as alpha diversity and
diet [8-10]. Clinical use of probiotics, especially genetically engineered probiotics, therefore will
benefit from a thorough understanding of their in vivo evolutionary trajectories under diverse
schemes of microbiome complexity and host diet. In this study, we use mouse models to determine
the selective forces acting on probiotics in vivo.

Figure 2.1: Parsing Probiotic E. coli Evolution In Vivo

We focus on the probiotic Escherichia coli Nissle 1917 (EcN), an E. coli clade B2
commensal (Figure 7.1). EcN has a long history of use in humans [11], has demonstrated efficacy
against inflammatory bowel disease [12], and has been gaining increased attention as a chassis for
engineered function [2, 4, 5, 13]. We expected several factors to drive adaptation of EcN in the
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mouse gut. First, EcN cannot natively degrade many of the complex polysaccharides present in
the intestine [14, 15] and is dependent on other species for production of metabolizable sugars
[16], which may lead to adaptations in carbohydrate utilization, especially in low-diversity
microbiomes. Second, the high prevalence of antagonistic interspecies interactions in the gut [17]
may drive adaptation in EcN’s encoded colicins [18]. Third, since EcN normally resides in multispecies biofilms on the outer mucin layer [16], introduction to the murine gut may drive adaptation
in adhesins, increasing their specificity to mouse mucins. Finally, expression of a Phe-degrading
enzyme (modeling an engineered probiotic therapy) [5] may impose a metabolic burden [19, 20].
We tested these hypotheses using both whole-genome sequencing of in vivo adapted
isolates and in vivo functional metagenomic selections (Figure 2.1). Isolates were adapted and
metagenomic libraries (derived from healthy human fecal samples) were selected in mice subject
to a spectrum of diets and microbiome complexities. In addition, some mice were the genetic
model (Pahenu2-/enu2-) for phenylketonuria (PKU). This combination of whole-genome adaptive
evolution and functional metagenomics enabled us to investigate the endogenous adaptations and
human gut metagenome-encoded genes that can confer a selective advantage to EcN. The
functional metagenomic selections served as an approximate model for adaptation via horizontal
gene transfer, which is a major mechanism driving bacterial evolution [21, 22], and frequently
associated with key functional determinants such as antibiotic resistance [23]. In total we analyzed
225 longitudinal samples from functional metagenomic selections in 33 mice (Table 2.1), and 401
EcN isolates from 20 mice (Figure 7.2, Table 8.3).
See also Figure 7.2, Table 8.1, and Table 8.4
for descriptions of the selection experiments, diet compositions, and the 13-member community.
Table 2.1: Summary of Functional Metagenomic Selection Experiments.

Microbiome
Germ-free
Germ-free

Diet
Mouse
Human
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# Mice
6
5

Germ-free
Germ-free
Germ-free
13-member
13-member
13-member

Human+Dextrin
Human+Inulin
Human
Human
Human+Dextrin
Human+Inulin

5
5
3
3
3
3

Results
Rationale for functional metagenomic selections in the low-diversity gut
The source of our metagenomic DNA was stool from two healthy human infants and six
healthy human mothers to approximate the diversity of microbial taxa present in the gut through
different life stages [24]. Our library comprised ~1.5x107 unique 2-5kb fragments of metagenomic
DNA. We confirmed in a longitudinal in vivo experiment that the empty vector remained stable in
EcN over 5 weeks in the mouse gut (Figure 7.3). By competing millions of recombinant EcN strains
against each other in vivo, we expected to observe significant enrichment of a subpopulation of
strains with DNA inserts conferring a fitness advantage to EcN. Specifically, we hypothesized
that functional metagenomic selections in germ-free mice would select for enzymes capable for
degrading complex polysaccharides, a function that E. coli typically depends on gut anaerobes to
carry out [14, 16].
Selection for carbohydrate utilization in the germ-free gut
Metagenomic libraries were delivered to six germ-free C57BL/6 mice. These mice
consumed a mouse diet (MD) composed primarily of plant-based carbohydrates and protein (Figure
2.2a, Table 8.1, Table 8.2). Over 5 weeks, we observed a striking reduction in the diversity of

metagenomic inserts - the same 5 sequences were selected in all 6 mice (Figure 2.2b). These inserts
rose from a low starting abundance (0.187% for the most abundant fragment on day 1 of selection),
to over 75% combined abundance in each mouse. Four out of these five inserts contained genes
encoding a predicted glycosyl hydrolase family 32 (GH32) enzyme, and several of these inserts
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also contained genes encoding predicted transporters and other enzymes involved in sugar
utilization (Figure 2.3b). To test our hypothesis that these inserts enhance carbohydrate utilization,
we cloned these metagenomic fragments into wild type (WT) EcN and looked for conferred carbon
source utilization using phenotypic microarrays (Cat# PM1 and PM2A, BIOLOG, Inc.).

A) Experimental design and sampling
timeline. Mice were gavaged on day 0. N: number of replicate mice. B-E) Relative abundance of
metagenomic fragments in replicate mice fed standard mouse diet and water (B), a high-fat human diet
and water (C), a high-fat human diet and dextrin (D), or a high-fat human diet and inulin (E). MD: fragments
enriched in mice fed Mouse Diet; HD: fragments enriched in mice fed Human Diet.
Figure 2.2: Functional metagenomic selections in EcN mono-colonized mice.

Each GH32-containing fragment enabled growth on sucrose, which commensal E. coli,
including EcN, are unable to consume [16] (Figure 2.3a). Several GH32-containing fragments
enabled growth on longer-chain oligosaccharides containing sucrose as a terminal moiety,
including raffinose and stachyose (Figure 2.3a). The growth rate of EcN strains containing two
different GH32-encoding fragments (MD02 and MD05) was higher on these longer-chain
oligosaccharides than sucrose (MD02: 0.04 h-1 on sucrose vs 0.208 h-1 on raffinose (p = 0.0017, ttest, two tailed, unequal variances) and 0.144 h-1 on stachyose (p = 0.011); MD05: 0.028 h-1 on
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sucrose vs 0.252 h-1 on raffinose (p = 8.8 x 10-5) and 0.153 h-1 (p = 0.00073) on stachyose),
indicating specialization toward these molecules. We hypothesized that GH32 activity by an EcN
subpopulation would release sugars upon which the rest of the EcN population can cross-feed. To
test this, we grew WT EcN on raffinose minimal media pre-conditioned by EcN strains expressing
recovered GH32 enzymes, or by WT EcN. We found WT EcN could only grow on media preconditioned by the EcN strains expressing GH32-encoding inserts (Figure 2.3d), indicating that
these strains can support cross-feeding within the EcN population.
The remaining fragment (MD04), which did not encode GH32, encoded a transcription
factor which was identical (100% nucleotide identity) to the gadX gene in EcN, and also contained
the native gadX promoter. GadX plays an important role in acid tolerance by regulating the
expression of the gad operon, whose combined activity generates a cycle that reduces cytosolic
H+ [25]. Presence of MD04 enabled EcN to recover more rapidly than WT from a 30-minute
exposure to acidic conditions (pH 2.5) (Figure 2.3c). Also, expression of this fragment in EcN
uniquely increased cell density at 24 hours after switching from LB to minimal media with
galactose, a mucin component, as the sole carbon source [26] (Figure 2.3a). At high extracellular
concentrations, galactose is imported into E. coli by a low-affinity galactose permease (GalP),
which is a proton symporter [27]. Overexpression of GadX may therefore also mitigate an increase
in cytosolic pH in galactose minimal media. Together with Gene Ontology (GO) annotation of the
genes contained within recovered fragments (Figure 2.4a), these results indicated that the dominant
selective pressure on EcN in the mono-colonized mouse gut is limited carbon source availability.
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A) Growth curves of
strains expressing fragments enriched in the functional selections on minimal media supplemented with
different carbon sources. *P < 6x10-3, Student’s t-test comparing time taken to reach Abs600nm=0.25
between WT and MD04. B) Annotations of select metagenomic fragments enriched in the functional
selections. C) Growth curves of 3 biologically-replicate EcN strains expressing the gadX DNA insert (MD04)
or EcN carrying empty vector (WT) after a 30-minute pulse in acidic (pH 2.5) or neutral (pH 7.0) conditions.
* P < 0.001, Student’s t-test for time needed to return to the max Abs600nm prior to the pulse between
MD04 fragments and WT, Bonferroni correction. D) Growth of WT EcN on 1% raffinose minimal media
pre-conditioned by EcN strains carrying MD01 or MD02, or by WT EcN, or on unconditioned 1% raffinose
minimal M9 media (left). No growth was observed in uninoculated conditioned media (right). * P < 0.001,
Student’s t-test on the K parameter of logistic models fit to the data using the growthcurver R package,
Bonferroni correction for multiple comparisons. The shaded regions represent the standard deviation of
8 experimental replicates. See also Figure 7.4.
Figure 2.3: Selection for carbohydrate utilization and acid tolerance in EcN mono-colonized mice.
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A)
Heatmap of the relative abundances of GO classifications present in EcN mono-colonized mice and mice
pre-colonized with a 13-member defined community at the end of the selection period. Dendrograms
represent the clustering applied to group similar rows/columns of the heatmap. B) Growth curves of EcN
strains harboring metagenomic inserts shown in (D) on gluconate minimal media, or (C) glucose. N = 6
experimental replicates, error bars represent one standard deviation above and below the mean. D)
Annotations of the metagenomic fragments characterized in B-C. See also Figure 7.2, Figure 7.5, and Table
8.4.
Figure 2.4: Comparison of functions enriched in functional selections in mice with different gut microbiome complexities.
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Diet-dependent selection
Because we found strong selection for expanded carbohydrate utilization in the previous
experiment, we hypothesized that polysaccharide-specific enrichment of DNA inserts would occur
in response to dietary prebiotics. To test this hypothesis, we delivered the EcN library to 3 groups
of 5 germ-free mice. All mice were maintained on a high-fat, high-carbohydrate diet which mimics
the diet of Western humans (HD) [28]. One group of mice consumed HD alone, while the other
two were supplemented with the prebiotics inulin or dextrin in the drinking water. Inulin is not
degradable by WT EcN, while dextrin can support limited EcN growth [14] (Figure 7.4). Over 5
weeks, we again observed convergence toward ≤6 metagenomic fragments in each dietary
condition (Figure 2.2c-e). Supporting our diet-dependency hypothesis, the collection of enriched
fragments in each condition was different. However, one fragment was enriched in all three groups
(HD04). Among enriched fragments, HD04 alone contained a gene encoding a GH32 enzyme,
replicating our prior observations. Indeed, this fragment enabled EcN to consume sucrose and a
water-soluble extract of HD, possibly due to the high amount of sucrose (341 g/kg) it contains
(Figure 2.3a).
We classified ORFs in each enriched fragment into GO Pathways (Figure 2.4a). We
observed strong clustering of ORF annotation based on prebiotic supplementation. Reflecting the
ubiquity of fragment HD04, “Carbohydrate Metabolic Process” was abundant (>23%) in all
samples. In the presence of dextrin, we also observed “Pyrimidine Nucleotide Biosynthetic
Process”, reflecting a predicted glutamate synthase. In the presence of inulin, the major fragment
(reaching 32-67% relative abundance in all mice at the end of the experiment) contained a gene
encoding a predicted “ATPase-coupled sulfate transmembrane transporter”. In the absence of
prebiotic, the dominant fragment was HD04. No fragment besides HD04 enabled increased growth
on dextrin or inulin, or on HD extract broth. We conclude that in these mice the dominant selective
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pressure remained the ability to degrade long-chain polysaccharides, but that once this function
was fulfilled by a subpopulation of GH32-carrying EcN, secondary functions were enriched in a
diet-specific manner.
Advantageous functions in a simplified microbial community.
Based on these results, we hypothesized that in the presence of polysaccharide-degrading
taxa, non-polysaccharide degrading functions would be advantageous to EcN. To test this
hypothesis, 8 germ-free C57BL/6 mice were colonized with 13 human gut-derived bacteria which
model phylogenetic makeup of the human microbiome [29] (Table 8.4), after which the EcN library
was delivered and allowed to colonize for 5 weeks. 16S rRNA sequencing revealed that EcN
colonized these mice at an average relative abundance of 15.3% (Figure 7.5). Sequencing revealed
a high diversity of enriched functions relative to the mono-colonization experiments. While no
individual fragment reached a high abundance (>20%) in all mice in the same experimental
treatment, we did observe functional convergence. As in prior experiments, the GO term
“Carbohydrate Metabolic Process” was consistently recovered across the majority of replicates.
We also observed condition-specific enrichment for “Gluconate Metabolic Process”, reflecting a
E. coli transcriptional regulator (gntR) which achieved >7.6% abundance in mice containing the
13-member defined community (Figure 2.4a,d). We hypothesized that these fragments altered the
ability of EcN to metabolize gluconate. When these fragments were introduced to un-adapted EcN,
the recombinant strain was no longer able to grow on minimal media containing gluconate as the
sole carbon source, yet maintained its growth on glucose (Figure 2.4b,c), consistent with strong
overexpression of gntR. Gluconate utilization has been shown to be necessary for E. coli to
colonize the conventional or streptomycin-treated mouse gut [30, 31], so the recovery of fragments
abolishing gluconate utilization could indicate an environment-specific benefit to gluconate use.
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Together, these data indicated that the primary selective pressures faced by EcN in the lowdiversity mammalian gut are related to carbon source limitation, and that once other taxa were
introduced this selective pressure was removed. The presence of a strong constitutive promoter in
our cloning vector did not bias ORF orientation. Rather, across all experiments and all recovered
fragments, full-length ORFs in the same orientation as the promoter accounted for only 47.0% of
full-length ORFs. We were intrigued by the recovery of E. coli genes in our selections (gadX and
gntR). Based on this observation, we asked what genomic changes EcN undergoes after in vivo
passage.
Within-genome evolutionary change
We next performed whole-genome sequencing on 401 EcN isolates collected from mice
with four levels of microbiota complexity: mono-colonized with EcN, colonized with a defined
community, streptomycin treated, or conventional. Mice from each of these conditions were either
fed MD, HD, or HD+dextrin (Figure 7.2, Table 8.1, Table 8.2, and Table 8.3). We observed 456 total
(336 unique) genomic changes across 171 genes (Figure 2.5, Figure 7.6b) relative to a high-quality
closed assembly for WT EcN we generated (GenBank Accession CP035486-CP035489). The most
highly-mutated strain had 5 SNPs, while the average strain had 0.86 SNPs/genome. From
longitudinal sampling of 2 mice fed a human diet and treated with streptomycin prior to EcN
gavage, we estimate the mutation rate of EcN in the mouse gut to be 0.007 (± 0.002)
SNPs/genome/generation [Figure 7.6a], assuming an in vivo generation time of 100 minutes [32],
which is in broad agreement with that obtained for E. coli grown in vitro in the absence of antibiotic
exposure: 0.001 SNPs/genome/generation [33]. As evidence for consistent in vivo selective
pressures, we observed multiple instances of SNP accumulation in the same gene in isolates from
separately caged mice.
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Figure 2.5: Summary of mutations detected in in vivo adapted EcN isolates. The EcN chromosome, its 2 native plasmids

pMut1 and pMut2, and the expression vector pZE21 are depicted in a Circos plot. Light gray regions are
scaled 100x that of the rest of the chromosome for visibility. Genes of interest (orange) are labelled
around the plot. The outer track depicts all detected intergenic (orange) and nonsynonymous (green)
SNPs. The next track depicts all small insertions (blue) and deletions (red). The third tack depicts all large
deletions > 1kb (shaded purple). The inner track depicts the number of isolates that contained each
mutation. Mutations found in only one isolate are excluded the inner track for visibility. Isolate counts for
each mutation are capped at 25, which only affects the rsmG mutants, (n = 167). See also Figure 7.6, Table
8.3, Table 8.5, and Table 8.7.
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Adaptations involving nutrient utilization.
We found 10 different mutations to nagC in 19 isolates (Figure 2.6a). These isolates were
from 5 monocolonized mice used in the functional metagenomic selections. All mutations resulted
in either a premature stop codon, elimination of the start codon, or a frameshift. NagC is a repressor
of utilization of the mucin component N-acetylglucosamine (GlcNAc) [26]. We hypothesized that
NagC inactivation would enhance the ability of EcN to consume GlcNAc. To test this hypothesis,
three isolates with mutations to nagC were cured of their metagenomic vector (which encoded
either GadX or GH32). We performed in vitro diauxic growth experiments and found that while
these plasmid-cured nagC mutants grew similarly to WT EcN on glucose or GlcNAc minimal
media, they were able to grow better on GlcNAc under glucose-limiting conditions (Figure 2.6b).
In porcine mucin minimal media under glucose-limiting conditions, the mutants had diauxic
growth profiles that differed from WT, but these differences were not statistically significant
(Figure 7.7a). nagC mutants were exclusively isolated from mice mono-colonized with EcN
populations expressing GH32 enzymes; mutations enhancing growth on a less-preferred carbon
source may be due to a low diversity of polysaccharide degradation functions present and a
concomitant carbon source limitation in the gut. It has also been found that nagC is mutated during
adaptation to osmotic stress [34], which may provide EcN an advantage during transit through the
GI tract.
gntT was found to be mutated in 6 different ways across 21 strains isolated from five
different mice, including 2 isolates with >10kb deletions containing this gene (Figure 2.5, Figure
2.6c). The 4 other mutation types included 3 early stop codons and a D395N mutation. gntT

encodes a high-affinity gluconate transporter [35]. gntT mutants were significantly enriched in
mice that had been pre-colonized with a 13-member defined community (p = 1.06x10-6,
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Maximum parsimony gene phylogenies
for adapted isolates based on their nucleotide sequences for (A) nagC and (C) gntT. The length of the
branches corresponds to the number of SNPs separating the isolate gene sequence from the reference
sequence. Color tracks depict the treatment conditions and the Mouse IDs from which isolates were
isolated. The prefix of each Mouse ID indicates the cage in which the mouse was housed. B) Growth curves
of nagC mutants on 0.4% glucose minimal media (left), 0.4% GlcNAc minimal media (middle), and 0.2%
GlcNAc and 0.2% glucose minimal media (right). N = 3 experimental replicates per strain, * P < 0.05,
Welch’s t-tests comparing the K parameter of logistic growth models fit to the data for WT or the mutant
isolates, with Benjamini-Hochberg correction for multiple comparisons. D) Growth curves of gntT or
gntT/nagC double mutants on gluconate (left), GlcNAc (middle), or porcine gastric mucin minimal media
(right). ‘fs’: frameshift mutation S197T. * P < 1x10-5, Welch’s t-tests comparing the empirical areas under
the curves for WT and the mutant isolates, Bonferroni correction for multiple comparisons. E) Growth
curves of EcN transformed with plasmid-borne gntR-containing inserts from the functional metagenomic
selections in 1.5% porcine gastric mucin (left, middle, 2 independent experiments), or in 20 mM GlcNAc
minimal media (right). N = 4-6 experimental replicates per strain, *P < 0.05, Welch’s t-tests comparing the
empirical areas under the curves for WT and the mutant isolates, Benjamini-Hochberg correction for
multiple comparisons. F) gntT mutants were grown in 20 mM glucose (top) or 20 mM GlcNAc (bottom)
minimal media supplemented with indicated gluconate. G) Summary of F, showing the areas under the
growth curves (AUC) and the K parameter of logistic growth models fit to the data. N = 2-4 experimental
replicates per strain, * P < 0.05, Welch’s t-tests, Benjamini-Hochberg correction for multiple comparisons.
Black stars indicate both Isolates 3 and 21 had a significantly greater value than WT at a given gluconate
concentration. Blue – only Isolate 3. Red – only Isolate 21. For all panels, K and AUC values were calculated
using the growthcurver R package. Error bars and shaded regions represent one standard deviation above
and below the mean. See also Figure 7.7.
Figure 2.6: Phylogenies and phenotypic effects of nagC and gntT mutations.

hypergeometric test), although gntT mutants were also observed in EcN-monocolonized mice
(Figure 2.6c). We hypothesized that gntT mutants would have an impaired ability to utilize
gluconate, and so we tested the growth of two representative isolates in gluconate minimal media:
Isolate 21 (gntT D395N) and Isolate 3 (gntT/nagC double mutant). Isolate 3 was unable to grow
before 20 hours, and Isolate 21 had significantly impaired growth (Figure 2.6d). Although this was
the same phenotype conferred by the GntR-encoding fragments we recovered, we did not observe
any mutations in gntR or in its surrounding intergenic regions in our isolate genomes.
Since we recovered inactivation of gluconate metabolism in independent experiments that
spanned mouse litters, cages, and years, we investigated further. Surprisingly, we discovered that
Isolate 3 and 21 grew better than WT on GlcNAc minimal media. Further, both grew better on
porcine gastric mucin minimal media (Figure 2.6d). These results were unexpected as there is no
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apparent regulatory or metabolic link between gluconate and GlcNAc utilization. Interestingly, we
found that WT EcN transformed with gntR-containing fragments were able to grow better than
WT on porcine gastric mucin minimal media (Figure 2.6e), yet were not able to grow better than
WT on GlcNAc minimal media. GntR is a negative repressor of GntT; the data suggest repression
of the entire Gnt-I gluconate utilization system, but not inactivation or inhibition of GntT alone,
precludes enhanced consumption of GlcNAc. Both adaptations, however, enhance growth on
mucin.
A metabolite in the Entner-Duodoroff pathway responsible for gluconate metabolism, 2keto-3-deoxy-6-phosphogluconate, is toxic to E. coli [36]. We hypothesized that in the lowdiversity, carbon-limited mouse gut where all gluconate utilization fragments or mutants were
identified, increased degradation of the mucin layer increased local gluconate concentration,
leading to toxicity. We found that in glucose minimal media, growth profiles of gntT mutants
remained the same across gluconate concentrations of 0.5-8 mM while growth of WT EcN
progressively declined (Figure 2.6f, g). However, in GlcNAc minimal media these dynamics
changed. The growth profiles of Isolate 3 (gntT/nagC) and WT were similar, whereas Isolate 21
(gntT) had significantly improved growth at 1 mM gluconate but approached the other strains at
higher gluconate concentrations (Figure 2.6f, g). The D395N mutation (present in Isolate 21) was
common among gntT mutants, with 11/21 isolates from 3 separately caged mice hosting this
mutation, suggesting this mutation offered a greater fitness advantage. Indeed, when grown on
porcine gastric mucin minimal media, Isolate 21 consistently outperformed Isolate 3 and WT,
although all strains responded similarly to increasing gluconate concentrations (Figure 7.7b).
Notably, both WT and Isolate 3 exhibited two growth stages (suggesting diauxic growth) on
porcine gastric mucin minimal media while Isolate 21 did not. Together, these data suggest that
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there is a link between gluconate and GlcNAc utilization in EcN, and that inhibited gluconate
utilization is advantageous when mucin components are the primary carbon source.

Maximum parsimony gene
phylogenies for adapted isolates based on their nucleotide sequences for (A) kfiB, (C) sgrR, and (D) rsmG,
as in Figure 5. B) Percentages of kfiB mutant cells adherent to Caco-2 (left) or HT29-MTX (right)
monolayers after 3 washes. Shown are the means of ratios of adherent CFU to total CFU counts (N = 3
experimental replicates). Error bars are one standard deviation above and below the mean. * P < 0.05, **
P < 0.001, Welch’s t-test with Benjamini-Hochberg correction for multiple comparisons.
Figure 2.7: Phylogenies and phenotypic effects of kfiB, sgrR, and rsmG mutations.

Adaptations involved in stress response
sgrR was mutated 4 different ways in 7 isolates from 2 mice (Figure 2.7c). These mutations
were nonsynonymous and did not result in a stop codon. All strains were isolated in the context of
a very low diversity microbiome. Under conditions of excess sugar phosphates, SgrR is necessary
to protect the cell from stress [37]. It is possible that in the low-diversity gut, lack of the preferred
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substrate glucose resulted in cytosolic accumulation of phosphates of less efficiently metabolized
sugars, such as GlcNAc-6-P or gluconate-6-P. Additionally, rssB was mutated 4 different ways in
9 strains. Strikingly, all were frameshift mutations. RssB regulates RpoS expression by directing
it to the ClpX protease. RssB mutants display elevated RpoS levels [38]. RpoS is a master regulator
of the stress response in E. coli, and rpoS mutants show enhanced resistance to stress [39].
Adaptation in membrane-associated functions
kfiB was mutated in 24 strains from 4 mice, each with the same loss of an early stop codon
at amino acid 366, resulting in a full-length protein of 562 amino acids [Figure 2.7a]. This potential
gain-of-function variant was significantly enriched in mice that were pre-colonized with a defined
community (p=3.01x10-15, hypergeometric test). kfiB is a member of the K5 capsule
polysaccharide (heparosan) biosynthesis cluster, which has been implicated in mediating the
interaction between EcN and epithelial cells [40, 41]. We hypothesized that our kfiB variants would
exhibit altered adhesion to human epithelial cells. To test this hypothesis, we carried out an
adhesion assay with 3 representative kfiB mutants and either Caco-2 or HT29-MTX cell
monolayers. HT29-MTX cells produce MUC3, a membrane-bound mucin found throughout the
gastrointestinal tract [26]. We found that the kfiB mutation provided significantly enhanced
adhesion to Caco-2 and HT29-MTX cells (Figure 2.7b). This loss of truncation may reflect readaptation of our reference EcN strain, which likely has been passaged often under laboratory
conditions, to in vivo conditions.
Antibiotic resistance mutations
In streptomycin-treated mice, we observed that the majority of isolates (167/204) contained
mutations in rsmG, which encodes a 16S rRNA methyltransferase (Figure 2.7d). The three positions
we identified with mutations (53, 71, and 79) were also mutated in prior work to give low-level
streptomycin resistance [42]. We also observed 2 mutations to rpsL in 11 strains. All mutations
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occurred at residue 86 and converted it to a cysteine or serine. These mutations only occurred in
streptomycin-treated mice, and 10/11 times occurred in conjunction with a mutation in rsmG.
Residue 86 is adjacent to residues that have been mutated previously to provide streptomycin
resistance to EcN [43]. These streptomycin-resistant genotypes were preserved 5 weeks after
streptomycin exposure, suggesting that this resistance did not carry a fitness trade-off. These
results could indicate residual streptomycin present in the mouse gut, and are highly relevant
considering the common practice of administering probiotics and fecal microbiota transplants after
antibiotic administration [44, 45].
No in vivo plasmid acquisition
We searched our genome assemblies for sequences that did not map to the EcN genome.
Interestingly, we did not observe acquisition of new sequences. The cause for this may be that EcN
contains two endogenous plasmids [46] in addition to the cloning vector we used for this study,
which may pose a barrier due to plasmid incompatibility groups or other defense mechanisms. In
agreement with these results, E. coli Nissle has been shown to be a poor recipient of horizontallytransferred DNA [47].
In vivo excision of large genomic sections
In total, we observed 8 deletions larger than 1kb in size in 7 isolates. Two of these large
deletions (24.3kb and 15.5kb in size) encompassed gntT. While EcN contains 5 putative phage
regions [48] (Table 8.5), only one (11.5kb) was observed to be excised. 3 deletions (23.3kb, 25kb,
and 93kb in size) contained inverted repeat sequences, transposase, or integrase sequences. Copy
number variation analysis indicated that multiple isolates from the same mouse exhibited copy
number increases in two hypothetical proteins; a BLAST search revealed that these hypothetical
proteins align significantly to an integrase and an inovirus Gp2 family protein. Together, these
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results indicate that large deletions or duplications occur in the EcN genome at low but significant
rates during gut colonization, partially mediated by phage and transposon activity.
PKU treatment by engineered EcN
PAH-deficient PKU creates a blockage in the tyrosine synthetic pathway leading to Phe
accumulation in tissues, which can be neurotoxic and impair cognitive development. As a model
for an engineered probiotic therapy, we expressed PAL2 from Arabidopsis thaliana in EcN [49]
under the control of a weak, medium, or strong synthetic promoter [50](Anderson, 2006). The
rationale for using different promoters is the sexual dimorphism exhibited in the Pahenu2 mouse
model, where females show higher serum Phe than males [51]. These expression cassettes were
placed on a high copy plasmid and transformed into EcN. As expected, the weak promoter drove
slower Phe consumption in vitro than the medium or strong promoters (Figure 2.8a).
In vivo, male PKU mice treated with EcN expressing PAL2 with a strong promoter, and
female mice treated with strains harboring either the strong or weak promoter, saw significant
reductions in serum Phe concentrations 24 hours after probiotic gavage (Figure 2.8b, c). In male
mice, serum Phe levels were reduced to half of their baseline levels by the strongly-expressing
probiotic (Figure 2.8b). As expected, we observed differences in efficacy among male and female
mice (Figure 2.8c), and between the weak and strong promoters. No serum Phe reductions were
observed after 1 week. We recovered isolates containing the PAL gene from feces one week after
delivery, and did not observe any mutations to PAL2. Only 1/16 strains accrued genomic changes,
corresponding with an estimated mutation rate of 0.001 SNPs/genome/generation. The two SNPs
we observed in this strain were 1) a nonsynonymous mutation in the endoribonuclease ybeY and
2) a nonsense mutation in 4-alpha-glucanotransferase malQ. No other isolate sequenced during
this study had mutations in these genes. Given the low frequency of the recovered mutations, our
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data did not support the hypothesis that PAL2 expression confers a significant selective pressure
to EcN in the PKU gut.

A) Phenylalanine concentration over time
in minimal media supplemented with glucose and 10 μM Phe, and inoculated with EcN expressing PAL2
under promoters of indicated strength. Shown are the mean of three experimental replicates. Error bars
represent one standard deviation above and below the mean. * P < 0.01, Welch’s t-test with Bonferroni
correction for multiple comparisons. B-C) Paired serum Phe concentrations for male (B) and female (C)
homozygous mutant Pahenu2 mice before and 24 hours after gavage with WT EcN or EcN expressing PAL2
under a high (p18) or low (p08) strength promoter. Shown are means and standard deviations for three
replicate mice. *** P < 0.0001, ** P < 0.01; P-values were calculated using the generalized linear
hypothesis test with Bonferroni correction (glht function from the multcomp R package) on the coefficient
estimates from a linear mixed-effects model generated by regressing Phe concentrations on the
interaction of mouse gender, measurement timepoint (before or after treatment), and treatment (lme
function from the nlme R package). Random intercepts by mouse were specified in the model. The model
accounts for repeat measures variability.
Figure 2.8: In vitro and in vivo degradation of phenylalanine by EcN:PAL2.
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Discussion
Unlike conventional abiotic therapeutics, the performance characteristics of probiotics can
vary during treatment in response to natural selection. While probiotics have been broadly used in
humans for decades, engineering probiotics for therapeutic applications in humans will only be
acceptable if it is demonstrated that probiotics exhibit long-term safety. This study represents a
necessary first step towards this aim and takes advantage of strictly controlled mouse models. We
have demonstrated that in the context of low microbiome diversity, the greatest selective pressure
on EcN is carbon source limitation. In this context, we also observed consistent inactivation of
gluconate metabolism, and report evidence of a possible link between metabolism of gluconate
and GlcNAc. Our observation of mutations in stress response pathways in low-diversity guts
suggest that low gut diversity, known to be pathologic to the host [52], can also subject the present
bacteria to stress which might exacerbate genomic instability. We found the lowest evidence of
selection in a high diversity microbiome, but as a probiotic chassis for engineered therapies we
can expect future clinical use of EcN to occur in the context of dysbiosis. Future work should
therefore include a systematic assessment of probiotic efficacy and adverse effects in relationship
to personalized microbiome features prior to treatment. These results collectively indicate that EcN
defines its gut niche through metabolic competition, painting EcN as not an opportunistically
offensive player, but instead as a scavenger and survivalist.
In the context of engineered PAL activity in PKU mice, we achieved up to 50% reduction
in serum Phe levels, depending on strain design and the extent of hyperphenylalaninemia,
indicating the opportunity for personalized engineered probiotic therapies. We were unable to
observe significant changes to the genome or plasmids of our engineered probiotic over one week
of treatment, supporting EcN’s suitability as a chassis for engineered therapies. Coupled with
continued development of biocontainment approaches [53], we envision the experiments described
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herein as a general pipeline to be applied to other probiotic strains in development, in the context
of diverse healthy and dysbiotic microbiomes and other in vivo habitats to better understand their
safety and engineering potential. The major selective pressures operating on any engineered
probiotic may be substantially different than their WT counterparts and would warrant further
study of their in vivo evolutionary trajectories. As such, this work presents a generalizable
framework for developing and regulating living therapeutics.
Materials and Methods
Microbial Strains
E. coli Nissle was obtained as a kind gift from Dr. Phillip I. Tarr (Washington University
in St. Louis School of Medicine) and authenticated via whole-genome sequencing. Unless
otherwise indicated, EcN was grown in LB media under aerobic conditions at 37 °C. Agar was
added at a concentration of 15 g/L for growth on solid media. For maintenance of the pZE21
plasmid [54] and its derivatives, kanamycin was added to a final concentration of 50 µg/mL after
autoclaving.
Thirteen strains that were selected to mimic a healthy human microbiota composition were
obtained as a kind gift from Dr. Andrew Goodman (Yale University) (Table 8.4) and authenticated
via sequencing of the 16S region. Strains were cultured in TYG medium supplemented with D(+)-Cellobiose (0.1% w/v; Sigma), D-(+)-Maltose (0.1% w/v; Sigma), D-(-)-Fructose (0.1% w/v;
Sigma), Tween 80 (0.05% v/v; Sigma), Meat Extract (0.5% w/v; Sigma), ATCC Trace Mineral
Supplement (1% v/v), ATCC Vitamin Supplement (1% v/v), N-butyric acid (4mM), propionic
acid (8mM), isovaleric acid (1mM), and acetic acid (30mM) as in Goodman et. al. [55], referred
to as Mega Medium. Culturing occurred under anaerobic conditions in a soft-sided plastic
anaerobic chamber (Coy Laboratory Products). Stocks of strains were stored in E-Z crimp top vials
(Wheaton) at -80˚C in Mega Medium with 20% glycerol. Stocks were titered by plating on BHI
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blood agar plates. Strains were pooled immediately prior to gavage such that each member was
equally represented, and washed 3x in PBS. Eubacterium rectale and Ruminococcus torques
displayed poor recovery rates from freezer stocks, so overnight cultures at early stationary phase
were included in the final pool in lieu of stocks. Mice were gavaged with a total dose of 1x108
CFU in a volume of 200 µL.
Mice
All mouse experiments were approved by the Washington University in Saint Louis School
of Medicine Division of Comparative Medicine. E. coli Nissle monocolonization experiments
were performed in germ-free C57BL/6 mice (University of Michigan). Upon arrival, mice were
provided food and water ad libitum for one week prior to colonization. Mouse experiments were
not blinded. For the mouse chow experiment, mice were provided autoclaved feed (Purina
Conventional Mouse Diet (JL Rat/Mouse 6F Auto) #5K67) and autoclaved water. Human diet
consisted of Envigo TD.88137, irradiated and vacuum-sealed. Inulin or Dextrin (Sigma) was
provided in the drinking water at a concentration of 20 g/L, and autoclaved. 6 (for the mouse chow
experiment) or 5 (for the Human Diet experiment) co-housed male mice were exposed to 108
colony forming units of E. coli Nissle via oral gavage of 100 µL cell suspension in phosphate
buffered saline on day 1 of the experiment. Feces were collected at weekly intervals and
immediately frozen at -80 °C. At the end of the experiment, mice were sacrificed through carbon
dioxide asphyxiation and cecal contents were collected.
Experiments involving the 13-member synthetic microbiota were also performed in 3-5
week old germ-free C57BL/6 mice (University of Pennsylvania Gnotobiotic Mouse Facility).
Upon arrival, 3 germ-free mice (1-2 male, 1-2 female) per condition (monocolonized + human
diet, 13-member + human diet, 13-member + human diet + dextrin, 13-member + human diet +
inulin) were housed separately in germ-free isolators. Mice were acclimated to their diet for one
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week prior to colonization with the synthetic microbiota. The synthetic microbiota was allowed to
stabilize for one week prior to delivery of 108 colony forming units of E. coli Nissle via oral gavage
of 100 µL cell suspension in phosphate buffered saline on day 1 of the experiment. Fecal samples
were subsequently collected weekly for 5 weeks, and immediately frozen at -80 °C. At the end of
the experiment, mice were sacrificed through carbon dioxide asphyxiation and cecal contents were
collected.
Experiments involving the conventional mouse microbiota were performed in a specificpathogen-free facility with mice 3-5 weeks of age. 2 cages of 5 mice (Jackson Labs C57BL/6J
(RRID:IMSR_JAX:000664)) for each condition were maintained on the Human Diet with or
without prebiotic for one week after arrival. After one week, mice were deprived of food and water
for 4h, and given either 20mg streptomycin in 100 µL water, or 100 µL water alone via oral gavage.
After this treatment, food and water was immediately returned. Daily over the next three days, 108
CFU of EcN was delivered in 100 µL PBS via oral gavage. Fecal samples and intestinal contents
were collected as above.
Experiments involving PKU mice (C57BL/6 mice homozygous for the Pahenu2 mutation)
were performed in a specific-pathogen-free mouse facility. For each condition (High PAL
expression, Low PAL expression, or No PAL expression), 3 Male and 3 Female PKU mice (1012 weeks of age, Washington University in St. Louis) were co-housed by gender and condition
and maintained on Phe-containing mouse chow (18 mice total from 5 different litters). 100 µL
blood was sampled from the femoral artery one week before the experiment to serve as a baseline
for each mouse. Then, 109 CFU of the appropriate EcN strain was delivered via oral gavage. One
day after gavage, 100 µL blood was again sampled from the femoral artery. Fecal samples were
collected 1 week after gavage. After collection, all blood samples were allowed to coagulate then
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centrifuged in BD Microtainer ® SST ™ tubes for 2 minutes at 10,000g to collect serum. Serum
samples were then passed through 10 kDA molecular weight cut-off filters by centrifugation. Phe
levels of the filtrates were determined using a Phenylalanine Assay Kit (MAK005, SigmaAldrich).
For assessment of in vivo plasmid loss, 10 male C57BL/6J (RRID:IMSR_JAX:000664)
mice 3-5 weeks of age housed in two separate cages were deprived of food and water for 4h and
given 20 mg streptomycin in 100 μL water as above. Daily over the next three days, 108 CFU of
EcN containing the pZE21 vector was delivered in 100 μL PBS via oral gavage. Fecal pellets were
collected on the final day of gavage and weekly for 5 weeks. Pellets were weighed and then
homogenized in 300 μL PBS on a bench-top vortexer. Dilutions were plated in parallel on
MacConkey agar and LB agar with 50 ug/mL kanamycin and incubated overnight at 37 C, with
the prior selecting for aerobic lactose fermenters and the latter selecting for EcN containing the
pZE21 vector. CFUs/mg feces were estimated for each sample after colony enumeration. The
colonies enumerated on the MacConkey agar plates were confirmed to be EcN by colony PCR of
the chromosomally integrated GFP locus. A LOESS regression was applied to the longitudinal
data for each selective agar.
Cell lines
Caco-2 or HT29-MTX cells were seeded overnight in a 24-well plate at 50,000 cells/cm2
in DMEM-HEPES media supplemented with Glutamax (10564-011, ThermoFisher) and 10%
Fetal Bovine Serum. They were incubated at 37 °C, 5.0% CO2 and 90% relative humidity. Caco2 cells (ATCC HTB-37) were derived from a human male, and HT29-MTX cells (Sigma Aldrich
12040401) were derived from a human female. The cell lines were authenticated by the
commercial vendors.
Plasmids used in this study
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All plasmids used in this study were constructed using a Golden Gate Assembly Mastermix
from NEB, according to the manufacturer’s instructions. Plasmid pSPAL2At containing the PAL2
enzyme was obtained from Addgene (cat #78286), as a kind gift from David Nielsen [49].
Metagenomic library construction
Metagenomic libraries were sourced from a prior study examining the antibiotic resistome
of the healthy maternal and infant microbiomes [24]. Frozen glycerol stocks containing these
libraries were thawed on ice, and plasmid DNA was extracted using a Qiagen Spin Miniprep kit.
100 ng of DNA was transformed into electrocompetent E. coli Nissle, and allowed to recover in
SOC media for 1h at 37 °C. After 1h, 1 µL of SOC media was plated on LB+kan, to count
transformants, and the remainder was placed in 50mL LB media containing kanamycin at room
temperature overnight. After overnight growth, the library was centrifuged at 4000 rpm for 7 m,
resuspended in 10mL LB+15% w/v glycerol, and frozen in 1mL aliquots at -80 °C. After freezing,
one aliquot was thawed on ice, and serial dilutions were plated on LB+kan media to count viable
cells. This procedure yielded a library containing 32.77 Gb of metagenomic DNA.
Functional metagenomic library sequencing
DNA was extracted from fecal samples and intestinal contents using the PowerSoil DNA
extraction kit (MoBio/Qiagen). 10 ng of this DNA was used as a template for a multiplex PCR
with primers 1-6 (Table 8.6) at equimolar concentrations using Taq Reddymix (Fisher Scientific).
PCR recipe per sample was as follows: 12.5 µL Taq Reddymix, 3 µL primer mix (10 µM total
concentration), 10 ng template, nuclease free water to 25 µL. PCR protocol was as follows: 94 °C
for 10 m, 94 °C for 45 s, 55 °C for 45 s, 72 °C for 5.5 m, go to step 2 24 times, 72 °C for 10 m, 4
°C forever. PCR products were purified using a Qiagen Spin PCR Purification Kit. 500 ng PCR
products in 200 µL elution buffer (from purification kit) were then placed in an AB1900 halfskirted plate (Fisher Scientific) and sonicated using a Covaris E220 sonicator. The settings on the
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sonicator were as follows: Peak Incident Power: 140, Duty Cycle: 10%, Cycles per Burst: 200,
Treatment Time: 600 s, Temp: 7 °C. Sonicated products were cleaned using a Qiagen MinElute
PCR purification kit according to the manufacturer’s instructions, and eluted in 22 µL elution
buffer. 20 µL sonicated products were end-repaired through addition of 2.5 µL DNA ligase buffer
with 10 mM ATP (NEB), 1 µL 1 mM dNTP, 0.5 µL T4 Polymerase (NEB), 0.5 µL T4 PNK (NEB),
and 0.5 µL Taq Polymerase (NEB), and incubating for 30 m at 25 °C, followed by 20 m at 75 °C.
Then, 0.8 µL T4 DNA ligase (NEB) and 5 µL pre-annealed sequencing barcodes were added to
the full end-repair reaction, followed by 40 m at 16 °C, and 10 m at 65 °C.
Sequencing barcodes were designed according to the template described in Primers 7-8
(Table 8.6), and synthesized by IDT in 2 96-well plates to a concentration of 500 µM. Each barcode
was designed to be at least 2 mismatches away from every other barcode. 2 µL of each primer pair
were added to 96 µL of TES buffer (10mM Tris, 1mM EDTA, 50mM NaCl, pH 8.0), and this
mixture was diluted 1:10 in TES buffer, to a final concentration of 1 µM. Adapters were annealed
by incubating at 95 °C for 1 m, followed by slowly cooling (0.1 °C per second) to 4 °C. Annealed
oligos were kept cold and transferred to a -20 °C freezer until use. Next, ligation products were
size-selected to 300-400bp in size through gel electrophoresis. Briefly, the total ligation volume
was loaded on a 2% (w/v) agarose gel in 0.5x TBE buffer using thin combs. This gel was run at
120V for 2h, or until the loading dye front reached ~2/3 of the way to the end of the gel. DNA
fragments between 300 and 400bp were excised, and purified using the Qiagen MinElute Gel
Extraction Kit, eluting in 15 µL elution buffer.
Sequencing adaptors were then added to the size-selected ligation products through PCR.
PCR recipe was as follows: 12.5 µL Phusion HF Mastermix (ThermoFisher), 9.5 µL nuclease-free
water, 1 µL 10 µM primer mix (Primers 9-10) and 2 µL gel-purified DNA. PCR conditions were
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as follows: 98 °C for 30 s, 98 °C for 10 s, 65 °C for 30 s, 72 °C for 30 s, return to step 2 17 times,
72 °C for 5 min, 4 °C forever. PCR products were then size-selected on a 2% agarose, 0.5x TBE
gel as above. Sequencing libraries were quantified on a Qubit fluorimeter, and pooled at equimolar
concentrations for sequencing. 100,000 2x150 paired-end sequencing reads were obtained per
sample.
Functional metagenomic sequencing analysis
Functional metagenomic contigs were assembled from sequencing reads and annotated
using PARFuMS [56, 57]. For each experiment, contigs were clustered at 95% nucleotide identity
using CD-HIT [58]. Then, vector-trimmed sequencing reads (from PARFuMS) were uniquely
mapped to each contig using bowtie2 [59], and mapping reads were counted using SAMtools [60].
Contig abundance was estimated as the fraction of reads mapping to each contig. To perform Gene
Ontology mapping, open reading frames (from PARFuMS) were mapped against all nonredundant
protein sequences using BLASTp [61], and annotated using InterProScan [62]. Outputs of these
two operations were then used as input to Blast2GO, according to manufacturer’s instructions.
Each contig was associated with a GO annotation if at least one of its constituent open reading
frames was. The abundance of each GO annotation was then estimated as the sum of contig
abundances associated with that GO annotation. Heatmaps of GO annotations were plotted using
the heatmaply package in R.
16S rRNA sequencing and analysis
We performed sequencing of the V4 variable region of the 16S rRNA gene on 7
longitudinal fecal samples from each of 17 mice (102 samples total). We used 515F/806R PCR
primers including Illumina flowcell adapter sequences to amplify the V4 region using the Earth
Microbiome Protocols [63] (described in more detail here: http://www.earthmicrobiome.org/ empstandard-protocols/16s/).
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The following 25 µL reaction was prepared in 96-well plates: 10 µL H20, 12.5 µL Taq
Hot-Start DNA Polymerase (Takara R028A), 1 µL forward primer (10 uM), 1 µL reverse primer
(10 uM), 0.5 µL template DNA (1 ng/uL). PCR cycle temperatures were as follows: 98 C for 30
s, then 35 cycles of [98 C for 10 s, 50 C for 30 s, 72 C for 30 s], then 72 C for 2 min. PCR reactions
were carried out in triplicate for each reaction. In addition, a template-less control reaction was
carried out for each primer pair. PCR products were assessed via gel electrophoresis to verify the
amplicon size and absence of contamination, then were quantified using the PicoGreen kit
(Invitrogen P11496), following the manufacturer’s protocols. 16S rRNA gene amplicons were
sequenced by 2x250 bp paired-end sequencing on the Illumina MiSeq platform using custom
primers (read 1: 5′-TAT GGT AAT TGT GTG CCA GCM GCC GCG GTA A-3′; read 2: 5′-AGT
CAG TCA GCC GGA CTA CHV GGG TWT CTA AT-3′; and index: 5′-ATT AGA WAC CCB
DGT AGT CCG GCT GAC TGA CT-3′) at a loading concentration of 8pM with 25% PhiX spikein.
OTUs were generated using USEARCH7 [64]. Reads were demultiplexed by sample and
read pairs merged (usearch -fastq_mergepairs -fastq_maxdiffs 0 -fastq_truncqual 3 fastq_maxmergelen 258 -fastq_minmergelen 248). Merged reads were quality filtered (usearch fastq_filter -fastq_maxee 0.5), dereplicated (usearch -derep_fulllength -sizeout), sorted and
singletons removed (usearch –sortbysize –minsize 2), clustered (usearch –cluster_otus), and
checked for chimeric sequences using the Gold database (usearch –uchime_ref –db gold.fa –
strandplus –nonchimeras). OTUs were renamed (uparse/fasta_number.py), reads were mapped
back to OTUs at 97% identity (usearch –usearch_global –strand both –id 0.97), and converted to
the final OTU table (uparse/uc2otutab.py). Taxonomy was assigned using the QIIME 1.9.0 [65]
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pipeline with the GreenGenes database. The OTU table was subsampled to 10,000 reads per
sample (single_rarefaction.py).
Isolate sequencing
To isolate in vivo-adapted EcN isolates, intestinal contents or fecal samples were vortexed
in phosphate-buffered saline and streaked on LB plates containing kanamycin. Single colonies
were placed in liquid media and grown at 37 °C overnight. Un-adapted EcN strains were also
grown overnight. Total DNA was extracted from each culture using the DNeasy UltraClean 96
Microbial kit (10196-4, Qiagen), and prepared for whole-genome sequencing using Nextera
Tagmentation [66]. Briefly, gDNA was brought to a concentration of 0.5 ng/µL in 1 µL volume.
To each sample, 1.25 µL TD buffer, 0.125 µL TDE1 enzyme, and 0.125 µL nuclease-free water
was added, and incubated at 55 °C for 15 m. Then, 11.2 µL KAPA HiFi master mix was added to
each tagmented sample. Indexed sequencing adaptors (5 µM each) were thawed, and 8.8 µL was
added to each sample. Then, PCR was performed using the following protocol: 72 °C for 3 m, 98
°C for 5 m, 98 °C for 10 s, 63 °C for 30 s, 72 °C for 30s, return to step 2 13 times, 72 °C for 5 m,
4 °C forever. PCR reactions were purified using AMPure XP beads according to the
manufacturer’s protocol, and eluted in 60 µL resuspension buffer. Sequencing libraries were
quantified using the Quant-iT PicoGreen dsDNA Assay Kit (Fisher Scientific), and pooled at
equimolar concentrations for sequencing. 2 million 2x150bp sequencing reads were obtained per
sample.
MinION sequencing
Genomic DNA from 30 mL of overnight culture of control EcN was extracted using a
Genomic DNA Buffer Set (19060, Qiagen) with the Qiagen protocol for Gram-negative bacteria
(Qiagen Genomic DNA Handbook 06/2015) and the Genomic-tip 500/G (10262, Qiagen). Purified
genomic DNA was sheared to a target fragment size of 10 kilobases using the Covaris g-TUBE™.
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All following steps were carried out in Eppendorf DNA LoBind tubes. Sheared DNA was repaired
using the NEBNext FFPE Repair Mix (M6630), and repaired DNA purified from the reaction
using Agencourt AMPure XP beads. DNA was then end-repaired and dA-tailed using the
NEBNext End repair / dA-tailing Module (E7546) and again purified with AMPure XP beads.
DNA was then prepared for MinION sequencing using the MinION Ligation Sequencing Kit 1D
(SQK-LSK108). Briefly, adapters were ligated to the DNA using the MinION Adapter Mix
(AMX1D) and NEB Blunt/TA Ligase Master Mix (M0367). Then the DNA product was purified
using AMPure XP beads and the Minion Adapter Bead Binding Buffer (ABB). 350 ng of DNA
product was then sequenced on a MinION R9.4 flow cell for 48 hours using the Running Buffer
with Fuel Mix (RBF) and the Library Loading Bead Kit (EXP-LLB001). Average read lengths
were 7 kilobases and the genome was sequenced with an average coverage of 50 reads.
Isolate sequencing data analysis
Illumina sequencing reads were quality-filtered and adaptor-trimmed using Trimmomatic
[67]. Isolate genomes were assembled with Illumina data using SPAdes [68]. The control EcN
genome (which had both Illumina and MinION data) was assembled using SPAdes in hybrid mode.
Illumina reads were mapped to the assembled genome using bowtie2 and MinION reads were
mapped using LAST [69]. Mapping results were converted to indexed, sorted bam files using
SAMtools and visualized using IGV [70]. The control EcN genome was then corrected manually
by inspecting read alignments for dips in coverage, and correcting these regions using MinION
data as well as homology to a published EcN genome [71] using an iterative process. After each
iteration, Illumina and MinION reads were re-mapped to the corrected genome, and read
alignments were inspected to verify an improved assembly. Coding sequences were annotated
using Prokka [72]. One region of spurious assembly was due to imperfect tandem repeats present
in the UpaH gene; this region was resolved by PCR amplification from the genome followed by
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Sanger sequencing. The result of this finishing process became the control genome to which all in
vivo-adapted isolates were compared.
Mutation Calling
Single-nucleotide polymorphisms and indels were annotated using two complementary
approaches. The first method was Breseq, using default parameters [73]. The second method was
VarScan2, where SNPs and indels were called if supported by a minimum read coverage of 30 and
80% abundance in those reads [74]. VarScan2 variant call format output was then annotated with
ANNOVAR [75]. Mutations called by each method were manually verified through visualization
of Illumina read alignments using IGV. Anecdotally, both methods did recover some false positive
mutation calls, primarily due to the presence of a homologous metagenomic DNA insert causing
spurious read alignments to the EcN genome. Phage sequences were identified using the Phaster
web server [48]. To look for potential plasmid sequences, assembled contigs for each isolate were
aligned to 1) all nonredundant nucleotide sequences, and 2) the control EcN genome using
BLASTn. Our criteria for plasmid sequences was the following: >500bp in length, <90% of bases
mapping to the EcN genome, no homology to the functional metagenomic insert present in the
strain (if any), and no obvious genomic contamination from other species. No contig satisfied these
criteria, and therefore we concluded that no acquired plasmid sequences were obviously present
in our in vivo adapted strains.
Annotation
To perform Gene Ontology mapping, mutated open reading frames were mapped against
all nonredundant protein sequences using BLASTp, and annotated using InterProScan. Outputs of
these two operations were then used as input to Blast2GO, according to manufacturer’s
instructions. The abundance of each GO annotation was then estimated as the number of open
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mutated open reading frames with that annotation among the strains within a certain condition.
Heatmaps of GO annotations were plotted using the heatmaply package in R.
Copy Number Variation
Copy number variation was assessed using the CNVkit pipeline [76]. Briefly, short reads
for each isolate were mapped to an indexed reference assembly using bowtie2 with the --verysenstitive-local option to generate SAM files. SAM files were then converted to sorted BAM files
using Samtools. Coverage was calculated in bins using the CNVkit coverage function and
compared to the coverage of the reference strain using the CNVkit reference function with the -no-edge option. Biases were adjusted using the CNVkit fix and segment functions. CNV hits were
called if the bias-adjusted log2 copy ratio was greater than 1.3 or less than -1.3.
Growth assays on functional metagenomic hits
Three biological replicates of EcN containing the appropriate plasmid were grown
overnight in LB media containing kanamycin at 37 °C under anaerobic conditions. These were the
overnight culture conditions for all growth assays unless otherwise indicated. The cell densities of
these overnight cultures were measured, and EcN was transferred to M9 MOPS minimal media
containing the carbon source of interest at a starting optical density of 0.01 in a 96-well plate.
BIOLOG plates were prepared with M9-MOPS minimal media [77] per the manufacturer’s
recommendations. A Breathe-Easy Sealing Membrane (Sigma) was placed over the plate. This
plate was placed in a plate reader set to maintain 37 °C and read absorbance at 600 nm every
minute for 72h.
To test the acid tolerance of EcN strain MD04, overnight cultures of MD04 and WT EcN
harboring the empty pzE21 plasmid were subcultured in LB broth pH 7.0 to an OD600 of
approximately 0.4, then were washed with PBS and resuspended in either LB pH 7.0 or LB pH 2.5
(adjusted with HCl). The cultures were incubated at 37 °C for 30 minutes, then were washed again
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and resuspended in LB pH 7.0 and grown for 15 hours at 37 °C in a plate reader with optical
density measured at 20-minute intervals.
To test whether EcN expressing glycosyl-hydrolase encoding fragments from the
functional metagenomic selection can support growth of WT EcN, overnight cultures of EcN
strains MD01, MD02, or WT EcN carrying empty pZE21 vector were subcultured in LB to an
OD600 of 0.5, then washed three times with PBS and resuspended in 1% raffinose minimal M9MOPS media. The cultures were incubated at 37 °C for 3 hours, then centrifuged at 6000g for 5
minutes. The supernatants were filter-sterilized using 0.2 μm filters. These pre-conditioned media,
as well as unconditioned 1% raffinose minimal M9 media were inoculated with WT EcN and
grown for 15 hours at 37 °C with optical density measured at 20-minute intervals.
To assess the ability of HD15 inserts to grow on mucin or GlcNAc, overnight cultures were
normalized to an optical density of 0.1 in 1.5% porcine gastric mucin M9-MOPs minimal media
or 20 mM GlcNAc M9-MOPs minimal media and incubated in a plate reader at 37 °C for 20 hours
with optical density measured at 20 minute intervals. The assay in porcine gastric mucin M9MOPs minimal media was repeated on separate days.
Growth assays on mutant isolates
nagC mutants were grown in standard or diauxic growth experiments. As before, overnight
cultures were normalized to an optical density of 0.1 in 0.4% glucose, 0.4% GlcNAc, or 0.2%
glucose / 0.2% GlcNAc M9-MOPS minimal media. Alternatively, overnight cultures were
transferred to 0.2% glucose / 0.75% porcine gastric mucin M9-MOPS minimal media. The plates
were set in a plate reader at 37 °C for 20 hours with optical density measured at 20 minute intervals.
Two representative gntT mutants were grown on 0.4% gluconate, 0.4% GlcNAc, or 1.5% porcine
gastric mucin M9-MOPS minimal media. Overnight cultures were normalized in M9-MOPS
minimal media supplemented with either of the three carbon sources at a starting optical density
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of 0.1 in a 96-well plate as before and incubated in a plate reader at 37 °C for 24 hours with optical
density measured at 20-minute intervals.
For the gluconate sensitivity assays overnight cultures of the same gntT mutants were
normalized as before in 20 mM glucose or 20 mM GlcNAc M9-MOPS minimal media
supplemented with either 0.5, 1, 2, 4, or 8 mM gluconate and incubated in a plate reader at 37 °C
for 20 hours with optical density measured at 20-minute intervals.
Epithelial cell binding assay
Overnight cultures of representative kfiB mutants or WT EcN were incubated in LB at 37
°C. The next day, wells with Caco-2 or HT29-MTX cells were inoculated with mutant or WT EcN
that had been washed and resuspended in PBS. The multiplicity of infection was 1:100. The human
and bacterial cells were co-incubated 37 °C, 5.0% CO2 and 90% relative humidity for 3 hours.
Media was aspirated from each well. Three replicate wells for each strain were gently washed 3x
with PBS, while three replicate wells for each strain were left untreated. All wells were then treated
with 100 µL of 1% Triton-X for 10 minutes at room temperature to lyse the human cells. 900 µL
LB was added to each well and the cells resuspended by pipetting. These cultures were diluted and
plated on LB agar plates and incubated overnight at 37 °C. The next day CFUs were enumerated,
and the percentage of adherent cells was calculated as the mean ratio of CFUs/mL from the washed
and unwashed wells for each strain.
In vitro phenylalanine degradation assay
EcN strains expressing PAL2 in the pZE21 plasmid under promoters of low (p08), medium
(p01), or high (p19) strength, or harboring only empty vector, were grown overnight in LB at 37
°C. The next day absorbance at 600nm of these cultures were measured and the strains were
transferred to M9 minimal media supplemented with 0.4% glucose and 20 µM L-phenylalanine
with a starting optical density of 1.0. Fractions of these cultures were removed at 0, 30, 60, and 90
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minutes and immediately centrifuged. Supernatants were passaged through 10 kDa molecular
weight cut-off filters and the phenylalanine in the filtrates was measured using a Phenylalanine
Assay Kit (MAK005, Sigma-Aldrich). Phenylalanine levels were reported as average absolute
nanomoles of phenylalanine per well. Three technical replicates were carried out for each strain.
Gene phylogenies and enrichment testing
We searched for genes with variants significantly enriched in specific diet conditions or in
specific microbiome complexities using the hypergeometric test for enrichment and Bonferroni
correction for multiple hypothesis testing. The significant genes included gntT, nagC, sgrR, rsmG,
and kfiB. Gene phylogenies were created for these genes by aligning the gene sequence for all
isolates involved in the comparison in which the gene variants were found enriched in a condition
(that is, all isolates along the axis of different diets, or the axis of microbiome complexity).
Alignments were generated using Clustal Omega. Maximum parsimony phylogenies for each gene
were generated using the Dnapars program included in PHYLIP 3.695 [78], and visualized using
iTOL [79].
E. coli phylogeny construction
Representative E. coli genomes were downloaded from NCBI. PROKKA was used to
generate general feature format (gff) files for each E. coli genome, including our assembled
reference EcN genome [72]. Roary was used to generate a core gene alignment, using these gff
files and the corresponding genome sequences [80]. The strain phylogeny was inferred with
RaxML using the GTRGAMMA model and 1000 bootstraps [81]. The best tree was visualized
using iTOL.
Analysis of selection
sgrR was analyzed for evidence of positive or negative selection. The previously generated
gene alignment and phylogeny were provided as input to the aBSREL, MEME, and FUBAR
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modules included in the HyPhy application hosted by the Datamonkey webserver [82]. Neither of
the three modules reported evidence of selection.
Quantification and statistical analysis
All of the statistical details of experiments, including significance criteria, sample size,
definition of center, and dispersion measures can be found in the figure legends and in the Results
section. For all in vitro experiments involving synthetic DNA, n refers to the number of biological
replicates of each strain (i.e. separate colonies) assayed per condition. For all in vitro experiments
involving in vivo-adapted probiotic isolates, n refers to the number of technical replicates of each
strain (i.e. same master stock). For mouse experiments, n refers to the number of mice in each
group. All significance values were Bonferroni or FDR (Benjamini-Hochberg)-corrected as
described. No sample size calculations were performed during the design of experiments. No
samples were excluded. No blinding was performed.
Data and software availability
The raw reads for functional metagenomic selections have been deposited in NCBI under
ID code PRJNA51754. Assembled contigs for functional metagenomic selections have been
deposited in DDBJ/ENA/GenBank under the accession SHCT00000000. The version described in
this paper is version SHCT01000000. The raw reads for all EcN isolates have been deposited in
NCBI under ID code PRJNA517347. The assembled wild-type EcN genome has been deposited
in NCBI under ID codes CP035486-CP035489. 16S rRNA sequencing for experiments involving
the 13-member community have been deposited in NCBI under ID PRJNA517716. Other
supplementary materials and data available from Crook et al. [83].
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Chapter 3 : Transcript barcoding illuminates the expression level of
synthetic constructs in E. coli Nissle residing in the mammalian gut.

Abstract
The development of robust engineered probiotic therapies demands accurate knowledge of
genetic construct expression in the gut. However, the monetary and ethical costs of testing
engineered strains in vertebrate hosts are incompatible with current high-throughput design-buildtest cycles. To enable parallel measurement of multiple construct designs, we placed unique DNA
barcodes in engineered transcripts and measured barcode abundances via sequencing. In standard
curve experiments the barcode sequences exhibited consistent relationships between input and
measured abundances, which allowed us to use transcript barcoding to measure expression levels
of 30 GFP-expressing strains of E. coli Nissle in parallel. Applying this technology in culture and
in the mouse gut, we found GFP expression in the gut could often be predicted from expression
levels in culture, but several strains exhibited gut-specific expression. This work establishes the
experimental design parameters and advantages of transcript barcoding to measure the
performance of many engineered probiotic designs in mammalian hosts.
Introduction
As the primary site of nutrient absorption, and a key modulator of host immunity, the gut
plays a critical role in human health [1]. Central to this role are the trillions of microbes which
inhabit the intestinal lumen, termed the gut microbiota [2]. In return for privileged access to unused
dietary material, the microbiota performs a variety of useful functions, including producing energy
molecules and vitamins, competitively excluding pathogens, and immune signaling [3, 4]. As a
consequence, certain taxonomic and/or genetic compositions of the microbiota are associated with,
and can often cause, disease states in humans, including obesity [5], inflammation [6],
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susceptibility to infection [7], diabetes [8], and neurological disorders [9]. With these outcomes in
mind, there has been a ballooning interest in altering the ecology and biochemistry of the gut for
therapeutic purposes via small drug molecules [10], fecal microbiota transplants [11], prebiotics
[12], and probiotics [13].
Probiotics are defined as live microorganisms that, when administered in adequate
amounts, confer a health benefit. Probiotic microbes include lactic acid bacteria, Escherichia coli
Nissle, and the yeast Saccharomyces boulardii. While the mechanisms by which probiotics confer
health benefits differ [14], probiotics share the property that they are generally recognized as safe
for human consumption. Coupled with the genetic tractability of many probiotic strains, probiotics
have recently been recognized as privileged chassis for genetic engineering to alter the
biochemistry of the gut. These next-generation probiotics promise to augment or repair gut
function via engineered behaviors including disease detection [15], biomolecule synthesis [16],
toxin degradation [17], or programmed cell death [18]. Probiotics are very interesting from a drug
delivery perspective due to their massive scalability of manufacture, ease of distribution, and
ability to bypass digestive enzymes and deliver their genetic payloads in a site-specific manner.
Furthermore, probiotics often achieve high patient compliance [19] and do not permanently
colonize [20], enabling control over drug dosage.
The gut environment, however, imposes barriers in the design of engineered bacterial
therapeutics. These include the substantial differences and variability in levels of nutrients, interspecies competition, and immune pressure in the gut compared to more controlled environments
like the shake flask or bioreactor. As microbes are known to alter their physiology and metabolic
activity in response to changing environmental conditions [21] we hypothesized that the behavior
of engineered probiotics, in particular the transcript abundance of engineered constructs, would be
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different in the gut than in axenic culture. Further, the expression of synthetic constructs driven by
native promoters may be different than the expression of the corresponding native genes due to
differences in genomic context or copy number. Precise tuning of gene expression and thus protein
concentrations is critical to the efficacy of engineered microbial activity [22]. Taken together, this
rationale motivated us to measure the expression of synthetic constructs in gut-resident probiotics.
Libraries of synthetic constructs typically comprise different expression levels,
organization, or copy numbers of one or several genes. The high similarity of expressed sequences
between strains precludes pooled expression analysis via RNA-seq. Instead, transcript levels of
cloned genes are typically measured by growing multiple replicate cultures per construct, followed
by RNA extraction and qPCR. However, for experiments involving many genes, or difficult-tomultiplex culture conditions, this approach becomes problematic. The gut is a good example of
these limitations because, like in other applications of engineered strains, many strains must often
be tested in order to find the optimal design. However, modelling the gut often requires complex
in vitro setups [23] or vertebrate animal models, which are expensive and sometimes unethical to
scale to match testing demand. For example, reporter proteins (such as LacZ or anaerobic
fluorescent proteins) require a separate experimental group per construct tested. New methods are
therefore required to measure the performance of many engineered microbes in non-culture
habitats. In response to the challenge of testing many constructs, transcript barcoding has been
used to measure the expression of multiple constructs in the same culture [24-26]. These
approaches are high throughput and exhibit high precision [24]. However, to our knowledge these
approaches have not been used to test gene expression of synthetic constructs in probiotics residing
in the gut, and the accuracy of these approaches, as measured using synthetic barcode mixtures of
known abundance, has not been tested.
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Here we characterize the precision and accuracy of the transcript barcoding approach using
synthetic barcode mixtures. We then use this technique to measure in parallel the expression
activity of a model 30-member promoter library in the commonly-used probiotic E. coli Nissle
(EcN), with barcoded GFP as the carrier transcript. These activities were compared between
traditional culture conditions and different sites in the mouse gastrointestinal tract. These
experiments illuminated gene expression variability between individuals and different gut sites
and establish a platform for future studies seeking to measure the expression of cloned genes in
the mammalian gut.
Results
Environmental context alters the EcN transcriptome
The gut is known to support varying rates of microbial growth [38] and a radial gradient in
oxygen levels [39]. To determine how the transcriptome of EcN is modulated by different growth
states or oxygen levels, EcN was grown in LB media under aerobic or anaerobic conditions, and
RNA-seq was performed on RNA extracted from cultures growing under exponential growth or
stationary conditions. Principal Component Analysis of expressed genes revealed substantial
clustering by condition (Figure 7.8a, b), confirming that gut-relevant conditions indeed cause gene
expression changes in EcN. RNA-seq also illuminated the expressed regions of EcN’s endogenous
plasmids pMut1 and pMut2, whose functions are currently unknown (Figure 7.8c). Based on this
analysis, and the known dependence of cloned gene activity on environmental context in other
organisms [40], we hypothesized that cloned genes might also exhibit altered expression in EcN
depending on the environment. Moreover, we hypothesized that the expression of cloned genes
driven by native promoters might not be predictable based on transcriptomic data of native genes,
due to differing genomic context and dilution of transcription factors.
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Barcodes enable accurate measurements of nucleic acid abundance in pooled samples
Due to the high cost of measuring the expression of cloned genes via qPCR in mice, we
pursued a transcript barcoding approach [24-26]. An overview of the barcoding and analysis
approaches we pursued is shown in Figure 3.1. Because PCR would be necessary to add sequencing
adaptors and prepare enough DNA for sequencing, we were concerned that each barcode sequence
might exhibit a different detection frequency, thus skewing our results. To minimize these issues,
we adopted two strategies. First, our barcodes were chosen to exhibit a GC content between 40%
and 60%. Second, during PCR we appended unique molecular identifiers via one of two strategies.
Our first approach, the 2-UMI method, employed a 3-cycle PCR with forward and reverse primers
containing 19bp degenerate regions, followed by additional cycles with non-degenerate primers to
append sequencing adaptors and increase the concentration of the desired product. Our second,
approach, the 1-UMI method, employed a single primer extension reaction with a primer
containing a 16bp degenerate region, followed by additional cycles with non-degenerate primers
to append sequencing adaptors and increase the concentration of the desired product. Specific
experimental details are provided in the Materials and Methods.
To measure the precision and accuracy of these methods, we constructed a set of 30
synthetically barcoded GFP genes, each with a unique 7 bp barcode at the 3’ end of the gene,
directly after the stop codon. We chose to place barcodes at the 3’ end, rather than the 5’ end, of
GFP to minimize potential changes in gene expression. These barcoded sequences were purified
and mixed in equal ratios, followed by processing in triplicate using either the 1-UMI or 2-UMI
method. We found that the observed abundances of UMIs exhibited a consistent, barcode-specific
bias, such that certain promoters in independently-prepared samples were consistently under- or
over-represented across the synthetic mixtures we prepared. The extent of this bias was higher in
magnitude (0.24-2.3-fold from expected abundance) for the 2-UMI method than for the 1-UMI
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method (0.7-1.3-fold from expected abundance) (Figure 3.2a). Correcting for this bias revealed a
tight correlation between input sequence abundance and abundance inferred by sequencing in
samples that were not used for the bias calculation (2-UMI method: r2 = 0.9716, p = 2.7 x 10-113,
1-UMI method: r2 = 0.9560, p = 1.9 x 10-88) (Figure 3.2b, c).

Figure 3.1: Overview of the transcript barcoding approach. Each promoter of interest was used to drive GFP, which

was barcoded at its 3’ end. Strains harboring each expression construct were then mixed and delivered to
the appropriate growth context (mice or culture). After, DNA and RNA were extracted, cDNA was
synthesized from RNA, and one of two approaches were followed to prepare promoter-specific barcodes
for sequencing. In the 2-UMI method (left), barcode-containing sequences were subjected to 3 cycles of
PCR with two primers, each containing a different unique molecular identifier (UMI). This 3-cycle PCR was
followed by a PCR reaction to add Illumina sequencing adaptors. In the 1-UMI method (right), barcodecontaining sequences were subjected to a single primer extension reaction, using a single primer
containing a UMI. This reaction was also followed by a PCR reaction to add Illumina sequencing adaptors.
The output of both methods was then sequenced, and the number of UMIs identified per promoter
barcode in both the cDNA and DNA fractions were counted. The ratio of UMIs/barcode between cDNA
and DNA fractions is proportional to promoter strength.
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A) Relative amounts detected of UMIs
incorporated in an equimolar mixture. Error bars indicate the standard deviation observed among three
independent experiments. B) Relationship between input barcode abundance and measured barcode
abundance after sequencing and bias correction for the 2-UMI method. C) Relationship between input
barcode abundance and measured barcode abundance after sequencing and bias correction for the 1UMI method. A different synthetic barcode mixture, which samples the “input abundance” range more
densely, was prepared to test the 1-UMI method. Related to Figure 7.8, Figure 7.9, and Figure 7.10.
Figure 3.2: UMI incorporation exhibits reproducible, sequence-specific bias.

Barcoding reveals DNA-normalized mRNA levels in culture-grown EcN
To test the efficacy of the barcoding approach, we curated a library of 30 promoters. 20 of
these promoters were taken from a previously-published constitutive promoter library, which
spanned over a 100-fold range of gene expression [41], while the remaining 10 were taken from
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the EcN genome. These 10 promoters were chosen based on a recent gut metatranscriptome dataset
obtained from the fecal matter of healthy individuals [42]. This report detailed the abundance of
transcripts mapping to genes from a variety of taxa. Of these, we chose the 10 E. coli genes
exhibiting the lowest subject-to-subject variation, while spanning a wide range of RNA abundance
(over 2000-fold) for cloning. This 30-member library was used to drive GFP expression in EcN,
and the resulting per-cell fluorescence values were measured by flow cytometry (Figure 3.3a). p19
was the strongest, the acnA promoter was the weakest, and the native promoters tended to be
weaker than the synthetic promoters. We observed a fairly strong (r2 = 0.61) correlation between
the reported strengths of the synthetic promoter library, and the strengths we measured in EcN
(Figure 7.9a). Interestingly, we observed no (r2 = 0.0029) correlation between RNA levels in the
gut metatranscriptome and protein levels for the native promoters in culture (Figure 7.9b). This
discrepancy may be due to imperfect coupling between RNA and protein levels [43], or it may be
due to the differing environmental conditions between the two experiments. We next added the 30
barcodes to these GFP reporters and measured the resulting fluorescence. We found a high
correlation between GFP protein levels with and without barcodes, (r2 = 0.9903, p=9.1 x 10-32),
supporting their ability to serve as non-invasive reporters of promoter activity (Figure 3.3b).
We then applied the 2-UMI method to measure transcript levels in these 30 barcoded
strains across 8 conditions, which encompass all combinations of Aerobic vs Anaerobic,
Exponential growth vs Stationary phase, and LB vs M9 media. We expected that each strain might
exhibit a different growth rate, and so we extracted both DNA and RNA from each sample, and
measured barcode abundance in each. Barcode counts from the DNA and RNA species were
normalized within each sample. We then took the ratio of the RNA relative abundances to the
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A) Fluorescence levels exhibited in strains
expressing GFP from the indicated promoter. Error bars indicate the standard deviation in mean per-cell
fluorescence values observed among 3 biological replicates. B) Relationship between fluorescence levels
exhibited in strains expressing either barcoded or barcode-less GFP across the promoters used in this
study. Error bars indicate the standard deviation in mean per-cell fluorescence values observed among 3
biological replicates. C) Heatmap of Pearson correlations between log2ratios measured in each culture
condition. Asterisks indicate significant correlation (p < 0.05) after Bonferroni correction for multiple
Figure 3.3: Activities of the promoter library in EcN grown in culture.
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hypothesis testing. Conditions are ordered by average linkage hierarchical clustering. D) Log2ratios
exhibited in strains grown in the indicated culture condition. Error bars indicate the standard deviation in
log2ratios observed among 3 biological replicates. Related to Figure 7.12.

corresponding DNA relative abundances in order to compute RNA expression on a per-DNA basis.
The data we report is the logarithm (base 2) of this ratio (log2ratio) (Figure 3.3d). RNA/DNA ratios
correlated with GFP protein levels (r2 = 0.88) in aerobic conditions during exponential phase
(Figure 7.10a), which is the only condition under which GFP protein levels were measured.
However, correlating these ratios with the regularized logarithm of read counts for EcN’s
endogenous genes across all 4 LB media conditions yielded no trend (r2 = 0.097) (Figure 7.10b),
supporting our focus on cloned genes vs endogenous genes. Except for cells in stationary phase
growing in M9 media under aerobic conditions, the log2ratios were significantly correlated across
in vitro conditions (Figure 3.3c). However, some individual promoters exhibited significant
condition-dependent gene expression. For example, both mocA and purC exhibited significant
differences (p < 0.05) in expression in exponential phase compared to stationary phase when grown
in LB aerobically, while the activity of p01 was particularly affected by stationary phase after
aerobic growth in M9 media (Figure 7.12). These results agree with recent reports of conditiondependent expression in cloned genes for other organisms [40], and support the use of transcript
barcoding as a high-throughput approach to measure the expression levels of many constructs
under several different conditions.
Barcoding reveals DNA-normalized RNA levels in EcN residing in the mouse gut
Encouraged by the high throughput of the barcoding method, we asked whether the same
approach could reveal differences in expression of the synthetic library when placed in the mouse
gut. The 30-member library was grown overnight in LB media and delivered to 4 mice (2 males,
2 females) via oral gavage. Contents of the stomach, small intestine, and large intestine were
collected after 6 hours, based on data indicating that ingested tracers are present throughout the GI
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tract at this time [44]. RNA and DNA levels of each barcode were then measured via the 1-UMI
approach, due to its lower yield of off-target amplicons than the 2-UMI approach for these samples.
While the number of barcoded sequences we recovered was generally lower in the gut than in
culture, the distribution of log2ratios was still approximately normal, supporting the use of
statistical tests based on the normal distribution (Figure 7.11). This analysis indicated a large range
(~8 log2) of gene expression in vivo across the promoters, except for in the small intestine which
exhibited relatively high inter-subject variability and low dynamic range (Figure 3.4a). Hierarchical
clustering revealed that the synthetic and native promoters behaved differently across gut sites,
with synthetic promoters generally exhibiting stronger activity than native promoters (Figure 3.4b).
This result was independent of the mouse in which the activities were measured. Furthermore,
many pairs of promoters exhibited significantly different gene expression levels, and these
differences were more pronounced in the large intestine than in the stomach or small intestine
(Figure 7.13).
In agreement with the culture-based data, we found that promoter activities were generally
correlated across gut and culture conditions (Figure 3.4c). This correlation indicates that some
culture-based conditions could be good predictors of promoter activity in the gut, thereby
supporting their use in rapid prototyping of engineered probiotic strains. We found that log2ratios
recovered from cells at stationary phase grown in M9 media under anaerobic conditions were
sufficient to predict activities in stomach and large intestine, but no culture condition or
combination thereof, even the culture condition most highly correlated with activities in the small
intestine (aerobic LB at stationary phase), did well at predicting gene expression in the small
intestine (Figure 3.5, Figure 7.14). In agreement with this, the overall distributions of promoter
activities and variances depended significantly on the gut site (Figure 7.15), indicating that the
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activities of some individual promoters might depend on gut site. Indeed, 9/30 promoters exhibited
significantly different (p < 0.05) activities between gut sites (e.g. prhtA exhibited a difference in
RNA/DNA ratio of 13-fold between the stomach and the small intestine) (Table 8.8).

Figure 3.4: Activities of the promoter library in EcN in the gut. A) Log2ratios exhibited by the strains detected in the

large intestine, small intestine, and stomach. Error bars indicate the standard deviation in mean log2ratios
observed across 4 mice. B) Heatmap of log2ratios in vivo. Rows and columns are ordered by complete
linkage hierarchical clustering. C) Heatmap of Pearson correlation between log2ratios measured in the in
vitro culture conditions and the large intestine, small intestine, and stomach. Asterisks indicate significant
correlation after Bonferroni correction for multiple hypothesis testing. Conditions are ordered by average
linkage hierarchical clustering. Related to Figure 7.11, Figure 7.13, and Figure 7.15.
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Figure 3.5: Predicted vs observed in vivo log2ratios and power analysis. Expected vs observed in vivo log2ratios in the

(A) stomach , (B) small intestine, and (C) large intestine. Expected values were generated with linear mixed
effects models using the most highly correlated in vitro condition for each gut site. Model summary
statistics are available in Appendix Figure 7.14. The inset values are the marginal / conditional R2. D)
Power analysis. Number of mice (vertical axis) required to observe significant differences of a given effect
size (legend) for the indicated number of multiplexed promoters (horizontal axis), assuming Bonferroni
correction for multiple hypothesis training. Sample sizes were calculated with power = 0.8. Related to
Figure 7.11 and Figure 7.14.

Our dataset enabled us to perform a power analysis for detecting differences between gut
sites in promoter activity based upon the inter-individual variability we observed. When comparing
promoter activities between gut sites we observed a pooled standard deviation for the log2ratio
averaging 1.2. Therefore, based on a desired statistical power and effect size (difference in means
divided by pooled standard deviation), it is possible to compute the number of mice required (Figure
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3.5d). For example, to identify promoters exhibiting an 8-fold change in gene expression (effect

size of 3/1.2) between gut sites among a set of 30 promoters at a power of 0.8, 8 mice are required.
Conversely, with the 4 mice used in this study, only effect sizes of 4.74, or 2(4.74*1.2) ~= 50-fold,
changes in expression could be detected among 30 promoters at a power of 0.8. Because the interindividual differences in gene expression we observed are high, the ability to use one group of
mice per promoter library, rather than per promoter, makes transcript barcoding a particularly
desirable approach to measuring cloned gene expression in the mammalian gut.
Discussion
In this work, we measured the ability of transcript barcoding to report the activities of
synthetic constructs in the mammalian gut. We first directly measured the accuracy of this
approach using nucleic acids of known concentration. We found that, even when using unique
molecular identifiers, separate DNA sequences were unevenly recovered during sequencing library
preparation. These effects were substantial, up to 9.7-fold for the commonly-used 2-UMI method,
and up to 1.8-fold for the commonly-used 1-UMI method. However, these biases were consistent
for the unique molecular identifiers across input concentrations, allowing for approaches to
account for them. First, barcode abundances can be compared as a ratio between conditions to
cancel out the bias, which was implemented here as a ratio between barcode abundances in the
RNA and DNA pools. As a second approach, multiple barcodes could be used to track each
promoter, effectively averaging out the bias. Therefore, it is important that UMI-based studies
incorporate one of these two methods – studies which use UMIs to measure the abundance of
individual sequences on an absolute basis are predicted to exhibit high technical repeatability (i.e.
precision) but low correlation with actual sequence abundance (i.e. accuracy). Alternatively, given
more data, it might be possible to train models of UMI incorporation and PCR bias to avoid these
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issues and improve quantitative accuracy for the myriad techniques in which these methods are
used, including next-generation sequencing and vector library construction.
Having validated the accuracy and precision of the barcoding approach, we next applied it
to measure gene expression of cloned EcN genes in culture and in the mammalian gut. We found
that promoter activities were significantly correlated across sites, indicating that, at a broad level,
in vitro activities can be used to predict promoter activities in the stomach and large intestines.
However, we also found evidence that promoters exhibit differing levels of activity in different
regions of the intestine. The existence of such differences is understandable, as the abundances of
various chemicals (e.g. pH, bile acids, water, short-chain fatty acids, etc) and other microbial
species vary substantially along the gut. These differences could combine to make synthetic
construct expression in the gut context-dependent, which is important for several reasons. First,
promoters that change activity based on gut site are useful, for example, to design probiotics that
change their behaviours upon entering the gut, to deliver biomolecules in a site-specific fashion
(e.g. small intestine vs large intestine), or to initiate behaviours upon exiting the gut [45-47].
Second, many biomolecules which are interesting to deliver to the gut (such as drugs) have defined
therapeutic windows. The ability to predict promoter activity in different gut sites will enable the
design of engineered probiotic therapies with well-defined pharmacokinetics [47]. Third, the
performance of some synthetic regulatory circuits depends heavily on the precise expression levels
of its regulatory components [48]. Indeed, we were able to use these promoter strength
measurements to design probiotics which expressed a therapeutic protein (PAL2) at predictable
levels in vitro and in vivo, which we characterized in previously published work [49]. Engineered
EcN expressing PAL2 is currently being investigated in clinical trials as an oral therapy for
phenylalanine hydroxylase-deficient phenylketonuria (PKU) [16], and is therefore a clinically
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relevant example of a therapeutic protein that can be delivered by an engineered probiotic. We
previously demonstrated that strains containing p19-PAL2 were able to reduce serum
phenylalanine levels up to 50% in a murine model of PKU, while strains containing p08-PAL2
reduced serum phenylalanine to lesser extent, results which agreed with our measurements of p08
and p19 strength using barcoded GFP [49]. This agreement demonstrates the utility of measuring
promoter strengths in parallel using barcoded GFP to inform the construction of engineered
therapeutic strains. Looking forward, measuring the extent to which promoters change their
activity in the gut will allow probiotic engineers to implement more complex decision-making
abilities.
In this study we measured the distributions of cloned gene expression in probiotics residing
in the gut. This information is critical to the design of well-powered experiments to measure the
performance of synthetic parts in gut-resident probiotics. Moreover, this analysis revealed the
extent to which transcript barcoding can reduce the number of mice required to detect differences
in promoter activity. Specifically, this approach allows one group of mice per promoter library,
rather than per promoter, which is a significant cost and ethical advantage.
Taken together, this work establishes transcript barcoding as a desirable method for
measurement of cloned gene expression in organisms residing in habitats that are difficult to model
in vitro. Looking forward, this approach can be extended to any organism for which genetic tools
exist, and any habitat to which engineered microorganisms can be applied. We anticipate that given
the current ease with which new synthetic constructs can be constructed or synthesized, transcript
barcoding will find increasing use to rapidly test and identify engineered strains exhibiting the
desired in situ behaviour.
Materials and Methods
Strains, Media, Plasmids, and Primers
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EcN was obtained as a kind gift from Dr. Phillip I. Tarr (Washington University in St.
Louis School of Medicine) and authenticated via whole-genome sequencing. Strains were grown
in either LB media or modified M9-MOPS media at 37°C [27]. Agar was added at a concentration
of 15 g/L for growth on solid media. For maintenance of the pZE21 plasmid [28] and its
derivatives, kanamycin was added to a final concentration of 50 μg/mL after autoclaving. Aerobic
growth was performed with shaking (250 rpm) on a Thermo Fisher MaxQ 2000 shaker. Anaerobic
growth was performed in a vinyl anaerobic chamber (Type C, Coy Laboratory Products) without
shaking [29]. All plasmids used in this study were constructed using Golden Gate Assembly
MasterMix from NEB, according to the manufacturer’s instructions. Upon construction, all
plasmids were transformed into chemically-competent EcN, thus generating biological triplicates.
Chemical Transformation of EcN
Chemically-competent EcN was prepared by growing overnight in 100mL LB at 37 ºC.
This culture was diluted to OD600 0.1-0.2 using cold LB, after which it was grown for an
additional 2-3 h at 37 ºC, until the culture reached an OD600 of 0.3-0.5. This culture was
centrifuged at 3000 x g for 5 min at 4ºC. The supernatant was discarded, and cells were
resuspended in 1/10 of their original volume in ice cold 100 mM CaCl2 dissolved in a 15% v/v
glycerol/water mixture. This cell suspension was kept on ice for 30 min. This cell suspension was
again centrifuged at 3000 x g for 5 min at 4ºC, and resuspended to 1/50 of its original volume in
the ice-cold CaCl2/glycerol solution. 50 µL aliquots of this mixture were frozen at -80 ºC. To
perform transformations, one aliquot of cells per transformation was thawed on ice. About 5 µL
of ligation reaction or purified plasmid as added, and the resulting cell/DNA mixture was gently
mixed without pipetting. These mixtures were then transferred to a PCR block pre-chilled to 4 ºC.
After 30 minutes, the temperature was raised to 42 ºC for 5 min, after which the temperature was
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returned to 4 ºC. After at least 3 minutes at 4 ºC, cells were added to 250 µL of SOC medium in a
centrifuge tube and incubated on their sides at 37 ºC for 1 hour with shaking (250 rpm). After this
recovery step, cells were plated onto the appropriate selection media.
Transcriptomic analysis of EcN
EcN containing pZE21 was grown overnight in LB media containing kanamycin (LB+Kan)
under aerobic conditions. These cultures were used to inoculate triplicate 25 mL cultures in
LB+Kan. Aerobic cultures were shaken, but anaerobic cultures were not. At an optical density
(600 nm) of 0.3, 5 mL of each culture was centrifuged (3000 x g for 5 minutes at room
temperature), resuspended in 0.25 mL of water, placed in an equal volume of DNA/RNA shield,
and stored at -80 °C. After overnight growth, 1 mL of each aerobic culture and 3 ml of each
anaerobic culture was centrifuged (3000 x g for 5 minutes at room temperature), resuspended in
0.25 mL water, and placed in an equal volume of DNA/RNA shield. All samples were processed
with a ZymoBIOMICS DNA/RNA Miniprep Kit (Zymo) according to manufacturer’s instructions.
Ribosomal RNA was depleted and double-stranded cDNA was synthesized according to previous
work [30]. Sequencing libraries were prepared from double-stranded cDNA using the Illumina
Nextera Library Preparation Kit. Sequencing was performed on an Illumina NextSeq Sequencer
with a High Output Flowcell. Reads were trimmed and quality-filtered using trimmomatic (v. 0.33)
[31] and mapped to the EcN genome using bowtie2 (v. 2.3.5) [32]. Read counts for each gene were
tabulated using FeatureCounts (v. 1.4.5) [33] and differential expression analysis was performed
using ALDEx2 (v. 1.16.0) [34] in R.
Flow Cytometry
Strains were grown overnight in LB+Kan media and sub-cultured into fresh LB+Kan
media at an optical density (600 nm) of 0.01. These cultures were grown for 2 hours before
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measuring GFP fluorescence directly on a FACSCalibur flow cytometer (Becton Dickinson).
Analysis of FCS files was performed using FlowJo (BD Life Sciences). Sterile media served as a
control to identify non-cell particles, which were the only particles not included in the gated,
analyzed population.
Generation of standards for each promoter barcode
Triplicates of each of the 30 EcN strains harboring a unique barcoded promoter-GFP
plasmid construct were grown overnight in LB+Kan, and plasmid DNA was extracted using a spin
miniprep kit (Qiagen), generating 3 independent extracts of each plasmid. Each plasmid was PCRamplified

for

35

cycles

using

primers

GTGCTGAAGTCAAGTTTGAAGG

and

AGTTGGAACCTCTTACGTGC using Q5 Hotstart DNA Polymerase 2X mastermix (NEB)
according to manufacturer’s instructions. PCR products were separated on a 2% agarose gel and
the band corresponding to the expected amplicon size (583 bp) was extracted using a Minelute Gel
Extraction Kit (Qiagen) according to manufacturer’s instructions, with the exception that all steps
were performed at 21,000 x g, and buffers PE and EB were allowed to incubate in the column for
5 minutes before centrifugation. Concentration of the resulting DNA fragments was quantified
using the Qubit kit (ThermoFisher). These fragments were then used to assemble barcode mixtures
of known relative proportions. An equimolar mix (total concentration of 1 ng/µL) was used to
measure barcode-specific bias values for the 1-UMI and 2-UMI methods. For both methods, we
additionally constructed 4 barcode mixes (total concentration of 1 ng/µL) covering a 1000-fold
range of barcode abundances to validate these barcode-specific bias values.
Creation of strain mixtures for culture-based and mouse experiments
Triplicate EcN strains maintaining each plasmid were grown overnight in 96-deepwell
plates in LB+Kan under aerobic conditions with shaking. The absorbance (600 nm) of each culture
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was measured and cultures were pooled at equal optical densities and mixed with an equal volume
of 30% v/v glycerol. The resulting mixture was divided into 1 mL aliquots and frozen at -80 °C
until future use.
Culture-based EcN growth and 2-UMI (unique molecular identifier) method for barcoded
transcript sequencing
100 µL of the strain mixture was thawed on ice and used to inoculate triplicate 25 mL in
vitro cultures in either aerobic or anaerobic environments. Aerobic cultures were shaken, but
anaerobic cultures were not. Culture samples were taken at both exponential and stationary growth
phases. Specifically, at an optical density of 0.3, 10 mL of each culture was centrifuged (3000 x g
for 5 minutes at room temperature), resuspended in 0.5 mL of phosphate-buffered saline, placed
in an equal volume of DNA/RNA shield, and stored at -80 °C. After overnight growth, 1 mL of
each culture was centrifuged (3000 x g for 5 minutes at room temperature), resuspended in 0.5 mL
phosphate-buffered saline, and placed in an equal volume of DNA/RNA shield. All samples were
processed with a ZymoBIOMICS DNA/RNA Miniprep Kit (Zymo) according to manufacturer’s
instructions. Purified RNA was further treated with DNAse I supplied in the RiboPure RNA
Purification Kit, Yeast (Ambion) according to manufacturer’s instructions. Reverse transcription
proceeded with primer TTCGTTTTATTTGCCCGGG using a High-Capacity Reverse
Transcription Kit (ThermoFisher) according to manufacturer’s instructions. 1.5 µL of RNAse A
(Qiagen) was added to the resulting mixture and digestion was performed at 37 °C for 1 hr. Next,
a 3-cycle PCR was performed using Q5 Hotstart DNA polymerase on either the barcode mixes
(standard curve), retained culture DNA, or synthesized culture cDNA with primers
ACACTCTTTCCCTACACGACGCTCTTCCGATCT-NNNNNNNNNNNNNNNNNNN-XXX
XXX-GGCATGGATGAGCTCTACAAATAA and CTCGGCATTCCTGCTGAACCGCTCTTC
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CGATCT-NNNNNNNNNNNNNNNNNNN-XXXXXX-TTCGTTTTATTTGCCCGGG
(standard

curve

experiments),

or

ACACTCTTTCCCTACACGACGCTCTTCCGATCT-

NNNNNNNNNNNNNNNNNNN-XXXXXX- TGGCATGGATGAGCTCTAC and CTCGGCA
TTCCTGCTGAACCGCTCTTCCGATCT-NNNNNNNNNNNNNNNNNNN-XXXXXX- TGA
GCCTTTCGTTTTATTTGCC (culture experiments), where each “N” refers to a base which is
equally likely to be A, C, T, or G, and “XXXXXX” denotes a sample-specific unique molecular
identifier (UMI). This PCR was performed according to the manufacturer’s instructions, with 5
µL of template, 1.5 picomoles of each primer, a melting temperature of 65°C, an extension time
of 15 s, and 3 total cycles. The PCR products were purified using Agencourt Ampure XP beads
(Beckman Coulter). 5 µL of product was then used as a template for an enrichment PCR using Q5
HotStart DNA polymerase. This PCR was performed using primers AATGATACG
GCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT and CAAGCA
GAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCT
according to manufacturer’s instructions: 15 picomoles of each primer, 72°C Tm, and 35 total
cycles. The expected product (227 bp) was separated on a 3% gel, excised, purified using a
Minelute Gel Extraction Kit (Qiagen), and quantified using a Qubit (ThermoFisher). Amplicons
from each sample were pooled and analyzed on an Illumina Miniseq sequencer.
Growth of EcN in the mouse gut and 1-UMI method for barcoded transcript sequencing.
All mouse experiments were approved by the Washington University in Saint Louis School
of Medicine Division of Comparative Medicine. Through the duration of the experiment, mice
consumed standard chow (LabDiet #5053). 109 colony forming units of the strain mixture in 100
µL PBS was delivered to each of 4 C57BL/6 mice (2 male, 2 female, 5 weeks of age) via oral
gavage and placed in separate cages. 6 hours later, mice were sacrificed via CO2 asphyxiation, and
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the contents of the stomachs, proximal small intestines, medial small intestines, ceca, and colons
were collected in screw-cap vials containing DNA/RNA Shield (Zymo). These vials were then
processed using a ZymoBIOMICS DNA/RNA Miniprep Kit (Zymo) according to manufacturer’s
instructions. The resulting RNA was treated with DNAse I as above. The RNA was reverse
transcribed

as

above,

with

the

exception

that

the

primer

sequence

CTCGGCATTCCTGCTGAACCGCTCTTCCGATCT-NNNNNNNNNNNNNNNN-XXXXXXTGAGCCTTTCGTTTTATTTGCC was used. RNAse A treatment after cDNA synthesis was then
performed as above. cDNA was purified using a Minelute PCR Purification Kit (Qiagen). Retained
DNA from each sample was subjected to a primer extension reaction using the same primer (but a
different sample-specific barcode) using Q5 HotStart DNA polymerase according to the protocol:
98 °C for 15 s, 65 °C for 15 s, and 72 °C for 15 min. The reaction (50 µL total) incorporated 5 µL
of template and 150 picomoles of primer CTCGGCATTCCTGCTGAACCGCTCTTCCGATCTNNNNNNNNNNNNNNNN-XXXXXX-TGAGCCTTTCGTTTTATTTGCC. After this reaction
completed, 3 µL of exonuclease I (NEB) was added, and the mixture was incubated for 1 hr at 37
°C, followed by 5 minutes at 98 °C. These reactions were purified using Agencourt Ampure XP
beads (Beckman Coulter). Next, a 35-cycle PCR was performed on the purified DNA and cDNA
products using Q5 Hotstart DNA polymerase according to manufacturer’s instructions, with an
annealing temperature of 72 °C and an extension time of 15 s, with primers
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC
T and CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAACCGCTCT
TCCGATCT. The expected product (199 bp) was separated on a 3% gel, excised, and purified
using a MinElute Gel Extraction Kit, and quantified using Qubit. Amplicons were pooled at
equimolar ratios and sequenced on an Illumina Miniseq lane.
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Sequencing analysis
Reads were first trimmed to the appropriate length using trimmomatic (v. 0.33) [31].
Paired-end reads were then merged using usearch (v. 7.0.1090_i86linux64) [35]. Merged reads
were processed as follows: regions of interest were extracted including UMI(s), sample barcode,
promoter barcode, and flanking regions including GFP and terminator. Reads containing >1 error
in GFP and terminator regions were discarded. Reads which contained >1 error in either sample
barcode or promoter barcode regions were also discarded. Finally, the number/sequence of unique
UMIs (and how many of each UMI) corresponding to each promoter/sample was counted. These
UMI sequences and counts were fed into UMI-tools (v. 0.5.0) [36], which accounted for
sequencing error in UMI sequences. Finally, the number of unique UMIs for each sample/barcode
was enumerated.
Statistical analysis
Barcode counts, where each barcode was unique to one of 30 promoters, were normalized
to generate within-sample relative abundances of the respective constructs. For each sample, the
relative abundance of each promoter construct observed in the mRNA-derived cDNA library was
divided by the relative abundance observed in the corresponding DNA library. These ratios were
transformed by calculating their logarithm base2 (log2ratio) and serve as an estimate of relative
promoter activity within each sample. The log2ratios were averaged for each promoter across the
three replicates of each in vitro condition. The in vivo log2ratios were averaged across the replicate
mice and the major gut regions of stomach, small intestine (proximal, medial, and distal), and large
intestine (cecum and colon). Pearson correlations between culturing conditions and gut sites were
calculated using the corrplot (v. 0.84) package in R with Bonferroni correction for multiple
hypothesis testing. Hierarchically clustered heatmaps for in vivo log2ratios and pairwise
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comparisons were generated with the pheatmap (v. 1.0.12) package in R, with Bonferroni
correction. Normality of the in vivo log2ratios was assessed with Shapiro-Wilk’s test using the
shapiro.test function in the stats (v. 3.5.1) package in R, and differences in mean log2ratios
between gut sites was assessed by ANOVA, using the anova function from the same package.
Default parameters were used in both cases. Differences in activity between in vitro conditions for
each promoter, or between the promoters themselves in the gut, were assessed by pairwise
Student’s t tests with Bonferroni correction for multiple hypothesis testing, using the
compare_means function (ggpubr v. 0.2 package in R). The same function was used to compare
activity between gut sites for each promoter, with Benjamini-Hochberg correction for multiple
hypothesis testing.
To calculate a mean pooled standard deviation in the context of comparing promoter
activities between gut sites, the standard deviation of the log2ratios was calculated for each
promoter in each of the three gut sites. Then, for each promoter p, a pooled standard deviation was
2
2 ⁄
calculated for each pair of gut sites i and j as 𝑆𝐷𝑝𝑖𝑗 = √(𝑆𝐷𝑝𝑖
+ 𝑆𝐷𝑝𝑗
) 2. The mean of all such

pooled standard deviations was reported. For the power analyses, the pwr.t.test function from the
pwr (v. 1.2.2) package in R was used. To calculate the number of mice n needed to detect
differences of a certain effect size (function parameter d), we scaled the sig. level parameter by the
number of multiplexed promoters, using a base sig. level of 0.05, thereby emulating Bonferroni
correction for multiple hypothesis testing. For example, assuming 30 promoters would be tested,
the sig. level parameter was set to 0.05/30 = 0.00167. In all cases the power parameter p was set
to 0.8.
Linear mixed effects models were fit separately for the log2ratios in the stomach, small
intestine, and large intestine using the lme4 (v. 1.1.21) package in R. In each case the log2ratios
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from the most highly correlated (Pearson) in vitro condition for that gut site was the only fixed
effect. For all three models, Mouse ID was set as the random effect. Model summary statistics,
including marginal and conditional R2 using the method of Nakagawa et al. [37], were calculated
using the tab_model function from the sjPlot (v. 2.6.4) package in R. Expected values were
generated using the fitted function from the stats (v. 3.5.1) package.
Data and software availability
Demultiplexed reads for the EcN transcriptome have been deposited at NCBI under
accession numbers SRR10424477 through SRR10424487. Raw reads for the in vitro barcode
sequencing experiment have been deposited at NCBI under accession number SRR9062664. Raw
reads for the in vivo barcode sequencing have been deposited at NCBI under accession number
SRR9062663. Other supplementary materials including plasmid and primer sequences, code, and
raw barcode counts are available from Crook et al. [50].
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Chapter 4 : Genetically stable CRISPR-based kill switches for
engineered microbes
Abstract
Microbial biocontainment is an essential goal for engineering safe, next-generation living
therapeutics. However, the genetic stability of biocontainment circuits, including kill switches, is
a challenge that must be addressed. Kill switches are among the most difficult circuits to maintain
due to the strong selection pressure they impart, leading to high potential for evolution of escape
mutant populations. We engineered two CRISPR-based kill switches in the probiotic Escherichia
coli Nissle 1917, a single-input chemical-responsive switch and a 2-input chemical- and
temperature-responsive switch. We employed parallel strategies to address kill switch stability,
including functional redundancy within the circuit, modulation of the SOS response, antibioticindependent plasmid maintenance, and provision of intra-niche competition by a closely related
strain. We demonstrate that strains harboring either kill switch can be selectively and efficiently
killed inside the murine gut, while strains harboring the 2-input switch are additionally killed upon
excretion. Leveraging redundant strategies, we demonstrate robust biocontainment of our kill
switch strains and provide a template for future kill switch development.
Introduction
Probiotic microbes have become effective chasses for engineering diagnostic and
therapeutic technologies. One of the most commonly engineered probiotic strains is Escherichia
coli Nissle 1917 (EcN). Engineered strains of EcN have been successfully used to diagnose and
treat bacterial infections [1, 2], cancers [3-5], gastrointestinal bleeding [6], inflammatory disorders
[7-9], and obesity [10] in a variety of animal models. EcN strains engineered to treat metabolic
disorders are being evaluated in human clinical trials with promising early-phase results [11, 12].
However, there are important safety concerns associated with organisms genetically engineered
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for medical applications. Probiotics are living organisms that have the potential to mutate and
evolve undesirable traits over the course of diagnosis or treatment. Such adaptations can include
loss of beneficial functions of the engineered system, gain of deleterious functions such as
competitive exclusion of native microbes, pathogenic potential against the host, or environmental
contamination if they spread outside the host [13-16]. To mitigate these concerns, engineered
probiotics should possess biocontainment systems that enable both selective removal from the host
and prevent their environmental dissemination [17].
Biocontainment circuit designs are focused on preventing proliferation in the wild, and
typically involve an input that is specific to the permissive environment and repressive to the
killing circuit, such that upon exit of the permissive environment the lethal components are
expressed [18]. Several such biocontainment strategies have been developed with varying degrees
of efficacy and stability, including use of auxotrophy [11, 19, 20] and synthetic amino acids [2123]. While approaches like synthetic auxotrophy are evolutionarily stable in that they do not
readily give rise to escape mutants [21], a limitation of these methods is that they may require the
probiotic environment to be supplemented with additional survival factors (‘permissive
molecules’). Completely withholding these molecules in the gut, for example by administering an
auxotrophic strain without the essential compound, effectively limits probiotic lifespan in vivo
[11], but may also limit therapeutic potential depending on the rate of probiotic cell death in
absence of the permissive molecules. Alternatively, the permissive molecules may theoretically be
supplied to patients in conjunction with the probiotic, but this design complicates administration
as well as the selective removal of probiotics from within the gut since time to full clearance of
the permissive molecules may be difficult to control. In addition, if the permissive molecules are
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natively present in the gut then these circuit designs can be overcome by cross-feeding,
compromising control of the engineered microbe [20, 21, 24].
An inverse kill switch design would then be one in which the baseline state in the gut is
permissive, without supplementation of exogenous molecules; correspondingly, the lethal
components of the circuit are expressed in response to supplied inducers, or environmental signals
external to the gut. Numerous genetic circuits have been developed that initiate cell death in
response to a chemical inducer [25-28]. Similarly, biocontainment circuits have been developed
in E. coli using temperature sensors tuned to differentiate physiological and environmental
temperatures [18, 29, 30]. These kill switches control cell survival using a variety of mechanisms
including expression of toxins and lysis proteins [18, 25-27], degradation of essential proteins [26],
and cleavage and degradation of the genome by Cas9 proteins [28]. Both temperature-sensitive
circuits designed by Piraner et al. and Stirling et al. used the E. coli CcdB-CcdA toxin-antitoxin
system to control cell survival. The kill switch engineered by Piraner et al. used a modified version
of the Salmonella typhimurium-native PtlpA-tlpA sensor and achieved a 4-log reduction in fecal cell
number [30], while the kill switch engineered by Stirling et al. used the E. coli-native PcspA
promoter and achieved a 5-log reduction in fecal cell number [29]. Notably, functional redundancy
offered by the combination of the PcspA-controlled temperature-sensitive kill switch with an
orthogonal pH-sensitive kill switch mechanism synergistically improved in vitro killing efficacy
such that surviving colony counts were below the 11-log limit of detection [18]. However, kill
switches that induce cell death by expressing toxins, lysis proteins, and proteases are prone to
mutational inactivation, often leading to population dominance of non-functional variants, or have
not been characterized for genetic stability [26]. To overcome this stringent evolutionary selection,
such kill switch systems must be designed to be highly stable. The temperature-inducible toxin-
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antitoxin kill switch engineered by Stirling et al. was shown to be stable over 140 generations of
growth in vitro and at least 10 days of growth in the mouse gut [29], while the combined
temperature- and pH-inducible kill switch was stable over at least 100 generations in vitro [18]. In
contrast, a CRISPR-based system has been shown to be stable for 1700 generations when applied
to plasmid removal [28]. However, it is unclear whether the same stability would persist if the
system was applied to cell death.
To engineer a genetically stable probiotic with viability that is controllable both inside and
outside the host, we used a step-wise design approach to develop two CRISPR-based kill switches
(CRISPRks) in EcN. First, we built a single-input kill switch that can initiate probiotic death in
response to the chemical inducer anhydrotetracycline (aTc). After iterative optimization for
stability and efficacy, this circuit became the foundation for a 2-input kill switch that can
additionally initiate death in response to the temperature decrease that occurs upon excretion from
the host. Both designs allow the engineered microbe to be selectively removed in situ from the gut,
while the final 2-input CRISPRks additionally prevents the microbe from surviving outside the
body. To achieve genetic stability of the kill switches, we applied parallel approaches of genetic
engineering and environmental control, including functionally redundant expression cassettes,
antibiotic-free plasmid maintenance systems, knockouts of key drivers of DNA-mutagenesis in the
SOS response, and provision of intra-niche microbial competition. Both kill switches exhibited
significant long-term stability, with efficient killing maintained after 28 days (224 generations) of
continuous growth in vitro. In mice, we innovatively leveraged intra-niche competitive inhibition
to selectively disadvantage the target EcN subpopulation [31]. The single-input CRISPRks
allowed the engineered probiotic to be completely eliminated from the mouse gut in response to
aTc consumption. Similarly, the 2-input CRISPRks achieved virtually complete eradication of the
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probiotic population when both chemical- and temperature-induction were applied. The principles
and genetic parts used in the CRISPRks described here have been employed in various microbial
species [32-34], highlighting the potential for deploying this biocontainment platform to other
engineered probiotic strains.
Results
Development of a chemical-inducible CRISPR-based kill switch for EcN
We first designed a kill switch that induces EcN cell death in response to the chemical
inducer aTc (Figure 4.1a, Table 4.1). To initiate cell death, we utilized a CRISPR/Cas9-based
approach. E. coli can repair double-stranded DNA breaks (DSBs), as caused by Cas9, through
RecA-dependent homologous recombination with sister genomes generated by DNA replication
[35]. However, the damage caused by Cas9 is lethal if each copy of the replicating genome is cut
[36]. To make CRISPR-based cell death dependent on the presence of aTc, we expressed Cas9

from a low copy plasmid and genome-targeting gRNAs from a medium copy plasmid using aTcinducible Ptet promoters.
We next sought a guide RNA (gRNA) that could target the genome and initiate cell death
with high efficiency. We hypothesized that gRNAs with multiple genomic binding sites would
have higher killing efficiencies as the gRNA-Cas9 complex would have a higher probability of
locating a target site. In addition, multi-locus genome cleavage should decrease the probability of
DSB rescue through homologous recombination [37], or genomic mutations in the target sites
rendering the cell immune to the kill switch. To explore the effect of target copy number, we tested
the aTc-response of six total gRNAs for three target genes present at various copies throughout
the genome: the single-copy groL gene, the three-copy ileTUV genes, and the seven-copy
rrsABCDEGH genes (Figure 4.1b, c). To quantify the efficiency for each gRNA, we defined the
term ‘fraction viable’ as the ratio of colony forming units (CFUs) obtained in the non-permissive
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condition (+aTc) to CFUs obtained in the permissive condition (-aTc). Interestingly, the killing
efficiencies for the multi-target gRNAs did not exceed the efficiencies of the single-target gRNAs.
At least one gRNA for each target gene achieved a fraction viable of 10-4-10-5. The kill switch
rapidly triggered cell death, with maximum killing efficiencies detected after just 1.5 h of aTc
induction (Figure 7.16a). However, efficiencies were significantly reduced by 2.5 h of induction,
suggesting that a subpopulation of cells harboring inactive kill switches were able to repopulate.
Improving kill switch stability through functional redundancy
To determine the source of kill switch inactivation, we identified isolates exhibiting lossof-function from the aTc-induction assay, and sequenced the cas9, gRNA, and tetR expression
cassettes. While a small number of isolates harbored mutated gRNA (10±14%) and tetR (3±6%)
cassettes, a large majority harbored mutated cas9 expression cassettes (80±19%), with mutations
predominantly in the Ptet promoters (Figure 4.1d). To decrease the probability of Cas9 expression
inactivation, we integrated functionally redundant Ptet-cas9 expression cassettes into four genomic
neutral integration sites [11] (Figure 4.1e). Each successive integration improved the efficiency of
the ile-2 gRNA kill switch, with the four Ptet-cas9 integration strain (Int X4) achieving a fraction
viable 10 times lower than the plasmid-based Cas9 expression strain (Figure 4.1f). Chromosomal
expression of four functionally redundant Cas9 cassettes did not alter the relative efficiency of the
six gRNAs (Figure 7.16b).
Diminishing returns were observed by the fourth Ptet-cas9 integration, suggesting a shift in
inactivation method. We sequenced non-functional Int X4 isolates and identified the promoter of
the Ptet-gRNA expression cassette as the primary source of instability (Figure 4.1g). Applying the
same principle of functional redundancy, we combined the groL-2 and ile-2 gRNA expression
cassettes onto one plasmid and achieved aTc-dependent cell death below the limit of detection
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Cas9-expressing plasmids include a
low (~5)-copy pSC101 origin of replication and gRNA-expressing plasmids include a medium (~20)-copy
p15A origin of replication.
Table 4.1: Names and descriptions of each no gRNA control and kill switch strain.

Genetic Parts
Strain Name

gRNAs

cas9

tetR

infA

tlpA

Knockouts

Figures

Control

None

Plasmid

Unoptimized

None

None

None

Figures 1C

Control

None

4 Integrations

Unoptimized

None

None

None

Figure 1H

Control

None

4 Integrations

Unoptimized

Optimized

None

None

Figure 3A

Control

None

4 Integrations

Unoptimized

Optimized

None

Figures 3A, 3I, 3J,
ΔrecA ΔpolB
4B, 4E, 5B, 5E, and
ΔdinB ΔumuBC
5F

groL-1

groL-1

Plasmid

Unoptimized

None

None

None

Figures 1C

groL-2

groL-2

Plasmid

Unoptimized

None

None

None

Figures 1C

ile-1

ile-1

Plasmid

Unoptimized

None

None

None

Figures 1C

ile-2

ile-2

Plasmid

Unoptimized

None

None

None

Figures 1C

rrs-1

rrs-1

Plasmid

Unoptimized

None

None

None

Figures 1C

rrs-2

rrs-2

Plasmid

Unoptimized

None

None

None

Figures 1C

Int X1

ile-2

1 Integration

Unoptimized

None

None

None

Figure 1F

Int X2

ile-2

2 Integrations

Unoptimized

None

None

None

Figure 1F

Int X3

ile-2

3 Integrations

Unoptimized

None

None

None

Figure 1F

Int X4

ile-2

4 Integrations

Unoptimized

None

None

None

Figures 1F and 1H

Initial 2-gRNA

groL-2 and ile-2

4 Integrations

Unoptimized

None

None

None

Figure 1H

Optimized 2-gRNA

Optimized groL-2
and ile-2

4 Integrations

Unoptimized

None

None

None

Figures 1H and 2A

ABX-independent 2-gRNA

Optimized groL-2
and ile-2

4 Integrations

Unoptimized

Unoptimized

None

None

Figure 2B

CRISPRks

Optimized groL-2,
ile-2, and rrs-2

4 Integrations

Unoptimized

Optimized

None

None

Figures 2C-F, 3A,
and 3E

CRISPRks Δrpdu

Optimized groL-2,
ile-2, and rrs-2

4 Integrations

Unoptimized

Optimized

None

ΔrecA ΔpolB
Figures 3A, 3F, 3I,
ΔdinB ΔumuBC and 3J

Initial 2-input CRISPRks
Δrpdu

Optimized groL-2,
ile-2, and rrs-2

4 Integrations

Unoptimized

Optimized

Present

ΔrecA ΔpolB
Figure 4B
ΔdinB ΔumuBC

[Optimized] 2-input
CRISPRks Δrpdu

Optimized groL-2,
ile-2, and rrs-2

4 Integrations

Optimized

Optimized

Present

ΔrecA ΔpolB
Figures 4B, 4D, 4E,
ΔdinB ΔumuBC 5B, 5E, and 5F

No gRNA controls

aTc-inducible kill switches

2-input kill switches
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A) Schematic of the aTc-inducible
CRISPR-based kill switch. Cas9 and gRNAs are expressed on independent plasmids by aTc-inducible Ptet
promoters. TetR, which regulates the expression of Ptet promoters in an aTc-dependent manner, is
constitutively expressed on the gRNA plasmid. In the presence of aTc, TetR is unable to bind to its target
Figure 4.1: Development of a chemical-inducible CRISPR-based kill switch for EcN.
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promoters, leading to expression of Cas9 and the gRNAs. The Cas9/gRNA complex then binds to and
cleaves its genomic targets, leading to cell death. B) gRNA target locations in the EcN genome: the single
copy groL gene (grey), the three copy ileTUV genes (blue), and the seven copy rrsABCDEGH genes (green).
C) Log10 CFUs for the no gRNA control and six gRNA expression plasmids in wild-type EcN with the Ptetcas9 expression plasmid. D) Sequencing results from 24 survivors from (C) with non-functional ile-2 kill
switches. E) Genomic neutral integration sites used for Ptet-cas9 integrations: within the lacZ gene,
between rhtB and rhtC, between agaI and rsmI, and between exo and cea. F) Log10 Fraction Viable for EcN
strains with plasmid-based, one genome-integrated (Int X1), two genome-integrated (Int X2), three
genome-integrated (Int X3), and four genome-integrated (Int X4) Ptet-cas9 expression cassettes. All strains
contain the same ile-2 gRNA plasmid. G) Sequencing results from 24 survivors from (F) with non-functional
Int X4 kill switches. H) Log10 CFUs for EcN with four genomic Ptet-cas9 integrations and different
combinations of the groL-2 and ile-2 gRNAs. ‘+opt’ represents the respective Ptet-gRNA cassette with an
optimized Ptet promoter. aTc concentration was increased to 500 ng/mL, from 100 ng/mL in (C), based on
the transfer curve characterized in Figure 7.16e. For all sequencing, the fraction mutated is the fraction of
total sequenced cassettes that contained a mutation. For all kill switch assays, exponential phase cells for
each strain were induced with 0 and 100 or 500 ng/mL aTc for 1.5 h. Values and error bars are the average
and standard deviation of biological triplicate, respectively. Statistical comparisons were performed using
two-tailed unpaired t-tests (*, P < 0.05; **, P < 0.01; ***, P < 0.001). See also Figure 7.16.

after 1.5 h and a fraction viable below 10-6.6 (Figure 4.1h). However, this initial 2-gRNA kill switch
caused significant cell death even in the absence of aTc, limiting the therapeutic potential of the
strain. To optimize gRNA expression and minimize leaky killing, we simultaneously mutagenized
the -35 sites of the two gRNA Ptet promoters and assayed colonies from the library (Figure 7.16c,
d). We isolated one 2-gRNA kill switch that maintained full killing in the presence of aTc without
leaky killing in the absence of aTc (Figure 4.1h). The optimized 2-gRNA kill switch achieved a
fraction viable of less than 10-8.6, surpassing the killing efficiency of 10-8 recommended by the
NIH Office of Biotechnology Activities [38]. The optimized kill switch also displayed an
improved aTc sensitivity relative to the single ile-2 gRNA kill switch (Figure 7.16e).
Eliminating the reliance on antibiotics for efficient killing
When the antibiotic (ABX) used to maintain the gRNA expression plasmid was removed
from selection plates, we found the killing efficiencies of both 2-gRNA kill switches to be severely
reduced due to loss of the gRNA plasmid during replication (Figure 4.2a and Figure 7.17a). To enable
stability of the kill switch plasmid constructs in the absence of antibiotics, we implemented a
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modified version of a previously described ABX-free plasmid maintenance method [39, 40]. We
expressed the essential gene infA (required for initiation of protein synthesis) using an intermediate
strength constitutive promoter on the gRNA plasmid and knocked it out of the genome of the four
Ptet-cas9 integration strain. With this system, EcN needs to maintain the plasmid to provide InfA
and survive. The antibiotic resistance gene was not removed from the plasmid to allow for CFU
quantification in future experiments using mixed strains. Expressing InfA on the gRNA plasmid
eliminated the dependence on ABX but lowered the efficiency of the kill switches (Figure 4.2b and
Figure 7.17b).

Switching a plasmid to InfA-based selection has been shown to affect plasmid copy number
[39]. We therefore improved the efficiency of the ABX-independent 2-gRNA kill switches using
two methods: increasing gRNA expression by adding an rrs-2 gRNA expression cassette library
and tuning the strength of the constitutive infA cassette. We performed both optimization methods
independently for both the ABX-independent initial 2-gRNA and optimized 2-gRNA kill switches
(Figure 7.17c-f). Both methods improved kill switch efficiency but failed to restore complete
killing. However, when we incorporated a third gRNA expression cassette into the InfA-optimized,
optimized 2-gRNA kill switch, we obtained two variants that achieved complete killing in the
presence of aTc with uninhibited growth in the absence of aTc (Figure 7.18a, b). To identify the
superior CRISPRks variant, we assayed each for their aTc-response time, aTc-sensitivity, and
long-term stability (Figure 4.2c and Figure 7.18c-f). Both variants were inactivated at similarly low
rates, with a small population of non-functional cells appearing after 14 days (112 generations) of
growth in vitro. However, the Mut14 variant displayed a significantly better response time, aTc
sensitivity, and long-term killing efficiency. The Mut14 CRISPRks achieved complete killing by
3 h of aTc induction, responded to aTc with a half-maximal concentration of 21 ng/mL, and
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displayed highly stable killing over 28 days of growth (Figure 4.2c-e). In addition, the kill switch
reliably achieved complete killing of EcN in diverse nutrient conditions, with a linear correlation
between generation time and log fraction viable at 1 h (Figure 4.2f, g).

Figure 4.2: Eliminating the reliance on antibiotics for efficient killing. System schematics and log10 CFU values for the

following kill switch strains: (A) optimized 2-gRNA circuit, which has four genome-integrated Ptet-cas9
expression cassettes (X4) and optimized groL-2 and ile-2 Ptet-gRNA expression cassettes, (B) ABXindependent 2-gRNA circuit, which has four genome-integrated Ptet-cas9 expression cassettes (X4),
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optimized groL-2 and ile-2 Ptet-gRNA expression cassettes, and an unoptimized constitutive infA
expression cassette to complement a genomic infA knockout, and (C) CRISPRks, which has four genomeintegrated Ptet-cas9 expression cassettes (X4), optimized groL-2, ile-2, and rrs-2 Ptet-gRNA expression
cassettes, and an optimized constitutive infA expression cassette to complement a genomic infA
knockout. Exponential phase cells for each strain were induced with 0 and 500 ng/mL aTc for 1.5 h (A),
and 1.5 or 3 h (B and C) in LB with and without spectinomycin. CFUs were determined by plating onto LB
agar with and/or without spectinomycin. Differences between the circuit in A and the circuits in B and C
are in highlighted in the construct schematics in red. gRNA, tetR, and infA cassettes are located on the
same plasmid (connected lines), while cas9 is located exclusively in the genome. ‘Both’ denotes whether
antibiotics were present in both the liquid and solid phase media. D) aTc-inducible killing transfer curve
for the CRISPRks strain after 3 h of induction in LB without antibiotics. Points represent experimental data
while the line represents the fitted curve. E) Long-term stability assessment of the CRISPRks strain. Each
day for 28 days, three replicates of the strain were diluted 250X into fresh LB without antibiotics and
grown for 24 h. Every 3-4 days, exponential phase cells were induced with 0 and 500 ng/mL aTc for 3 h
and plated on LB agar without antibiotics for CFU quantification. F) Log10 CFUs of the CRISPRks strain in
response to 500 ng/mL aTc in M9+0.4% glucose (poor), M9+0.4% glucose+0.2% casamino acids
(intermediate), and LB (rich). G) Correlation between generation time and fraction viable. Fraction viable
values of <-8 or <-9 had no colonies obtained from cultures receiving aTc. Values and error bars are the
average and standard deviation of biological triplicate, respectively. See also Figure 7.17 and Figure 7.18
and Table 8.9.

Complete killing is achieved by the CRISPRks in vivo after knocking out key components of the
SOS response and providing intra-niche competition
Having demonstrated the dependence of the kill switch on growth conditions, we next
sought to predict kill switch efficacy in vivo. We developed an in vitro assay that more closely
mirrors the gut, a complex environment with lower levels of oxygen, nutrients, and mixing than
standard in vitro conditions. When induced with aTc in minimal media, micro-aerobically, and
without shaking, the CRISPRks (circuit schematic in Figure 4.2c) achieved a fraction viable of 103.3

after 24 h of induction (Figure 4.3a). After induction, we detected a large fraction of surviving

colonies with kill switch inactivation (Figure 4.3b). By 48 h of induction, the CRISPRks
monoculture had rebounded to pre-induction levels (Figure 4.3a). We hypothesized that
supplementing the assay with microbes that fill the same niche as the CRISPRks strain could
prevent the rapid regrowth of escape mutants and maximize killing efficiency [31]. We introduced
competition into the assay by incubating the spectinomycin-resistant CRISPRks strain at a 1:1
ratio with a chloramphenicol-resistant control strain. In this mixture, the CRISPRks strain achieved
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an improved fraction viable of 10-4.2 after 24 h of aTc induction (Figure 4.3a and Figure 7.19a).
Although a population of the 1:1 consortium cells with non-functional kill switches was detected
among the colonies that survived aTc induction, it was significantly smaller than the population
detected from the CRISPRks monocultures (Figure 4.3b). Importantly, the fraction viable remained
stable over the course of the experiment, suggesting that intra-niche competition is important to
prevent the repopulation of escape mutants.
CRISPRks escape mutants were observed in the assay emulating in vivo conditions but not
when tested under more optimal conditions (Figure 4.2f), suggesting that the mutations accumulated
de novo during the assay rather than existed in the inoculum population. Single DNA DSBs, as
induced by CRISPR-Cas9, have been shown to strongly induce the SOS response in E. coli [41,
42]. This response increases the mutation rate of the cell through the expression of recombinase
genes, including recA, and diverse error-prone DNA polymerase genes, including polB, dinB, and
umuDC. Thus, we hypothesized that a nutrient- and growth-limited environment, which have been
shown to reduce per cell protein production [43], reduces expression of the kill switch, impairing
the DNA-cleavage rate and allowing the survival of daughter cells with an induced SOS response
and elevated kill switch inactivation rate. To reduce SOS-response mediated DNA mutagenesis,
we knocked out recA, polB, dinB, and umuDC (Δrpdu) from the CRISPRks strain. The CRISPRks
Δrpdu kill switch maintained complete killing in optimal growth conditions (Figure 7.19b). In an
assay emulating in vivo conditions, the CRISPRks Δrpdu strain achieved a similar fraction viable
as the CRISPRks strain in the absence of competition (Figure 4.3a). However, CRISPRks Δrpdu
had a significantly smaller population of non-functional survivors after 24 h of induction,
indicating a reduced rate of inactivation, but with a similar mutation profile (Figure 4.3b-c). Most
mutations for both strains were in the promoters of the Ptet-cas9 and Ptet-gRNA expression

115

cassettes. No mutations were identified in the infA cassette or the gRNA target sites. Strikingly, in
the presence of competition from the control strain, CRISPRks Δrpdu cells were eliminated from
the culture by 72 h of aTc induction (Figure 4.3a and Figure 7.19a). Using the same assay, we found
that the CRISPRks Δrpdu strain was able to be eliminated from the culture at control:kill switch
ratios as low as 1:1000 (Figure 7.19c). This is important because it suggests the mitigation of kill
switch escape afforded by intra-niche competition is robust against stochastic variation in sample
preparation and colonization efficiencies of the two strains; further, a lower proportion of control
relative to engineered probiotic would help maximize therapeutic potential. Both the CRISPRks
and CRISPRks Δrpdu strains showed similar long-term killing efficiencies, kill switch inactivation
rates, and mutation patterns in optimal growth conditions (Figure 7.19d-f). As such, while the Δrpdu
knockouts significantly reduce induction-dependent kill switch inactivation, they have no impact
on the mutation rate during normal DNA replication.
We then tested the efficacy of the CRISPRks and CRISPRks Δrpdu strains in vivo.
C57BL/6 mice were treated with streptomycin to enable EcN colonization [44] (Figure 4.3d). 24
hours later, 108 CFU of kill switch or control EcN, with or without the Δrpdu knockouts, were
delivered to mice by oral gavage. 24 hours after EcN gavage, mice were switched to aTc treatment
water (105 ng/mL aTc + 5% sucrose) or control water (5% sucrose) ad libitum, and fecal samples
were collected longitudinally (Figure 4.3d). While both kill switch strains demonstrated significant
killing activity in vivo, the CRISPRks Δrpdu strain exhibited improved killing efficacy with a 4log reduction in fecal titers after 24 hours of aTc treatment, compared to a 1-log reduction for the
CRISPRks strain at the same timepoint (Figure 4.3e, f). In addition, as observed in vitro (Figure
4.3b), the Δrpdu knockouts mitigated the incidence of escape mutants; fewer CRISPRks Δrpdu
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isolates (57±37% versus 100±0%) recovered from stool at the 24-hour timepoint exhibited loss of
kill switch activity in follow-up in vitro assays (Figure 4.3g).
CRISPRks-mediated reduction of EcN titers in vivo was transient even with the Δrpdu
knockouts. Fecal kill switch titers in aTc-treated mice approached that of mice given control water
by 72 hours of treatment (Figure 4.3e, f). At this timepoint, 100% of recovered kill switch isolates
from aTc-treated mice demonstrated loss-of-function in follow-up in vitro assays (Figure 4.3g),
indicating a bloom of an escape mutant population in vivo. We additionally observed that fecal
titers of the control strains were low on average and highly variable at treatment baseline (Figure
7.19g, h). In contrast, fecal titers of CRISPRks strains consistently reached 5-6 logs at treatment

baseline (Figure 4.3e, f). We hypothesized that the spectinomycin-resistant kill switch strains were
cross-resistant to the streptomycin used for knockdown of the native microbiota, a phenotype not
afforded to the chloramphenicol-resistant control strains. Indeed, we observed that baseline fecal
titers of chloramphenicol-resistant EcN were dependent on the length of the interval between
streptomycin and EcN gavage, while those of an isogenic spectinomycin-resistant strain of EcN
were not (Figure 7.20a, b). We sought to optimize the microbiota knockdown protocol to
consistently achieve equal baseline titers of the control and CRISPRks strains, either by extending
the interval between streptomycin treatment and EcN gavage or through use of an alternative
antibiotic, and determined that waiting 72 hours after streptomycin treatment enables equivalent
baseline titers of chloramphenicol-resistant and spectinomycin-resistant EcN (Figure 7.20b). In
contrast, omission of any antibiotic treatment resulted in undetectable levels of either EcN strain
(Figure 7.20c), indicating a failure to colonize, while treatment with carbenicillin [45] 48 hours
before EcN gavage resulted in low and variable titers of both EcN strains (Figure 7.20d).
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Figure 4.3: Complete killing is achieved by the CRISPRks in vivo after knocking out key components of the SOS response and
providing intra-niche competition. A) Log10 CFUs of the CRISPRks and CRISPRks Δrpdu kill switch strains when

incubated alone or at a 1:1 ratio with the no gRNA control. Cells were cultured anaerobically at 37°C
without shaking in M9+0.4% glucose and induced with 0 or 500 ng/mL aTc. Fraction viable values of <-8
had no colonies obtained from cultures receiving aTc. Values and error bars are the average and standard
deviation of biological triplicate, respectively. B) Percent of cells that survived 24 h of aTc induction with
non-functional kill switches. 24 colonies (8 from each replicate) of each condition were tested for
functionality. C) Sequencing results from 24 CRISPRks and 24 CRISPRks Δrpdu survivors (8 from each
replicate) from (A) with non-functional ile-2 kill switches. The fraction mutated is the fraction of total
sequenced cassettes that contained a mutation. D) Schematic for testing the kill switches in vivo. 24 h
after a streptomycin treatment, 108 CFUs of CRISPRks or CRISPRks Δrpdu were gavaged into C57BL/6 mice.
24 h after gavage, mice receiving each kill switch strain were split into two groups. One group received
control water (5% sucrose) and the other group received aTc treatment water (105 ng/mL aTc + 5%
sucrose). Fecal samples were collected 0, 6, 24, and 72 h after gavage for CFU quantification. E and F)
Log10 CFUs/mg feces of (E) CRISPRks or (F) CRISPRks Δrpdu strains from mice receiving control water or
aTc treatment water. Points are the average of two technical replicates. Lines and error bars are the
average and standard error from 6 (E) or 4 (F) mice across two cages, respectively. G) Percent of CRISPRks
and CRISPRks Δrpdu cells that survived aTc treatment with non-functional kill switches. To assay for kill
switch functionality, exponential phase cells were induced with 0 and 500 ng/mL aTc for 3 h and the
absorbance at 600nm quantified. Induced to uninduced absorbance ratios within three standard
deviations of the no gRNA control strain were deemed non-functional. 24 colonies (12 from each cage)
at each timepoint were tested for functionality. H) Schematic for testing control and kill switch co-gavage
in vivo. 72 h after a streptomycin treatment, 108 CFUs of a 1:1 ratio mixture of the no gRNA control strain
and CRISPRks Δrpdu were gavaged into C57BL/6 mice. 24 h after gavage, mice receiving each kill switch
strain were split into two groups. One group received control water (5% sucrose) and the other group
received aTc treatment water (105 ng/mL aTc + 5% sucrose). Fecal samples were collected 0, 6, 24, and 48
h after gavage for CFU quantification. At the conclusion of the experiment (192 h), mice were sacrificed
and cecal contents were collected for CFU quantification. I and J) Log10 CFUs/mg feces (I) or cecal contents
(J) of CRISPRks Δrpdu from mice receiving a 1:1 ratio mixture of CRISPRks Δrpdu and the no gRNA control
strain. Points are the average of two technical replicates. Cecal contents were sampled 8 days after
gavage. Lines and error bars are the average and standard error from 4 mice across two cages,
respectively. K) Percent of CRISPRks Δrpdu cells that survived aTc treatment with non-functional kill
switches when gavaged alone or in a 1:1 ratio mixture with the no gRNA control strain. 24 colonies (12
from each cage) at each timepoint were tested for functionality. Statistical comparisons were performed
using two-tailed unpaired t-tests (B and C) or mixed model ANOVA with Sidak's multiple comparisons (EG, I, and J), (*, P < 0.05; **, P < 0.01; ***, P < 0.001). See also Figure 7.19 and Figure 7.20.

We therefore carried out another experiment in mice with the CRISPRks Δrpdu and control
Δrpdu strains with a 72 h interval between streptomycin and EcN gavage. Motivated by the
hypothesis that intra-niche competition by an isogenic non-kill switch EcN strain can support
eradication of the kill switch EcN population, we included an additional arm in which we cogavaged the kill switch and control strains at a 1:1 ratio (Figure 4.3h). This is an attractive approach
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when the goal is eradication of a specific population of engineered microbes, rather than a probiotic
species itself, from the gut. Using the 72 h interval, we were able to achieve equivalent baseline
titers of spectinomycin-resistant CRISPRks Δrpdu and chloramphenicol-resistant control Δrpdu
EcN (Figure 4.3i and Figure 7.20e, f). Remarkably, when CRISPRks Δrpdu EcN was co-gavaged
with control Δrpdu EcN, the CRISPRks Δrpdu strain was no longer detectable in stool by 48 hours
of aTc treatment (Figure 4.3i). Except for a single colony observed after plating undiluted fecal
homogenate, the CRISPRks Δrpdu strain remained undetectable in cecal contents after 8 days of
aTc treatment, demonstrating almost complete eradication of the engineering microbe from the
mice (Figure 4.3j). In contrast, titers of control Δrpdu EcN in the same mice remained stable over
the course of aTc treatment, as did titers of both strains (similarly co-gavaged) in mice treated with
control water (Figure 4.3i). Correspondingly, we were still able to detect EcN in the ceca of these
mice at sacrifice, with cecal titers not significantly different between the control strain in either
treatment arm and the CRISPRks Δrpdu strain in the control water arm (Figure 4.3j). After 24 hours
of aTc treatment in vivo, 100% of CRISPRks Δrpdu isolates recovered from mice colonized with
only this strain exhibited loss of kill switch function in vitro, while no loss of function was
observed in isolates of the same strain from co-gavaged mice (Figure 4.3k). These data indicate that
a combined approach of kill switch induction and intra-niche competition can mitigate the
emergence of escape mutant populations in vivo.
Development of a 2-input CRISPRks that responds to both aTc and reduced temperatures
Several temperature sensors have been characterized in other strains of E. coli [30, 46, 47].
Of these sensors, the PtlpA promoter with a modified TlpA regulator protein from Salmonella
demonstrated the highest fold-change in expression in response to a temperature reduction. TlpA
is a transcriptional regulator that assembles into homodimers and represses transcription from the
PtlpA promoter at low temperatures [48]. At high temperatures the dimers are unable to form,
120

allowing transcription. To characterize the sensor in EcN, we obtained the PtlpA-tlpA temperature
sensing system from Salmonella typhimurium SL1344 genomic DNA and used it to drive
expression of a green fluorescent protein (GFP) reporter. The wild-type TlpA sensor induced GFP
expression with a half maximal fluorescence at 43.4°C, significantly above our desired range
(Figure 7.21a). We next inserted five amino acid substitutions identified by Pirner et al. to generate
the modified TlpA sensor, TlpA* [30]. As previously reported, the mutations shifted the half
maximal fluorescence to a temperature of 35.6°C (Figure 7.21b). Expression of GFP was 97%
repressed at a temperature of 34°C compared to 37°C.
To make a 2-input CRISPRks that induces cell death in response to both aTc and a
temperature downshift (i.e., an OR gate), we replaced the constitutive promoter driving TetR
expression with the PtlpA-tlpA* temperature sensor (Figure 4.4a). With this design, TetR expression
is inhibited by TlpA* at low temperatures (< 33°C), de-repressing expression of the kill switch. At
37°C, TetR is expressed, and the kill switch remains sensitive to aTc. This initial 2-input
CRISPRks achieved complete cell death in response to aTc, but only a modest reduction in fraction
viable (10-1.7) at 30°C (Figure 4.4b). We hypothesized that the temperature-dependent response was
poor because the circuit inhibits new TetR production but not the activity of TetR already in the
cell. Numerous cell divisions may be required to dilute cytosolic TetR concentrations below the
threshold for kill switch induction. To test this hypothesis, we performed a liquid-phase,
temperature-response kill switch assay using a range of initial dilution factors, where larger
starting dilutions would allow more growth and smaller per-cell TetR concentrations. The killing
efficiency was directly correlated to the dilution factor, confirming the dependence on cell
divisions for kill switch activation (Figure 7.21c). To improve the response to temperature, we
sought to uncouple TetR removal from cell growth. We simultaneously optimized the expression
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A) Schematic of the
joint aTc- and temperature-inducible CRISPRks system. Cas9 is expressed from four genome-integrated
aTc-inducible Ptet-cas9 cassettes, and gRNAs are expressed from three aTc-inducible Ptet-gRNA expression
cassettes on a plasmid. TetR, which regulates the expression of the Ptet promoters in an aTc-dependent
manner, is expressed by the PtlpA promoter on the gRNA plasmid. Activity of the PtlpA promoter is regulated
by the TlpA* transcription factor. TlpA* is expressed from the same PtlpA promoter and regulates its own
expression in a negative feedback loop. In the presence of aTc or in temperatures less than 33°C, the Cas9gRNA complex is produced, leading to cell death. B) Log10 CFUs for the no gRNA control, initial 2-input
CRISPRks, and optimized 2-input CRISPRks. Exponential phase cells for each strain were induced with 0
and 500 ng/mL aTc at 37°C for 3 h. Cultures were then plated on LB agar without antibiotics and incubated
overnight at 37°C (both 0 and 500 n/mL aTc cultures) or for seven days at 30°C (0 ng/mL cultures) for CFU
quantification. C) The expression and stability of TetR was optimized for the 2-input CRISPRks by
simultaneously tuning the strength of the RBS and inserting a C-terminus SsrA degradation tag library onto
TetR. D) Long-term stability of the optimized 2-input kill switch. Each day for 28 days, three replicates of
the strain were diluted 250X into fresh LB without antibiotics and grown for 24 h. Every 3-4 days,
exponential phase cells were plated on LB agar without antibiotics and incubated overnight at 37°C and
for 7 days at 30°C for CFU quantification. Fraction viable values of <-7 had no colonies obtained from
cultures receiving aTc. E) Cell death transfer curve with respect to temperature for the no gRNA control
Figure 4.4: Development of a 2-input CRISPRks that responds to both aTc and reduced temperatures.
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and the optimized 2-input kill switch. Exponential phase cells were incubated in a thermocycler for 5 h at
a range of temperatures: 30, 30.6, 31.6, 32.8, 34.4, 35.6, 36.4, and 37°C. Points represent experimental
data while the line represents the fitted curve. Values and error bars are the average and standard
deviation of biological triplicate, respectively. See also Figure 7.21 and Table 8.9.

level and stability of TetR by inserting a ribosome binding site (RBS) library and a C-terminal
SsrA degradation tag library, respectively (Figure 4.4c). We tested over 500 2-input CRISPRks
Δrpdu variants from the combined RBS and degradation tag library and identified eight that
achieved efficient cell death at 30°C with minimal growth inhibition at 37°C ( Figure 7.21d). To
select the best kill switch, we assayed select variants for long-term stability and temperature
sensitivity (Figure 7.21e, f). The final selected variant was highly stable over 28 days of growth
(Figure 4.4d) and demonstrated an ultrasensitive response to temperature, with no killing at 3337°C and strong killing at temperatures less than 32°C (Figure 4.4e).
The 2-input CRISPRks efficiently kills EcN in response to both aTc treatment and excretion from
mice
We next tested the in vivo efficiency of the 2-input CRISPRks Δrpdu strain when gavaged
into streptomycin-treated mice alone, or in co-gavage with the cognate control strain at a 1:1 ratio
(Figure 4.5a). In a control arm, mice were instead singly-gavaged with the control strain as before.
To assay chemical induction of the 2-input kill switch, 24 hours after EcN gavage, mice were
switched to aTc treatment water or control water ad libitum, and fecal samples were collected
longitudinally over a week (Figure 4.5a). To assay temperature induction of the 2-input kill switch,
collected stool was processed at both 37°C and room temperature (22°C); results from samples
processed at 37°C reflect only within-gut aTc induction of kill switch activity, while those
processed at 22°C additionally reflect temperature induction of the kill switch after excretion.
When singly-gavaged, aTc induction of the 2-input CRISPRks Δrpdu strain within mice
resulted in a significant (3-log) reduction in fecal titers. However, this response was again transient
over the first 48 hours of treatment with the kill switch population rebounding to baseline levels
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by 72 hours and remaining high in stool on day 7 and in the ceca on day 8 (Figure 7.22b-c, top).
Temperature induction of the 2-input CRISPRks Δrpdu strain in stool collected from these mice
greatly improved killing efficacy; we consistently observed 1- to 2-log CFU/mg EcN in stool from
mice that were not induced with aTc, 5-log lower than control strain titers, indicating that this
reduction was driven by temperature induction alone (Figure 7.22b, bottom). When combined with
aTc induction in mice, temperature induction (i.e., post-excretion) further reduced fecal titers such
that we were unable to detect EcN in stool from these mice at the 24- and 48-hour timepoints
(Figure 7.22b, bottom). However, the kill switch population was not completely eradicated as we
were able to detect it in stool on day 7 and in the ceca on day 8 (Figure 7.22b-c, bottom).
Interestingly, we also observed greater variability in stool titers of the control strain in mice treated
with aTc compared to control water, including one mouse in which we were unable to detect
control strain at multiple timepoints (Figure 7.22a). This high variability may be due to aTc
induction of the Cas9 complex (which the control strain carries despite lacking gRNAs) leading to
decreased in vivo fitness, potentially coupled with a rise of control strain subpopulations with
inactivating mutations (e.g., mutations in the Ptet promoter driving Cas9 expression).
Co-gavage of the 2-input CRIPRSks Δrpdu strain with the control strain, providing intraniche competition, mitigated the bloom of an escape mutant population during aTc treatment
(Figure 4.5b, top). This was evidenced by significantly lower (p = 0.0006; mixed model ANOVA)
stool and cecal titers of the kill switch strain in aTc-treated mice compared to control strain titers
in the same mice, or to either strain in mice treated with control water. Correspondingly, fewer kill
switch isolates recovered from co-gavaged mice exhibited loss of function in follow-up in vitro
kill switch assays compared to isolates from singly-gavaged mice (29±6% compared to 92±12%
on day 3, and 67±24% compared to 100% by day 7) (Figure 4.5c). As in the single-gavage arm
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Figure 4.5: The 2-input CRISPRks efficiently kills EcN in response to both aTc treatment and excretion from mice. A) Schematic

for testing co-gavage of the control strain and 2-input CRISPRks in vivo. 72 h after a streptomycin
treatment, 108 CFUs of a 1:1 ratio mixture of the no gRNA control strain and 2-input CRISPRks were
gavaged into C57BL/6 mice. 24 h after gavage, mice were split into two groups. One group received control
water (5% sucrose) and the other group received aTc treatment water (105 ng/mL aTc + 5% sucrose). Fecal
samples were collected 0, 24, 48, 72, and 168 h after gavage for CFU quantification. At the conclusion of
the experiment (192 h), mice were sacrificed and cecal contents were collected for CFU quantification.
Fecal and cecal contents were plated at 37°C overnight or room temperature (RT) for 48 h. Samples were
also incubated in LB broth at RT for 24 h and plated at RT for 48 h for CFU quantification. B) Log10 CFUs/mg
feces (left) or cecal contents (right) of 2-input CRISPRks cells from mice receiving a 1:1 ratio mixture of 2input CRISPRks and the no gRNA control strain. CFUs were quantified at 37°C (top) or RT (bottom). Points
are the average of two technical replicates. Lines and error bars are the average and standard error from
6 mice across two cages, respectively. Statistical comparisons were made between control water and aTc
treatment (top) or control strain and 2-input CRISPRks (bottom). C) Percent of 2-input CRISPRks cells that
survived aTc treatment or control water with non-functional kill switches when gavaged alone (from
Figure 7.22b, top) or in a 1:1 ratio mixture of 2-input CRISPRks and the no gRNA control strain (from Figure
4.5b, top). To assay for kill switch functionality, exponential phase cells were induced with 0 and 500
ng/mL aTc for 3 h and the absorbance at 600nm quantified. Induced to uninduced absorbance ratios
within three standard deviations of the no gRNA control strain were deemed non-functional. 24 colonies
(12 from each cage) at each timepoint were tested for functionality through an in vitro aTc-response
assay. D) Sequencing results from 24 2-input CRISPRks survivors from Figure 4.5b, top with non-functional
kill switches. The fraction mutated is the fraction of total sequenced cassettes that contained a mutation.
Mutations in the PtlpA promoter are counted as mutations in both the tetR and tlpA expression cassettes.
E) RT growth assays for control and 2-input CRISPRks cells obtained from fecal or cecal samples at different
timepoints in Figure 4.5b. F) CFUs of control and 2-input CRISPRks cells from Figure 4.5e following 24 h of
RT growth. Points are the average of two technical replicates. Values and error bars are the average and
standard error from 6 mice across two cages, respectively. Statistical comparisons were performed using
mixed model ANOVA (C) or mixed model ANOVA with Sidak's multiple comparisons (B and F) (*, P < 0.05;
**, P < 0.01; ***, P < 0.001, ****, P < 0.0001). See also Figure 7.22.

(Figure 7.22), in samples from co-gavaged mice, temperature induction alone of the 2-input kill
switch resulted in high killing efficacy (1-log CFU/mg feces [grey circles] compared to 4-log
CFU/mg for the control strain in the same mice [white triangles]), but the kill switch population
increased in titer by day 7 (Figure 4.5b, bottom). When we sequenced non-functional isolates, we
identified mutations throughout the cas9, gRNA, tetR, and tlpA expression cassettes, suggesting
the presence of diverse inactivation mechanisms and that the stability of the kill switch cannot be
easily improved through additional functional redundances (Figure 4.5d). Again, no mutations were
identified in the infA cassette or the gRNA target sites.
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Strikingly, a combination approach, including provision of intra-niche competition by a
competing strain, within-gut chemical kill switch induction, and temperature kill switch induction
outside the gut, was effective at eradicating the kill switch population; with these conditions, we
were unable to detect the 2-input CRISPRks strain in stool beginning at the 24-hour timepoint and
through the end of the experiment, nor in the ceca on day 8 (Figure 4.5b, bottom [red circles]). In
addition to plating directly from stool and ceca to quantify EcN, we used fecal and cecal samples
to inoculate room temperature kinetic growth assays in rich media as a more sensitive measure of
temperature-induced biocontainment, where any EcN population that may have been below the
limit of detection of the direct plating assays has the opportunity to amplify (Figure 4.5e-f, Figure
7.22d-e). In line with the direct plating results, while on days 7 and 8 (cecal timepoint), we observed

some growth of the 2-input CRISPRks Δrpdu strain in cultures inoculated from mice not treated
with aTc (gray lines), we observed no growth over 24 hours of the kill switch strain in cultures
inoculated from mice that had been treated with aTc (red lines, Figure 4.5e); with the exception of
an average of 101.4 kill switch colonies observed at the 72-hour timepoint, plating from the kinetic
growth assays at their termination to quantify CFUs confirmed this result (Figure 4.5f). In contrast,
in growth assays inoculated from mice treated with aTc in the single-gavage arms, we observed
no significant difference in titers of 2-input kill switch strains and control strains (Figure 7.22d, e).
These data indicate that intra-niche strain competition is required to mitigate aTc-mediated
selection for kill switch mutants that escape both chemical and temperature induction modalities.
It is important that biocontainment systems minimally impact the protein production
capability and therapeutic potential of the engineered microbe. To determine how the kill switches
designed here impact protein expression in EcN, we quantified the expression of a constitutively
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Figure 4.6: Summary of sequencing results from non-functional kill switches and potential mechanisms of circuit inactivation.

A) Potential mechanisms of kill switch inactivation and cell survival. DSB, double-strand break. B)
Classifications of the observed mutations in Ptet-cas9, Ptet-gRNA, tetR, and tlpA expression cassettes. C)
Sequence of the most commonly observed inactivation mutation in the utilized Ptet promoters.

expressed GFP reporter using both a genome-integrated and plasmid-based cassette. Both the
CRISPRks Δrpdu strain and the 2-input CRISPRks Δrpdu strain achieved GFP expression levels
equivalent to wild-type EcN and the no gRNA control strain (Figure 7.23). This trend remained true
for both genome-integrated and plasmid-based expression methods. As such, the aTc-responsive
CRISPRks Δrpdu kill switch and the aTc- and temperature-responsive 2-input CRISPRks Δrpdu
kill switch can be effectively applied towards the biocontainment of engineered therapeutic and
diagnostic microbes.
Discussion
Robust control of the viability of engineered probiotics is essential for the host safety and
the environmental protection. The aTc-only and 2-input CRISPRks strains developed here allow
the growth of EcN to be tightly controlled during in vivo applications. To develop the two
CRISPRks strains, we explored a variety of methods for optimizing genetic stability, including
incorporating multiple functionally redundant Cas9 and gRNA expression cassettes (Figure 4.1 and
Figure 4.2), eliminating reliance on antibiotics for kill switch maintenance (Figure 4.2), knocking

out key SOS response genes involved in DNA mutagenesis (Figure 4.3), providing intra-niche
competition (Figure 4.3 and Figure 4.5), and combining two layered methods of viability control
(Figure 4.4 and Figure 4.5).
In this work, we addressed two routes of DNA mutagenesis that contributed to kill switch
instability (Figure 4.6a). First, we mitigated stochastic inactivation of kill switch constructs
resulting from the natural and slow accumulation of errors that occurs during DNA replication [49,
50]. Introduction of functionally redundant Cas9 and gRNA expression cassettes reduced the kill
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switch inactivation rate due to these processes, enabling kill switch stability for at least 28 days of
growth. However, we continued to detect inactivated CRISPRks variants after about 14 days of
growth (Figure 7.19d-f). The rate of evolution can potentially be further reduced by optimizing the
metabolic burden required to maintain the circuit [51], improving the accuracy of DNA replication
[52], and knocking out transposable elements [53, 54]. The second route of kill switch inactivation
involved SOS-mediated DNA mutagenesis in response to the DSBs caused by Cas9 (Figure 4.6a).
Escape mutants of our CRISPRks strain only arose via this process when tested in vivo or with in
vivo-like conditions where resources and growth are limited [55]. In these conditions, limited
induction of the kill switch may lead to incomplete cleavage of the multi-copy replicating
chromosome. Low levels of DSBs per cell would allow daughter cells to survive with intact copies
of the chromosome, but with an activated SOS response and an elevated rate of DNA mutagenesis.
In agreement with this hypothesis, expression of a genome-integrated GFP reporter is significantly
weaker in minimal medium compared to rich medium, suggesting lower Cas9 expression levels in
nutrient poor conditions (Figure 7.23). In addition, even single double strand breaks have been
shown to strongly induce the SOS response [41]. We successfully reduced SOS-mediated
inactivation through the Δrpdu knockouts, allowing for complete killing of the CRISPRks strain
in growth-limited conditions. Knocking out alternative recombinases with known low levels of
activity may further improve the stability of the 2-input CRISPRks in vivo [56]. In addition, our
current gRNAs target the chromosome near the origin of replication where growth-dependent copy
numbers would be highest (Figure 4.1b). Utilizing gRNAs that instead target the region where
growth-dependent chromosomal copy numbers are lower may decrease the number of daughter
cells that escape kill switch induction with intact genomes and reduce the potential for SOSmediated kill switch inactivation.

130

Mutations in the Ptet-cas9 and Ptet-gRNA cassettes each contributed to ~45% of the total
observed mutations, highlighting the importance of functionally redundant expression cassettes
(Figure 4.6b). Importantly, the Ptet promoters within these cassettes were the primary source of
instability. The Ptet promoter used in these kill switches contains two identical 19bp tet operator
sites. Over 50% of the total observed mutations were 25bp deletions including one of these
operators and most of the -35 site (Figure 4.6c). These deletions can occur through RecA-dependent
homologous recombination, or RecA-independent rearrangement of tandem repeat sequences by
replication slippage, sister-chromosome exchange-associated slippage, and single-strand
annealing [50]. Replacing the Ptet promoters with engineered variants that have only one tet
operator site or operator sites with lower sequence identity, or using alternative chemical-inducible
promoters lacking internal homology, may further improve the stability of the kill switches.
Biocontainment of genetically engineered organisms must not neglect biocontainment of
the corresponding recombinant nucleic acids, due to the possibility of horizontal gene transfer of
e.g. antibiotic resistance genes especially as mediated by plasmids [57, 58]. Our kill switch design
mitigates this possibility in that the only plasmid-borne elements include the Tet repressor, which
does not alone confer antibiotic resistance, and the gRNAs, which carry inherent specificity to the
EcN genome and whose transcription should have no cleaving effect in the absence of the Cas9
cassette. As such, the incorporation of the infA plasmid-maintenance system served to both
improve stability of the kill switch and reduce the risk of antibiotic resistance gene dissemination.
We included plasmid-borne spectinomycin and chloramphenicol resistance genes to selectively
distinguish our control and CRISPRks strains in co-culture and co-gavage experiments; clinical
iterations of the kill switch strains would omit these selective markers.
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Inspired by the competitive inter-strain exclusion properties observed in gut pathogens [59]
and commensals alike [31, 60], we hypothesized genetic approaches for mitigating kill switch
escape could be complemented at the population level by external competitive pressure. With the
goal of eliminating a specific subpopulation of engineered microbes and not a probiotic species
itself from the gut, we provided both CRISPRks EcN and control EcN in our animal models, and
demonstrated that kill switch induction in synergy with competitive exclusion enabled virtually
complete eradication of the kill switch population. Co- or pre-administration of a wild-type
probiotic strain in clinical applications of engineered probiotics could help prime the gut for
induced elimination of the engineered probiotic. However, ways to ensure the stability of both
populations prior to kill switch induction must be further investigated.
The performance of the kill switches could be further improved by addition of an
orthogonal kill switch mechanism, an approach that has recently been demonstrated to have a
multiplicative effect on efficacy [18]. In the absence of aTc exposure in the gut (i.e., induction
only with temperature upon excretion), there was an increasing incidence over time of
biocontainment failure for the 2-input CRISPRks (Figure 4.5b, bottom), suggesting that the strain
requires both induction modalities to perform robustly. Indeed, the 2-input CRISPRks also did not
achieve full efficacy in vitro when induced with temperature alone (Figure 4.4b), in contrast to the
single-input kill switch when induced with aTc in vitro (Figure 4.2c), indicating that PtlpA-driven
expression of tetR may be leaky even at low temperatures or that the TetR degradation rate is not
sufficiently high to robustly induce kill switch activation. Because the temperature- and aTc-driven
induction feed into the same kill switch mechanism, the combination of both inputs does not result
in a synergistic increase in efficacy. Similarly, induction with both temperature and aTc in the
context of intra-niche competition led to no detectable growth after direct plating of feces
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(approximately 2% of the entire fecal sample at the 1X dilution), nor after inoculating 24 hr growth
assays at room temperature to allow any putative escape mutants to amplify; the exception was at
the 72 hr timepoint, where after 24 hours of growth in rich media we observed a mean 583 CFU/mL
of the 2-input CRISPRks (Figure 4.5f). With a room temperature doubling time of 115 minutes
estimated from control strain titers from the same mice at the same timepoint, this implies a
baseline CRISPRks titer of 0.1 CFU/mL, or approximately 100 CFU in the entire fecal sample
given our inoculation scheme. This was not captured when plating directly from feces (Figure 4.5b,
bottom), highlighting the importance of survival assay sensitivity in the development of kill
switches. Escape events such as this could also be mitigated by addition of an orthogonal kill
switch circuit, in addition to further optimization of the tlpA and tetR cassettes.
In summary, we developed CRISPR-based kill switches in EcN to create a safe probiotic
chassis for future biomedical technologies. These kill switches allow EcN to proliferate under
normal gut conditions and initiate cell death in response to oral consumption of an inducer and
excretion from the body. We have demonstrated a kill switch approach to on-demand selective
removal of engineered microbes from the gut. We also explored diverse methods for improving
the stability of the kill switches and minimized key mechanisms of kill switch inactivation. The
engineered kill switches apply genetic parts (CRISPR/Cas9 and TetR/Ptet) that have been shown
to be functional in diverse microbes [32-34]. As such, similar kill switches can be engineered for
a larger panel of probiotic microbes. Furthermore, the temperature sensing module can be replaced
with sensors for alternative environmental conditions [46] and chemicals [61-63] to create 2-input
kill switches for novel applications. These microbial biocontainment tools will facilitate the
creation of living therapeutics or other microbes for environmental applications that are more
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robust, predictable, and controllable, which is critical for both regulatory approval and public
acceptance of genetically modified organisms.
Materials and Methods
Experimental model and subject details
All plasmids were assembled in and purified from E. coli DH10B. Purified plasmids were
subsequently transferred to and tested in wild-type or engineered E. coli Nissle 1917 variants
lacking the two native plasmids, pMUT1 and pMUT2.
All mouse experiments were approved by the Washington University in Saint Louis School
of Medicine Institutional Animal Care and Use Committee, and performed in AAALACaccredited facilities in accordance with the National Institutes of Health guide for the case and use
of laboratory animals. All mouse experiments were performed in female 8-week old C57BL/6
mice (Jackson Labs C57BL/6J, RRID:IMSR_JAX:000664) in a specific pathogen free barrier
facility maintained by WUSM DCM. Mice were provided feed (Purina Conventional Mouse Diet
(JL Rat/Mouse 6F Auto) #5K67) and water ad libitum. Mice were co-housed with up to 5 mice
per cage, and at least 2 cages per experimental arm to account for cage effects.
Oral gavage of mice was performed using 18ga x 38mm plastic feeding tubes (FTP-18-38,
Instech). To ablate the native microbiome prior to EcN colonization, each mouse was administered
20 mg streptomycin sulfate salt (S6501, Sigma-Aldrich) in 100 µL H2O via oral gavage [44].
Streptomycin treatment of mice, often used in Salmonella enterica colonization models [44], has
also been used extensively in colonization models for commensal and pathogenic strains of
Escherichia coli [13, 31, 64-68]. 24 or 72 hours after streptomycin administration, mice were
orally gavaged with 108 CFU EcN in 100 µL phosphate buffered saline (PBS). To test alternative
microbiome ablation strategies, mice were instead orally gavaged with 6 mg carbenicillin disodium
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salt (C1389, Sigma-Aldrich) in 100 µL H2O 48 hours prior to EcN administration [45], or left
untreated prior to EcN administration.
24 hours after EcN administration, mice were switched from standard drinking water to
aTc treatment water (105 ng/mL aTc + 5% sucrose, filter sterilized) or control water (5% sucrose,
filter sterilized), provided ad libitum. Treatment water and control water were prepared fresh and
replaced daily for the duration of each experiment. Fecal samples were collected at the indicated
timepoints. At the end of each experiment, mice were sacrificed through carbon dioxide
asphyxiation.
Plasmids, strains, and growth conditions
All plasmids were assembled in E. coli DH10B using the Gibson Assembly (100 mM TrisHCl, 10 mM MgCl2, 0.2 mM dNTPs, 10 mM DTT, 5% PEG-8000, 1 mM NAD+, 4 U/μL Taq
DNA ligase, 4 U/mL T5 exonuclease, 25 U/mL Phusion DNA polymerase) or Golden Gate
Assembly (1X T4 ligase buffer, 1X Cutsmart buffer, 40 U/μL T4 ligase, 1 U/μL SapI, 1 U/μL
DpnI) methods. Wild-type or engineered EcN variants were then transformed with the purified
and sequence-verified plasmids for kill switch testing. Plasmid DNA was isolated using the
PureLink Quick Plasmid Miniprep Kit (K210011, Invitrogen), and polymerase chain reaction
(PCR) products were extracted from electrophoresis gels using the Zymoclean Gel DNA Recovery
Kit (D4008, ZYMO research). Enzymes were purchased from New England Biolabs (Ipswich,
MA, USA).
To construct engineered EcN variants, we utilized lambda red-mediated CRISPR-Cas9
recombineering as previously described [69]. To create knockouts of specific genes, gRNAs for
the pgRNA plasmid were designed using the gRNA designer from Atum (atum.bio) to target the
gene of interest. 60 bp ssDNA oligos were designed with 30 bp arms homologous to the lagging
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strand of DNA synthesis flanking the region to be knocked out. For insertions, the pgRNA plasmid
was similarly constructed. The dsDNA insert was obtained by constructing a plasmid with the
DNA to be inserted flanked by 500 bp arms homologous to the insertion region. The full product
(both arms and insert DNA) were PCR amplified and purified by gel extraction. EcN harboring
pMP11 was then transformed with 100 ng of the respective pgRNA plasmid and either 1 μM of
the ssDNA oligo or 100 ng of the dsDNA insert to initiate recombination. All sequencing was
performed by Genewiz (South Plainfield, NJ, USA). Primers were purchased from Integrated DNA
Technologies (Coralville, IA, USA).
Unless otherwise specified, LB medium was used for culturing. For Figure 4.2f, Figure 4.3a,
Figure 7.19a, and Figure 7.19c, M9 minimal medium supplemented with 1 mM MgSO4, 100 μM

CaCl2, and 0.4% w/v glucose was used. 0.2% w/v casamino acids was also added to the M9
minimal medium as specified. Medium was supplemented with the following concentrations of
antibiotics as necessary: Ampicillin 100 μg/ml, chloramphenicol 34 μg/ml, kanamycin 20 μg/ml,
10 μg/ml gentamycin, and spectinomycin 100 μg/ml (Gold Biotechnology, Olivette, MO, USA).
Unless otherwise stated, cultures were incubated at 37°C with 250 rpm shaking.
Standard kill switch assays
EcN was transformed with kill switch plasmids by electroporation and plated on LB agar
with the relevant antibiotics. Single colonies were then transferred to 1 mL of LB in 14 mL round
bottom tubes (14-959-11B, Fisher Scientific) and grown in a shaking incubator at 37°C and 250
rpm for ~2 h until exponential phase (OD600 of 0.25-0.50) was reached. To test for aTc-inducible
cell death, these cultures were diluted to an OD600 of 0.01 in 1 mL fresh LB medium with the
specified concentrations of aTc [28]. At the indicated timepoints, samples were removed from the
cultures for viable colony forming unit (CFU) quantification. CFUs were determined by plating
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10 μL of serially diluted cultures onto LB agar with the relevant antibiotics unless otherwise
specified and incubating at 37°C overnight. For cultures where no colonies were obtained in the
undiluted sample, 100 μL was also plated to ensure a more accurate quantification. The fraction
of viable cells was calculated as the ratio of CFUs obtained from the induced culture to the number
of CFUs obtained from the uninduced culture. To test for temperature-inducible cell death, the
exponential phase cultures were serially diluted and plated onto two LB agar plates. One plate was
incubated at 37°C overnight while the other plate was incubated at 30°C for two weeks. For
temperature-sensitive assays, all liquid medium and LB agar plates were preheated to 37°C for at
least two hours prior to the addition of cells.
Long-term stability kill switch assay
A long-term stability assay was used for Figure 4.2e, Figure 4.4d, Figure 7.18e, and Figure
7.21e. On day 1, single colonies were transferred to 1 mL LB without antibiotics, incubated until

an OD600 of 0.25-0.50 was reached, and diluted to an OD600 of 0.01 for the standard aTc kill
switch assay or directly plated onto LB agar for the standard temperature kill switch assay as
before. The original undiluted cultures were then returned to the shaking incubator and cultured
for an additional ~22 h (24 h of incubation total). After the 24 h incubation, each culture was
diluted 250X into fresh LB without antibiotics and incubated for an additional 24 h. These daily
dilutions were repeated for a total of 28 days. Every 3-4 days, the culture was used for the kill
switch assays as described above. On assay days, culture samples were stored at -80°C in 15%
(v/v) glycerol.
Temperature-sensing transfer curve kill switch assay
For temperature-sensitive transfer curves, single colonies were then transferred to 1 mL of
LB in 14 mL round bottom tubes and grown in a shaking incubator at 37°C and 250 rpm for ~2 h
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until exponential phase (OD600 of 0.25-0.50) was reached. These cultures were then diluted to an
OD600 of 0.01 in 50 μL of fresh LB medium in PCR tubes and incubated at the specified
temperatures in a thermocycler for 5 h. CFUs were determined by plating 10 μL of serially diluted
cultures onto LB agar and incubating at 37°C overnight.
In vitro condition-poor competition kill switch assay
EcN strains with and without the Δrpdu knockouts were transformed with the no gRNA
control and the aTc-inducible CRISPRks. Single colonies for each of the four strains were grown
overnight in 5 mL LB at 37°C and 250 rpm. The following day, each culture was centrifuged at
3,000g, the LB supernatant was removed, and the cell pellet was resuspended in 5 mL M9+0.4%
glucose. For CRISPRks-only cultures, 1.5 mL of the respective CRISPRks strain was diluted into
two 15 mL conical tube at a final volume of 15 mL M9+0.4% glucose. For competitive mixture
cultures, 0.75 mL of each CRISPRks strain was also diluted at a 1:1 ratio with the respective no
gRNA control strain (1.5 mL total culture) into two additional 15 mL conical tubes. One of the
two conical tubes in each pair was induced with 500 ng/mL aTc. Each tube was capped to stop
oxygen transfer and incubated at 37°C without shaking. Every 24 h for 72 h, the cultures were
removed from the incubator, the CFUs were quantified, and the cells were diluted 10X into a new
tube with fresh M9+0.4% glucose and 500 ng/mL aTc.
Assays of intestinal samples for quantification of viable EcN
Fecal samples (and cecal samples post-sacrifice) were collected in pre-weighed sterile 2
mL microtubes, and weighed again to accurately measure sample mass. Samples were
homogenized in 500 µL PBS on a benchtop vortexer (2000 rpm for 3 min), serially diluted in PBS,
and plated on LB agar supplemented with 100 µg/mL spectinomycin dihydrochloride pentahydrate
(S4014, Sigma-Aldrich) to select for spectinomycin-resistant kill switch strains, and 34 µg/mL

138

chloramphenicol (AC227920250, Acros Organics) to select for chloramphenicol-resistant control
strains. All samples were plated on both chloramphenicol- and spectinomycin-supplemented LB
agar plates to confirm no cross-contamination of strains between experimental arms. Dilutions of
fecal or cecal homogenates plated for all experiments spanned 100 to 10-6 (i.e. undiluted
homogenate was plated for each sample). CFU/mg sample values were calculated from
enumerated colonies. Two technical replicates per intestinal sample were processed.
For experiments with the single-input CRISPRks (aTc-inducible only) strains, samples
were weighed, resuspended, serially diluted, and plated at room temperature (22°C), and plates
were incubated overnight at 37°C prior to colony enumeration. For experiments with the 2-input
CRISPRks (aTc- and temperature-inducible) strains, fecal samples were immediately placed in a
pre-warmed heatblock (37°C) inside an insulated container. Similarly, to maintain cecal samples
at 37°C, freshly sacrificed mice were kept in a 37°C incubator until dissection and collection of
cecal contents. Samples were weighed, resuspended, serially diluted, and plated inside a 37°C
warm room, using pre-warmed PBS and LB agar plates. After plating, LB plates continued to be
incubated at 37°C overnight prior to colony enumeration. To assay temperature-dependent
induction of the kill switch, samples were then moved to room temperature (22°C) and again plated
on spectinomycin- or chloramphenicol-supplemented LB agar plates. Plates were incubated at
22°C for 48 h prior to colony enumeration.
To assay biocontainment efficacy of the 2-input CRISPRks strains via room temperature
kinetic growth assays, 10 µL of the 100X dilution of each sample was inoculated into 190 uL LB
broth supplemented with 100 µg/mL spectinomycin or 34 µg/mL chloramphenicol in a 96-well
plate, and read in a plate reader (Biotek Powerwave HT) at room temperature (22°C) for 24 h
(kinetic read, 5 sec shake followed by absorbance reading at 600 nm [Abs600] at 20 min intervals).
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Additionally, at 3 h and 24 h, kinetic growth assay cultures were sampled, serially diluted, and
plated on LB agar supplemented with 100 µg/mL spectinomycin or 34 µg/mL chloramphenicol,
and incubated overnight at 37°C prior to colony enumeration.
Kill switch functionality assay
To assess whether colonies that survived kill switch assays maintained functional kill
switches, three no gRNA control colonies and the specified number of surviving kill switch
colonies were transferred to 600 μL LB in 96-deep well plates (E951032808, Fisher Scientific).
The plates were then incubated at 37°C and 250 rpm for 3 h and diluted 20X into 600 μL of fresh
LB with and without 500 ng/mL aTc. After 3 h of induction, the Abs600 was measured for each
culture, and the ratio of uninduced Abs600 to induced Abs600 was determined. Colonies with nonfunctional kill switches were defined as having Abs600 ratios within three standard deviations of
the Abs600 ratio of the no gRNA control.
Transforming gRNA plasmids into Ptet-cas9 integration strains
A temperature-curable TetR expression plasmid was constructed with a constitutive TetR
expression cassette, a temperature-sensitive oriR101 origin, and kanamycin resistance gene
(pAGR377). EcN strains with Ptet-cas9 genomic integrations were transformed with this plasmid,
plated on LB agar with kanamycin, and incubated overnight at 30°C. Cells with the pAGR377
were then made electrocompetent and transformed with the gRNA kill switch plasmids.
Transformed cells were recovered in 600 μL SOC at 30°C for 1 h. The cells were then plated onto
LB agar with spectinomycin to select for the kill switch plasmids and incubated overnight at 42°C
to cure pAGR377. Successful curing of pAGR377 was confirmed by streaking colonies on agar
plates with spectinomycin only and with both spectinomycin and kanamycin.
Generating antibiotic-independent kill switches
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To remove the antibiotic dependence of the kill switches, the infA essential gene was
knocked out of the genome and constitutively expressed on the plasmid of interest [39, 40]. To
generate an infA knockout EcN strain, the pMP11 CRISPR plasmid first was modified to
constitutively express InfA (pAGR309). The recombination protocol described above was then
used to perform and confirm the knockout. Next, the TetR expression plasmid was modified to
also constitutively express InfA (pAGR384). The infA knockout strain containing the modified
pMP11 plasmid was then transformed with AGR384 and plated on LB agar with kanamycin. The
transformants were incubated overnight at 37°C to allow for moderate curing of the ampicillinresistant modified pMP11 plasmid. Colonies from the plate were streaked onto LB agar plates with
and without ampicillin to identify colonies with successful curing of the modified pMP11 plasmid.
gRNA kill switch plasmids were constructed containing another constitutive InfA expression
cassette. Cells containing only pAGR384 were transformed with the InfA-expressing gRNA kill
switch plasmids and incubated overnight at 42°C to cure pAGR384. Successful curing of
pAGR384 was confirmed by streaking colonies on agar plates with spectinomycin only and with
both spectinomycin and kanamycin.
Growth and Fluorescence Measurements
Population absorbances at 600 nm (Abs600) were measured in 96-well black assay
microplates (07-000-088, Fisher Scientific) using a Tecan microplate reader (Infinite M200 Pro)
and converted to optical density OD600 when necessary. To measure GFP fluorescence, culture
samples were transferred to 200 μl filtered 0.9% (w/v) saline supplemented with 2 mg/ml
kanamycin in 96-well clear round bottom assay microplates (353910, Corning) for measurements.
Flow cytometry analysis was carried out using a Millipore Guava EasyCyte High Throughput Flow
Cytometer with a 488 nm excitation laser and a 512/18 nm emission filter. 10000 events for each
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sample, gated by forward and side scatter, were measured at a flow rate 0.59 μl/s. FlowJo (TreeStar
Inc.) was used to obtain the average fluorescence of the population. The fluorescence (au) of each
sample was calculated using the following formula: Fs = Fexperiment – FEcN, where Fs, Fexperiment, and
FEcN respectively represent the reported sample fluorescence, measured sample fluorescence, and
autofluorescence (background fluorescence of EcN lacking GFP).
Characterization of TlpA temperature sensors in EcN
The PtlpA promoter and tlpA gene were PCR amplified from Salmonella typhimurium
SL1344 genomic DNA and inserted upstream of gfpmut3 to form a negative feedback operon. To
convert tlpA to the modified TlpA (TlpA*) developed by Pirner et al., the following amino acid
substitutions were inserted into the tlpA gene: P60L, G135V, K187R, K202I, and L208Q [30].
After transforming EcN with each plasmid, single colonies were transferred to 5 mL of LB and
incubated overnight at 37°C and 250 rpm. The following day, cultures were diluted 1000X into 50
μL of LB in PCR tubes [30] (T3202N, Fisher Scientific). The PCR tubes were incubated in a
thermocycler running a temperature gradients between 31.5-45.5°C (TlpA) or 31-37.5°C (TlpA*)
for 24 h. The GFP fluorescence of the cultures was then quantified by flow cytometry as described
above.
Incorporating and optimizing temperature sensing in the kill switch
The PtlpA-tlpA* negative feedback cassette was inserted in place of the constitutive
promoter controlling TetR expression on the gRNA kill switch plasmid. To optimize the
expression and stability of TetR in the kill switch, a tetR RBS library and a C-terminal SsrA
degradation tag library were simultaneously inserted into the plasmid. The RBS library was
designed using the De Novo RBS Library Calculator v2.1 to have 128 different variants with
translation initiation rates spanning 20-100,000 au [70]. The initial RBS had a translation initiation
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rate of 1,500 au. The SsrA degradation tag library was constructed by randomly mutagenizing the
three nucleotides in the third to last codon of the SsrA degradation tag [71]. The total number of
potential unique construct variants was 3,328. The library was generated in E. coli DH10B and
tested in EcN.
Hill equation fitting
The Hill equation (Equation 1) was used to fit lines to the fluorescence, CFU, and
fraction viable data. The model was fit to the experimentally collected data by minimizing the
root mean square error (RMSE; Equation 2). Fitted values are listed in Table 8.9.

𝐹 = 𝐹𝑚𝑖𝑛 +

(𝐹𝑚𝑎𝑥 − 𝐹𝑚𝑖𝑛 )
𝐾 𝑛
1+( 𝐴)
[𝐿]

(1)

where
𝐹 = 𝐶𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒, CFUs/mL, or Fraction Viable
𝐹𝑚𝑎𝑥 = 𝑀𝑎𝑥𝑖𝑚𝑢𝑚 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒, CFUs/mL, or Fraction Viable
𝐹𝑚𝑖𝑛 = 𝑀𝑖𝑛𝑖𝑚𝑢𝑚 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒, CFUs/mL, or Fraction Viable
𝐾A = 𝐻𝑎𝑙𝑓 𝑚𝑎𝑥𝑖𝑚𝑎𝑙 𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡
𝑛 = 𝐻𝑖𝑙𝑙 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡
[L] = Ligand concentration or temperature

∑𝑁
𝑁=1(𝐹 − 𝐹𝑒𝑥𝑝 )
𝑅𝑀𝑆𝐸 = √
𝑁

2

(2)

where
𝐹 = 𝐶𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒, CFUs/mL, or Fraction Viable
Fexp = Actual experimental fluorescence, CFUs/mL, or Fraction Viable
N = Number of data points
Quantification and statistical analysis
All statistical tests were performed using GraphPad Prism or Excel. All statistical details
of experiments, including significance criteria, sample size, definition of center, and dispersion
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measures can be found in the figure legends and in the Results section. No sample size calculations
were performed during the design of experiments. No samples were excluded.
Data and software availability
All data and plasmid maps have been deposited to Mendeley Data (DOI:
10.17632/dwhfp2ycyw.1). Any additional information including primer sequences is available
from the Lead Contact upon request.
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Chapter 5 : The gut microbiome as an early predictor of preclinical
Alzheimer Disease
Abstract
The current paradigm of Alzheimer Disease (AD) pathology builds on a progression from
cognitively normal status, to cognitively normal with biomarker evidence of disease (preclinical
AD), to symptomatic AD characterized by both abnormal biomarker levels and cognitive
impairment. Recent work has demonstrated that the gut microbiomes of symptomatic AD patients
have distinct taxonomic compositions compared to healthy cognitively normal controls. However,
knowledge about changes in the gut microbiome prior to the onset of symptomatic AD is limited.
In this cross-sectional study we compared the taxonomic composition, microbial functional
potential, and abundances of metagenome-assembled genomes (MAGs) in a cohort of 43
cognitively normal individuals with preclinical AD and 50 cognitively normal individuals without
evidence of AD. Preclinical AD individuals had distinct gut taxonomic profiles compared to
healthy controls. Observed microbiome features correlated with amyloid, but not tau or
neurodegeneration biomarkers, suggesting changes in the microbiome occur early in the disease
process. We identified specific taxa and microbial pathways that were associated with preclinical
AD, and the inclusion of gut features improved the sensitivity of machine learning classifiers for
preclinical AD status. This observation of gut microbiome correlates of preclinical AD
neuropathology has the potential to improve our understanding of AD etiology, enable the
identification of gut-derived biomarkers of AD or AD risk, and inform the development of
therapeutic interventions.
Introduction
The human gut microbiome harbors a compositionally and functionally diverse community
of microorganisms that profoundly influences the health and well-being of its hosts [1, 2]. These
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communities include >1012 bacterial cells [2] and thousands of taxa that encode a vast repertoire
of pathways with diverse influence on host physiology and metabolism [1, 2]. Some gut microbes
train the mammalian immune system at birth, while others have lifelong immunomodulatory
activity [3, 4]. Gut microbiome dysbiosis, defined as bacterial populations correlated with poor
health outcomes and typified by diminished diversity, has been associated with numerous intestinal
and extra-intestinal disorders [2, 5-7]. Notably, gut dysfunction and aberrant intestinal microbial
content are increasingly being considered as biomarkers, and possibly drivers, of
neurodegenerative diseases like Alzheimer Disease (AD) [8].
Current concepts of AD pathobiology build on progression of individuals from cognitively
normal, to cognitively normal with biomarker evidence of disease (preclinical AD), to
symptomatic AD. These transitions are classified based on presence of amyloid (CSF or positron
emission tomography (PET)), tau (T) protein aggregation (CSF or PET), and neurodegeneration
(N) (CSF and magnetic resonance imaging (MRI)) [9]. The AT(N) paradigm suggests
neuropathology occurs years before symptom onset, defined when the clinical dementia rating
(CDR) score becomes abnormal [10]. However, the current AT(N) criteria do not take into account
potential gut microbiome dysbiosis. Evidence of dysbiosis preceding symptomatic AD will prompt
i) the possibility of complementing the AT(N) framework with gut-derived biomarkers that may
improve the accessibility and sensitivity of early screening measures, and ii) consideration for
therapies to halt AD progression that are specifically focused on the gut.
It has been reported that stools from individuals with symptomatic AD compared to those
obtained from healthy (cognitively normal) individuals have increased Bacteroidetes and
decreased Firmicutes [6], an imbalance found in other chronic inflammatory conditions [11].
Observed gut microbiomes changes correlated with classic cerebrospinal fluid (CSF) biomarkers
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of AD, including p-tau181 and Aβ42/40 [6]. Variant bacterial composition of stool in symptomatic
AD patients was accompanied by a dysregulated gut P-glycoprotein pathway [5], an alteration that
contributes to enteric inflammation and disrupted organ homeostasis, consistent with AD intestinal
dysfunction phenotypes [5]. Further support of a role for gut dysfunction in AD pathology, a
different study reported that symptomatic AD patients have increased circulating concentrations
of lipopolysaccharide (LPS) [12], presumably of gut origin. In animal models of AD, manipulation
of gut microbes decreases Aβ42 deposition and improves neurologic function [13, 14]. Finally,
gnotobiotic work demonstrated that gut bacteria from wild-type mice diminished AD pathology in
recipient mice [15].
The Alzheimer Disease Research Center (ADRC) at Washington University in St. Louis
(WUSTL) has long recruited and studied cognitively normal people with and without preclinical
AD [16-18]. In this study we leverage this existing cohort to investigate if cognitively normal
individuals with preclinical AD already have an AD-associated dysbiotic gut microbiome
compared to healthy individuals without preclinical AD, identify specific gut features that correlate
with preclinical AD status or canonical AD biomarkers, and if gut features can improve the
performance of machine learning classifiers for healthy versus preclinical AD status. Enhanced
understanding of preclinical AD-associated gut microbiomes is significant in that we may identify
new AD markers in stool, an easily acquired analyte. Further, these correlates will inform
hypotheses about how gut dysbiosis and dysfunction, concomitant with enteric and systemic
inflammation, may underlie or accelerate progression to severe neurodegeneration in those who
develop symptomatic AD.
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Results
Global differences in the microbiome profiles of healthy and preclinical AD individuals
Participants recruited from the Adult Children Study (ACS) [19] at the Knight Alzheimer
Disease Research Center (ADRC) at Washington University School of Medicine in St. Louis
submitted stool samples in 2019 and 2020, which were sequenced to an average depth of 20.2M
reads. As part of the ACS design, participants undergo multiple assessments (PET, MRI, CSF
lumbar puncture, blood draw) every 3 years, and clinical and cognitive testing including the
Clinical Dementia Rating (CDR) [10] every 3 years (< 65 years old) or every year (≥ 65 years old)
(Figure 5.1). The mean interval between stool sampling and PET imaging for amyloid and tau was
thus 2.7 years; similarly, the mean intervals between stool sampling and lumbar puncture for CSF
or blood draw were 2.6 and 3.6 years, respectively, while it was 5 months on average from
participants’ most recent CDR assessment (Figure 7.24). We defined AD preclinical status as CDR
0 and amyloid positive, with amyloid positive defined as 11C Pittsburgh compound B (PiB)-PET
standardized uptake value ratio (SUVR) > 1.2 [20]; healthy status is defined as CDR 0 and PiB
SUVR ≤ 1.2. As such we cross-sectionally compared the gut microbiomes of 50 healthy and 43
AD preclinical individuals balanced for age, sex, and years of education (Table 5.1). In addition to
AD biomarker data from neuroimaging and biofluid assays, gut microbiome sequencing
Table 5.1: Cohort demographics.

Participant demographics at the time of stool sampling stratified by AD

preclinical status.
level
N
Age (years) (mean (SD))
Sex (%)
Education (years) (mean
(SD))
Race (%)
APOE (%)

Female
Male

Black
White
ε4ε4+

healthy
50
75.74 (5.89)
29 (58.0)
21 (42.0)
16.62 (2.14)

preclinical
43
76.84 (5.28)
22 (51.2)
21 (48.8)
16.35 (2.29)

7 (14.0)
43 (86.0)
37 (74.0)
13 (26.0)

1 ( 2.3)
42 (97.7)
28 (65.1)
15 (34.9)
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P
0.350
0.652
0.556
0.103
0.481

provided three data sets for the cohort: relative abundances of microbial taxa at the species level
(profiled using MetaPhlAn2 [21]), relative abundances of microbial pathways (profiled using
HUMAnN 2.0 [22]), and median genome coverages of metagenome-assembled genomes, or
MAGs (assembled and quantified using the ATLAS pipeline [23]) (Figure 5.1, Figure 7.25).
While the Firmicutes/Bacteroidetes ratio for healthy controls (8.50, 95% CI [4.99, 12.00])
and preclinical AD (6.60, 95% CI [4.38, 8.82]) individuals did not significantly differ (Figure 5.2a),
nor did alpha (within-sample) diversities calculated on taxa, pathways, or MAGs (Figure 7.25d),

Stool metagenomic sequence data, as well as neuroimaging,
biofluid, and genetic AD biomarkers from 50 healthy (CDR 0, amyloid biomarker negative) and 43
preclinical AD (CDR 0, amyloid biomarker positive) participants were included in this cross-sectional study.
GM (gut microbiome), AD (Alzheimer Disease), AT(N) (amyloid, tau, and neurodegeneration), ML
(machine learning), PCoA (Principal Coordinates Analysis). Schematic created with BioRender. Related to
Figure 7.24.
Figure 5.1: Schematic of study design and analyses.
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A) Stacked taxonomic
(MetaPhlAn2) bar plots at the genus level by preclinical AD status, with color grouping at the phylum level
(inset legend). B) PCoA on unweighted UniFrac distances calculated from MetaPhlAn2 taxonomic profiles.
Global microbiome composition is significantly different between healthy and preclinical AD individuals
(P = 0.042, PERMANOVA). In addition, coordinates of healthy and preclinical AD samples are significantly
different along PCoA Axis 1 (P = 0.028, Student’s t-test). C) CAP ordination on unweighted UniFrac
distances calculated from MetaPhlAn2 taxonomic profiles, with preclinical AD status as the categorical
constraint (P = 0.042, PERMANOVA). In addition, sample coordinates along the CAP1 axis are significantly
different by AD status (P = 0.001, Student’s t-test). D) PCoA on Bray-Curtis dissimilarities calculated from
HUMAnN 2.0 pathway profiles. Sample coordinates along the PCoA2 axis are significantly different by
preclinical AD status (P = 0.042, Student’s t-test). E) PCoA on Bray-Curtis dissimilarities calculated from
MAG profiles (median genome coverages). Sample coordinates along the PCoA1 axis are significantly
different by preclinical AD status (P = 0.042, Student’s t-test). PCoA coordinates derived from: ●,
MetaPhlan2 taxonomic profiles; ▲, HUMAnN 2.0 functional pathway profiles; ■, MAG profiles. Ellipses
represent 95% confidence bounds around group centroids. *P < 0.05, **P < 0.01. Benjamini-Hochberg
adjusted p-values are reported. Related to Figure 7.25.
Figure 5.2: Healthy and preclinical AD individuals have distinct gut microbiome profiles.

principal coordinates analysis (PCoA) using between-sample UniFrac distances [24] revealed
global differences in gut taxonomic profiles (MetaPhlAn2) by preclinical status (P = 0.042,
PERMANOVA; P = 0.028, 95% CI [-0.12, -0.18], Student’s t-test on PCoA Axis 1 coordinates)
(Figure 5.2b). This prompted canonical analysis of principal coordinates (CAP) [25], in which
candidate explanatory variables (‘constraints’) were tested for their ability to explain variance in
sample coordinates within an unconstrained ordination; indeed, AD preclinical status explained
significant multivariate, i.e. taxonomic, differences in the cohort (P = 0.042, PERMANOVA; P =
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0.001, 95% CI [0.51, 1.58], Student’s t-test on CAP1 coordinates) (Figure 5.2c). In addition to
differences in taxonomic profiles, sample coordinates significantly differed by AD status along
Axis 2 from PCoA of microbial pathway profiles (HUMAnN 2.0) (P = 0.042, 95% CI [-0.046, 0.002] Student’s t-test), and along Axis 1 from PCoA of MAG profiles (ATLAS) (P = 0.042, 95%
CI [0.003, 0.142] Student’s t-test) (Figure 5.2d, e). These data suggest that gut microbiome changes
may arise early in the preclinical stages of the disease [5, 6]; how early these changes can occur
remains to be elucidated.
Gut microbiome profiles are correlated with amyloid, but not tau or neurodegeneration
To determine whether gut microbiome profiles were significantly correlated with specific
characteristics of preclinical AD, we carried out a pairwise Pearson correlation analysis between
the amyloid biomarkers (including PET amyloid (Centiloid) and CSF Aβ42/40), tau biomarkers
(including tau-PET and CSF p-tau), and neurodegeneration biomarkers (including CSF t-tau, white
matter hyperintensities (WMH) volume, cortical signature, hippocampus volume, and plasma
NfL) and summary measures of the gut microbiome: Shannon Diversity Index, Axes 1 and 2 from
PCoA of MetaPhlAn2 taxonomic or HUMAnN 2.0 pathway profiles, and enterotype (Figure 5.3a).
In addition, we investigated if changes in gut microbiome were associated with genetic risk factors
such as APOE ε4 allele status and polygenic risk score (PRS). Gut enterotypes, or groups of
taxonomic profiles into which individuals can be broadly clustered, were identified in an
unsupervised probabilistic clustering approach by fitting Dirichlet multinomial mixture models to
MetaPhlAn2 taxonomic profiles as previously described [26, 27]. This analysis identified two
enterotypes in the cohort with significant global differences in taxonomic composition (P = 0.001,
PERMANOVA) (Figure 7.26a, c) and alpha diversity (Richness, P < 0.001, 95% CI [4.29, 14.95];
Shannon,

P < 1E-5, 95% CI [0.19, 0.43]; Student’s t-tests) (Figure 7.26b). While sample

coordinates significantly differed across Axis 1 from the PCoA of MetaPhlan2 taxonomic profiles
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Figure 5.3: Gut microbiome profiles are significantly correlated with amyloid, but not tau or neurodegeneration biomarkers.

A) Pairwise Pearson correlations between microbiome summary metrics (green) and AD biomarkers (light
blue: amyloid; red: tau; orange: neurodegeneration; dark blue: genetic risk factors). Significant
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correlations are shown (P < 0.05, Benjamini-Hochberg adjusted), with the size of the circle inversely
proportional to the p-value. B) Linear regression of amyloid biomarkers with gut microbiome-derived
axes. Top: regression of PET amyloid (Centiloid) against PCoA2 (Taxa), that is, Axis2 from PCoA of
MetaPhlAn2 taxonomic profiles (P < 1E-12, ANOVA). Bottom: regression of CSF AB42/40 against PCoA2
(Pathways), that is, Axis 2 from PCoA of HUMAnN 2.0 pathway profiles (P = 0.004, ANOVA). C) Linear
regressions of PET tau and neurodegeneration (cortical signature) biomarkers against PCoA2 from
ordination of MetaPhlAn2 taxonomic (top) or HUMAnN 2.0 pathway (bottom) profiles. NS: not significant.
PCoA coordinates derived from: ●, MetaPhlan2 taxonomic profiles; ▲, HUMAnN 2.0 functional pathway
profiles. Benjamini-Hochberg adjusted p-values are reported. Also see Figure 7.26.

by both AD preclinical status (P = 0.028, 95% CI [-0.12, -0.18], Student’s t-test, Figure 5.2b) and
enterotype (P < 1E-10, 95% CI [0.14, 0.23], Student’s t-test, Figure 7.26a), there was no significant
enrichment of AD preclinical individuals in either enterotype group (p = 0.401, Fisher’s exact).
PET amyloid (Centiloid) was correlated with Axes 1 and 2 from PCoA of MetaPhlAn2
taxonomic profiles (ρ = 0.23, P = 0.032; ρ = 0.27, P = 0.014, respectively), as well as Axis 2 from
PCoA of HUMAnN 2.0 pathway profiles (ρ = 0.25, P = 0.019) (Figure 5.3a). The correlation of
Centiloid with MetaPhlAn2 PCoA Axis 1 is in keeping with the difference in Axis 1 sample
coordinates by AD preclinical status (Figure 5.2b) as Centiloid is derived in part from PiB SUVR
(see Methods and Materials), upon which AD preclinical status was defined. Further, the
correlation between Centiloid and PCoA Axis 2 (taxa) was driven by preclinical samples (P < 1E12, ANOVA comparing a model including the interaction between PCoA Axis 2 and preclinical
status against a null model) (Figure 5.3b [top], Table 8.10, Table 8.11). Axis 2 from PCoA of
HUMAnN 2.0 pathway profiles was additionally correlated with CSF Aβ42/40 (ρ = -0.33, P =
0.004) (Figure 5.3a), independent of AD preclinical status of the sample (P = 0.003, ANOVA)
(Figure 5.3b [bottom], Table 8.12, Table 8.13). In contrast, no microbiome measure included in this
analysis was significantly correlated with tau or neurodegeneration biomarkers (Figure 5.3a, c). As
abnormality of PET and CSF Aβ biomarkers (asymptomatic amyloidosis without
neurodegeneration) is considered the most antecedent signature within the staging framework for
preclinical AD [28], and as elevations in PET amyloid occur prior to onset of clinical symptoms
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of dementia and are associated with a greater risk of progression to symptomatic AD [29], these
results highlight the potential utility of gut microbiome correlates in early screening measures for
preclinical AD.
Specific gut microbiome features are associated with healthy or preclinical AD status
To identify specific taxa (profiled using MetaPhlAn2), microbial pathways (from
HUMAnN 2.0), or MAGs significantly associated with preclinical AD status we fit negative
binomial regression models to each of the three feature data sets, defining AD status as the only
fixed effect (Figure 5.4, Figure 7.27). The MetaPhlAn2 species most associated with preclinical AD
status (by magnitude of its model coefficient) was the Gram-negative anaerobe Barnesiella
intestinihominis of the Bacteriodetes phylum (coef = 1.274, 95% CI [1.272, 1.276], P = 0.0), while
the species most associated with healthy status in this cohort was Eubacterium limosum (coef = 3.33, 95% CI [-3.35, -3.31], P = 0.0), a Gram-positive commensal Clostridium (phylum
Firmicutes) (Figure 5.4a, Figure 7.27a). The top five MAGs (assembled genomes that were
inherently at the strain level resolution) associated with preclinical AD status were all in class
Coriobacteriia, Gram-positives of the Actinobacteria phylum (coefs = 2.862, 95% CI [2.859,
2.864]; 1.70, 95% CI [0.39, 3.01]; 1.688, 95% CI [1.685, 1.691]; 1.514, 95% CI [1.512, 1.516];
1.48, 95% CI [0.22, 2.74]; P = 0.0, 0.015, 0.0, 0.0, 0.029, respectively), while the MAG most
associated with healthy status was Blautia caecimuris, another Gram-positive commensal
Clostridium (coef = -1.743, 95% CI [-1.744, -1.743], P = 0.0) (Figure 5.4b, Figure 7.27b). Three
species were identified as significantly associated with AD preclinical status in negative binomial
regressions of both MetaPhlAn2 taxa (relative abundances), and MAGs (median genome
coverages): Barnesiella intestinihominis, Ruminococcus bromii, and Methanobrevibacter smithii
(Figure 5.4a, b). This concordance in analyses of two data sets derived from sequence data in
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Figure 5.4: Fitting negative binomial models to gut microbiome taxonomic, functional pathway, or MAG abundance data
identifies features significantly associated with AD preclinical status. Model coefficients (left panels) and prevalence

(right panels) of top-ranking features significantly associated with healthy (green) or preclinical AD
(orange) status for (A) MetaPhlAn2 taxa, (B) MAGs, and (C) HUMAnN 2.0 functional pathways. Shown are
taxa, MAGs, and pathways detected in at least 25 samples, with Benjamini-Hochberg adjusted p-values <
0.05, and with magnitude of the coefficient > 0.15 (taxa and pathways) or > 0.5 (MAGs). Error bars
represent the standard error of the coefficient. Orange triangles indicate species significantly associated
with AD preclinical status identified in independent analyses of both MetaPhlAn2 taxa and MAGs. Related
to Figure 7.27.

fundamentally different ways (MetaPhlAn2 relies on a database of clade-specific marker
sequences while MAGs are a product of assembling and binning all available reads) lends further
support to the association of these taxa with preclinical AD status.
Finally, the top two microbial pathways associated with preclinical AD status were both
part of the ribulose monophosphate (RuMP) cycle (coefs = 0.62, 95% CI [0.60, 0.64]; 0.527, 95%
CI [0.520, 0.535]; P = 0.0 in both cases), a route for the assimilation of the one-carbon compound
formaldehyde (produced by methanotrophic bacteria from the oxidation of methane) to form
central metabolism intermediates [30, 31], while the pathway most associated with healthy status
was cholate degradation (coef = -1.36, 95% CI [-1.38, -1.33], P = 0.0), i.e. metabolism of the
primary bile salt cholate into the secondary bile salt deoxycholate [32, 33] (Figure 5.4c, Figure
7.27c). Identification of specific gut microbiome feature associations with preclinical AD status,

beyond their potential utility as complements to the AT(N) framework [34] predicated on the
validation of these associations across broader cohorts, formed the foundation for mechanistic
hypotheses about etiological roles of the gut microbiome in AD progression.
Gut microbiome features improve the performance of classifiers for preclinical AD status
We next sought to determine if gut microbiome features improved the predictive
performance of Random Forest classifiers for AD preclinical status otherwise trained on basic
demographics and combinations of the amyloid (PET amyloid [Centiloid], CSF Aβ42/40), tau
(PET tau, CSF p-tau), neurodegeneration (CSF t-tau, WMH volume, cortical signature,
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hippocampus volume, plasma NfL), and genetic (APOE ε4 allele status, PRS) biomarkers (Figure
5.5a). As gut microbiome features in this study were associated with measures of amyloid, but not

tau or neurodegeneration (Figure 5.3), and as amyloid positivity underlies the definition of
preclinical AD status, we hypothesized that the greatest improvements in performance attributable
to gut microbiome features would be observed in the absence of amyloid biomarkers. We took an
exhaustive combinatorial approach to our model definitions, comparing the predictive
performance of models trained on every possible combination of the four biomarker categories
(amyloid, tau, neurodegeneration, and genetic risk), with the demographic variables age, sex, race,
and years of education included in each model (Alpha through Pi) (Figure 5.5a). Then for each
model we compared its predictive performance without and with the inclusion of gut microbiome
features: Shannon Diversity Index, enterotype, and either taxonomic relative abundances
(MetaPhlAn2) or MAG median genome coverages. To compare the performance of the different
models, we took a nested cross-validation approach in which each model was trained on 100
different balanced partitions of the cohort, and the performance metrics accuracy, negative
predictive value, positive predictive value, sensitivity, and specificity on the respective test sets
were collated (Figure 5.5b).
Supporting our hypothesis, inclusion of gut microbiome features did not improve classifier
performance in any model that included the amyloid biomarkers PET amyloid (Centiloid) and CSF
Aβ42/40 (models Alpha, Gamma, Delta, Epsilon, Iota, Kappa, Lambda, Mu) (Figure 5.5b). When
these biomarkers were omitted (model Beta), inclusion of microbiome features (MAGs, but not
MetaPhlAn2 taxa) improved mean negative predictive value (0.765 – 0.720 = 0.046, 95% CI
[0.001, 0.089], P = 0.043, ANOVA with Tukey HSD) and sensitivity (0.82 – 0.76 = 0.06, 95% CI
[0.01, 0.10], P = 0.011).
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Figure 5.5: Gut microbiome features improve the performance of Random Forest (RF) classifiers for AD status in the absence of
amyloid biomarkers. A nested cross-validation approach was used to compare the performance of RF

classifiers with and without gut microbiome features, across combinations of AT(N) and genetic
biomarkers of AD. A) Features included in the classifiers Alpha through Pi (shaded cells). Feature labels
are colored by data/biomarker type (green: gut microbiome; light blue: amyloid; red: tau; orange:
neurodegeneration; dark blue: genetic risk factors; black: base demographics). B) Performance metrics
for classifiers Alpha through Pi with and without gut microbiome features (gray: no microbiome features;
purple: including Shannon Diversity, enterotype, and MAG median genome coverages; green: including
Shannon Diversity, enterotype, and MetaPhlAn2 taxonomic relative abundances). Box plots summarize
performance metrics over 100 test/train partitions of the data. *P < 0.05, **P < 0.01, ANOVA with Tukey’s
HSD, Benjamini-Hochberg adjusted for multiple comparisons. C-D) Ranking for the top 10% most
important (C) MetaPhlAn2 or (D) MAG features summarized over 100 test/train partitions. Shown are
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features for model Pi, which included only gut microbiome features and base demographics. Blue triangles
indicate species in the top 10% most important features of RF classifiers trained on both MetaPhlAn2 taxa
or MAGs.

When both amyloid and tau biomarkers were omitted (model Zeta) inclusion of
microbiome features (MetaPhlan2 taxa) improved accuracy (0.730 – 0.697 = 0.033, 95% CI
[0.002, 0.065], P = 0.041) negative predictive value (0.73 – 0.66 = 0.07, 95% CI [0.02, 0.11], P =
0.004), and sensitivity (0.78 – 0.72 = 0.06, 95% CI [0.02, 0.11], P = 0.006). Similarly, inclusion
of MAGs improved negative predictive value (0.710 – 0.664 = 0.046, 95% CI [0.004, 0.088], P =
0.038), and sensitivity (0.77 – 0.72 = 0.05, 95% CI [0.01, 0.10], P = 0.026) compared to omission
of microbiome features (Figure 5.5b). Inclusion of MAGs in model Eta, which instead omits both
amyloid and neurodegeneration biomarkers, again improved negative predictive value (0.78 – 0.71
= 0.07, 95% CI [0.02, 0.12], P = 0.004) and sensitivity (0.83 – 0.77 = 0.06, 95% CI [0.02, 0.11],
P = 0.004), as did inclusion of MetaPhlAn2 taxa (negative predictive value: 0.77 – 0.71 = 0.06,
95% CI [0.01, 0.10], P = 0.014; sensitivity: 0.814 – 0.767 = 0.047, 95% CI [0.004, 0.090], P =
0.038). In model Theta, which omits both amyloid biomarkers and genetic risk factors, inclusion
of microbiome features improved sensitivity (MetaPhlAn2: 0.803 – 0.761 = 0.042, 95% CI [0.001,
0.083], P= 0.045; MAGs: 0.81 – 0.76 = 0.05, 95% CI [0.01, 0.09], P = 0.028) compared to
omission of microbiome features (Figure 5.5b).
In model Nu, which includes only basic demographics and tau biomarkers, inclusion of
microbiome features improved accuracy (MetaPhlAn2: 0.747 – 0.712 = 0.035, 95% CI [0.004,
0.065], P = 0.036; MAGs: 0.75 – 0.71 = 0.04, 95% CI [0.01, 0.07], P = 0.011]. Model Xi, trained
only on basic demographics and neurodegeneration biomarkers, saw improvements in sensitivity
with inclusion of MAGs, but not MetaPhlAn2, features (0.769 – 0.722 = 0.047, 95% CI [0.002,
0.092], P = 0.043). Inclusion of MAGs in model Omicron (otherwise trained only on basic
demographics and genetic risk factors) improved sensitivity compared to inclusion of MetaPhlAn2
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taxa (0.65 – 0.59 = 0.06, 95% CI [0.01, 0.12], P = 0.022), though neither significantly improved
sensitivity compared to the base Omicron model omitting all microbiome factors. Finally, in model
Pi (trained only on basic demographics), inclusion of MAGs improved negative predictive value
compared to both the base model (0.47 – 0.39 = 0.08, 95% CI [0.03, 0.13], P = 0.004) and when
MetaPhlAn2 taxa were included instead (0.47 – 0.39 = 0.08, 95% CI [0.03, 0.13], P = 0.004)
(Figure 5.5b).
Comparing the top 10% most discriminatory MetaPhlan2 taxa and MAGs after ranking
them by relative importance (i.e. predictive power) within the Random Forest classifiers revealed
concordance in the two data types, with six species shared among the top 10% of MetaPhlan2 taxa
and MAGs (18 and 24 taxa, respectively): Bacteroides cellulosilyticus, Alistipes shahii, Blautia
(previously Ruminococcus) obeum, Roseburia hominis, Clostridium leptum, and Collinsella
aerofaciens (Figure 5.5c, d). In addition, seven MetaPhlan2 taxa were shared among the top 10%
important Random Forest MetaPhlan2 features and the top MetaPhlan2 hits from the negative
binomial regression analyses (by magnitude of the coefficient) (Figure 5.4a): Blautia
(Ruminococcus) obeum, Eubacterium limosum, Eubacterium hallii, Roseburia hominis,
Eubacterium rectale, Barnesiella intestinihominis, and Ruminococcus bromii. Similarly, eight
MAGs were among both the top 10% important MAG features within the Random Forest analyses
and the top MAG hits from the negative binomial regressions (Figure 5.4b): Bacteroides
cellulosilyticus (MAG173), Blautia caecimuris (MAG339), Oscillospiraceae CAG-103
(MAG083),

Eubacterium

sp.

(MAG269),

Monoglobus

pectinilyticus

(MAG156),

Lachnospiraceae UBA11774 (MAG346), Negativibacillus sp. (MAG021), and Coriobacteriaceae
sp. (MAG012). Different strains of Collinsella aerofaciens were identified as top-ranking MAG
features in the Random Forest and negative binomial regression analyses (MAG042 and MAG390,
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respectively). Identification of specific species as associated with, or predictive of, preclinical AD
status in independent analyses (regression analyses, machine learning classification) on separate
data types (taxonomic profiles derived from marker sequence abundances, coverages of assembled
bacterial genomes) provided additional support to their relevance as microbial signatures of
preclinical AD.
In multiple Random Forests models (Beta, Xi, Pi) inclusion of MAGs but not MetaPhlAn2
taxonomic features improved performance of the classifiers by either sensitivity, negative
predictive value, or both; the opposite, where inclusion of MetaPhlAn2 taxa but not MAGs
improved classifier performance, held true in only one case (model Zeta, accuracy metric) (Figure
5.5b). Overall, inclusion of microbiome factors in the absence of amyloid biomarkers improved

sensitivity but not specificity, underscoring the potential utility of gut profiling in early screening
for AD as a complement to the canonical AT(N) framework.
Discussion
The prevalence of neurodegenerative disease continues to increase as life expectancies
grows globally [35] without concomitant improvement in therapies for dementia [14]. AD is the
most common form of dementia in older adults [14]; significant investigative efforts over the last
three decades have determined that there is a time interval between the first neuropathological
changes (extracellular deposition of amyloid plaques in the brain’s gray or white matter, and
abnormal tau aggregations within brain neurons) and the first clinical cognitive signs of AD
dementia [9]. This interval can extend 10 years or more and has led to the concept of preclinical
AD [9], and the systematic validation of specific biomarkers (e.g. PET amyloid with PiB
radioligand, CSF assays of Aβ42, Aβ40, and tau) as criteria for the classification of preclinical AD
within a research framework, and as predictors of disease progression towards symptomatic AD
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[36]. While some anti-amyloid antibody therapies have recently been granted accelerated approval
or breakthrough therapy designation by the US Food and Drug Administration [37], early detection
of the molecular hallmarks of AD pathology continues to be critical for participant recruitment to
observational studies and clinical trials towards the development of effective treatments [38].
The gut-brain axis, or the flow of information between the gut, the enteric nervous system,
and the central nervous system, has increasingly been proposed to play a causal role in
neurodegenerative disease [39, 40]. Seminal experiments in gnotobiotic animal models have
identified the gut microbiota, and its metabolic products including short chain fatty acids, as
playing a critical role in neurogenerative processes including blood-brain barrier formation and
maintenance, myelination, maturation of microglia, and neurogenesis [39, 41-43]. In Parkinson
Disease, another age-associated neurological disorder, it has been proposed that α-synuclein
immunoreactive aggregates may originate in the enteric nervous system and progress to the central
nervous system via the vagus nerve [8, 44]; indeed, truncal vagotomy has been associated with a
reduced risk of Parkinson Disease [45] and individuals with Parkinson Disease exhibit increased
intestinal inflammation, permeability [46], and gut microbiome dysbiosis [43]. In a gnotobiotic
murine model of Parkinson Disease, transfer of microbiota from human donors with Parkinson
Disease led to increased neuroinflammation and motor symptoms compared to mice colonized
with healthy human donor stool [41].
Similarly, persons with symptomatic AD have been found to exhibit altered gut
microbiome taxonomic profiles compared to healthy controls [5, 6, 47, 48]. Stool from
symptomatic AD individuals led to reduced P-glycoprotein expression in vitro in T84 epithelial
cell functional assays, where P-glycoprotein is an efflux pump (expressed both in intestinal
epithelial tissue and in the blood brain barrier) broadly specific to a variety of xenobiotics [5].
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Microbiota transplantations from wild type mice into a recent transgenic mouse model of AD
(ADLPAPT) that recapitulates the amyloid plaque deposition, neurofibrillary tangles, and memory
deficits that are the hallmarks of AD in humans, reduced the formation of these plaques and tangles
as well as cognitive impairment, and rescued normal colonic expression of specific genes related
to intestinal and circulating immune cell activity [15]. Work in a different murine model of AD
(APPPS1) demonstrated that Aβ plaque deposition in the brain was mediated by microbiotaderived short chain fatty acids [49]. While the mechanisms that govern the impact of the gut on
AD severity and progression remain to be fully elucidated, findings such as these may lead to gut
microbiome-directed interventions that reverse or ameliorate AD pathology. In a recent study,
specific strains of Faecalibacterium parusnitzii isolated from healthy participants in a cohort
comparing healthy controls and individuals with mild cognitive impairment or AD reduced
cognitive impairment in a murine model of brain amyloidosis [50]. Similarly, dietary
supplementation of AD model mice (FxFAD) with mannan oligosaccharide modulated short chain
fatty acid production by gut microbes, suppressed neuroinflammation, and alleviated cognitive
impairment [51].
The timing of the associations observed between the gut microbiome and enteric
dysfunction, and AD biomarkers and cognitive symptoms, is critical to the determination of
whether gut features may have utility as antecedent predictors of AD, have the potential to play a
causal role in AD pathogenesis, and/or may serve as targets for intervention. Antecedent gut
signatures of AD have the potential to complement the current AT(N) framework by improving
accessibility and sensitivity of early screening measures, as stool is a cheaply acquired analyte and
sequencing costs continue to decrease [52]. Use of stool as an analyte could help address inequities
in access to PET-CT scanners in the USA and globally [53], and its acquisition is less invasive
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than lumbar puncture for CSF. Because stool samples can be acquired at home their use could
increase coverage of community testing programs, especially in populations with mobility issues
or poor access to hospital settings [54].
In this study we asked whether aberrant gut microbiome profiles are already present in the
preclinical stage of AD, when amyloid biomarker levels are abnormal but prior to onset of any
clinical symptoms. Leveraging an existing cohort of healthy and preclinical AD individuals, we
sequenced stool metagenomes to a depth of ~20 million reads each on average, enabling the
assembly of genomes from metagenomes, comparisons at the strain level, and investigation of
microbial functional potential. We observed that indeed there is evidence of differing microbiome
composition and microbial functional potential even at the preclinical stage; further, gut sample
coordinates along PCoA axes were correlated with PET and CSF amyloid biomarkers, but not
markers of tau or neurodegeneration. While the study design precludes any determination of
causality, the association of gut features with the definitive molecular hallmarks of early AD
pathology underscore their potential as complementary predictive biomarkers.
We identified specific taxonomic and pathway associations with preclinical AD status. The
two microbial pathways most associated with preclinical AD status were both part of the RuMP
cycle for carbon assimilation from formaldehyde produced by methanotrophic gut bacteria;
interestingly, methanogenesis from H2 and CO2 was also associated with preclinical AD status, as
was biosynthesis of factor 420 (a cofactor involved in methanogenesis [55]) and the methanogen
archaeon Methanobrevibacter smithii. Methane production, attributable in large part to anaerobic
gut archaea, increases with age [56], and has been associated with the constipation-predominant
form of irritable bowel syndrome [57]; further, M. smithii was negatively correlated with fecal
concentrations of butyrate, a short chain fatty acid [58]. The role of gut methano-genesis and -
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trophism in healthy aging merits further investigation. Of note, the pathway Bifidobacterium shunt
(also known as the fructose-6-phosphate pathway, the products of which are lactate and the short
chain fatty acid acetate [59, 60]) was associated with healthy status, where short chain fatty acids
have been shown to mediate amyloid plaque deposition and neuroinflammation [49, 51, 61].
Production of the secondary bile salt deoxycholate was additionally associated with healthy status;
bile acid metabolism has been previously implicated in healthy aging in both mice [62] and humans
[63].
Of the taxa found significantly associated with AD preclinical status, increased proportions
of taxa in genera Alistipes, Barnesiella, and Bacteroides (all in the Bacteroidetes phylum) have
also been previously reported in symptomatic AD individuals [5]. However, we did not observe a
significant difference in the overall Bacteroidetes to Firmicutes ratio between healthy and
preclinical AD individuals, in contrast to what was previously reported in a comparison of healthy
and symptomatic AD individuals [6]. Capturing the Bacteroidetes to Firmicutes ratio
longitudinally as persons progress from preclinical to symptomatic AD will elucidate if this
microbiome metric develops concomitantly with AD. The top five MAGs associated with
preclinical AD status were all in the Coriobacteriaceae family of the Actinobacteria phylum,
including two annotated as Collinsella sp. and Collinsella aerofaciens; treatment with Collinsella
aerofaciens was previously found to increase disease incidence in a murine model of the
autoimmune disease rheumatoid arthritis (arthritis-susceptible HLA-DQ8 mice), and increased gut
permeability and pro-inflammatory cytokine expression in vitro in the human CACO-2 epithelial
cell line [64]. In addition, Collinsella aerofaciens was negatively associated with a year-long
dietary intervention in elderly participants (65-79 years old, N = 612) that reduced inflammatory
markers and improved global cognitive ability and episodic memory [65]. On the other hand
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Eubacterium limosum, here associated with healthy status, was previously reported to be 15-fold
more abundant in healthy centenarians (> 100 years old) compared to young adult (20-40 years
old) and elderly (60-80 years old) controls [66]. Together, these associations support the
hypothesis of an enteric neuro-immune axis in neurodegenerative disease [8]. Here, we report such
associations are already detectable in preclinical AD. Further investigation is needed to validate
these associations in broader preclinical AD cohorts, assess causality, and determine whether these
associations extend to symptomatic AD or are succeeded by other gut features concomitant with
disease progression.
We characterized the improvement in performance of Random Forest classifiers for
preclinical AD status afforded by microbiome features, in the presence of different combinations
of canonical AD biomarkers and genetic risk factors. Because AD preclinical status is defined by
amyloid levels (specifically, PiB-PET SUVR in this study), addition of microbiome features to
models already including amyloid biomarkers could not significantly improve predictive
performance by any assessed metric (accuracy, negative or positive predictive value, sensitivity,
or specificity). In almost every model where PET amyloid and CSF Aβ42/40 were omitted,
inclusion of microbiome features improved predictive performance by at least one metric (7/8
models). Sensitivity was improved most often (5/8 models), followed by negative predictive value
(4/8 models) and accuracy (2/8 models). The improvements in sensitivity and negative predictive
value, but not specificity and positive predictive value, indicate that the proportion of false
negatives (but not false positives) is decreased with the addition of gut features. Thus, gut features
have the potential to enhance early screening measures to identify candidates for follow-up CSF
or PET amyloid assays to determine preclinical AD status. Notably, in multiple models (Beta, Xi,
Pi) addition of MAGs but not MetaPhlAn2 taxa improved classifier performance; other models
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also offer evidence of greater predictive power afforded by MAGs compared to MetaPhlAn2 taxa
(Omicron, Eta). This suggests that taxonomic associations with AD status may be strain specific,
which indeed was recently demonstrated in a mouse model of AD [50], and encourages the pursuit
of strain-level resolution in future gut microbiome-wide association studies for any disease, which
is not achievable through 16S rRNA gene sequencing.
Our study has limitations. First, the time intervals between neuroimaging and biofluid
assessments and stool samplings raises the possibility that true biomarker levels of participants at
the time of stool sampling may have differed from the available biomarker values. While the rate
of AD progression is such that biomarker values are not expected to change significantly over the
course of 3 years [67] (the interval at which participants undergo neuroimaging and biofluid
assessment under the ACS study design), this estimation is at a population level and it is possible
that in the interim individual participants may have traversed an inflection point in their biomarker
values. Similarly, while the composition of the adult gut microbiome is generally stable over time
[68, 69], it is susceptible to perturbation in response to significant changes in environmental factors
such as diet, activity, medication, and aging itself [70-72]. Future studies will benefit from timematched biomarker assessments and stool samplings, and from longitudinal sampling of
participants in order to account for natural intra-subject variation in microbiome composition. In
addition, preclinical AD status does not imply that an individual will necessarily progress to
symptomatic AD; long-term longitudinal tracking of participants with time-matched
neuroimaging, biofluid assessments, cognitive assessments, and stool sampling will enable the
identification of individuals that indeed progress to mild cognitive impairment or symptomatic
AD, and corresponding analyses to determine if there are gut features predictive of this transition.
Second, while stool metagenome sequencing affords a wealth of information about taxonomic
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composition and functional potential of the gut microbiome, even at strain level resolution, this
study could be bolstered by a broader ‘omics approach including metatranscriptomics to assay the
repertoire of microbial genes that are actively expressed at time of sampling, and metabolomics to
profile the bioactive small molecules present in the gut. In particular, assaying metabolites that
have been implicated in neurodegenerative disease, such as short chain fatty acids and secondary
bile salts, and corresponding correlation analyses with taxonomic composition data will strengthen
mechanistic hypotheses about the role of specific gut taxa in AD. Similarly, clinical measures of
gut health including markers of systemic and enteric inflammation, and gut permeability, will
strengthen our understanding of preclinical AD-associated gut dysbiosis and dysfunction;
longitudinal measurements will enable the determination of whether microbiome dysbiosis
precedes host enteric dysfunction or vice versa, within the context of AD.
Materials and Methods
Study Design
The objective of this cross-sectional, observational study was to identify differences in the
GM profiles of healthy (n = 50) and preclinical AD (n = 43) participants, and any correlations of
GM features with AD biomarkers. Symptomatic (Clinical Dementia Rating, CDR > 0) participants
were excluded. The AD biomarkers included in analyses were Centiloid, calculated from
Pittsburgh compound B (PiB)-PET and
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11

C

F-florbetapir (AV45)-PET, as well as tau-PET, CSF

Aβ42/40, CSF phosphorylated tau (p-tau-181), CSF total tau (t-tau), plasma neurofilament light
(NfL), and from MRI: white matter hyperintensities (WMH) volume, hippocampus volume, and
cortical signature. In addition, we include Polygenic Risk Score and APOE allele status.
Participants for this stool study were recruited from the Adult Children Study [19] at the Knight
Alzheimer Disease Research Center (ADRC) at Washington University School of Medicine
(WUSM), St. Louis, in which participants undergo assessments (PET, MRI, CSF lumbar puncture,
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blood draw) every 3 years, and clinical and cognitive testing every 3 years (participants less than
65 years old) or every year (participants 65 and older). Biomarker and clinical measures from the
most recent available neurological and cognitive assessments of each participant were used. On
average, stool samples were collected within 2.7 years of participants’ most recent PET imaging
date (median 1.7 years, standard deviation 2.1 years, maximum 8.4 years, minimum 3 days), within
2.6 years of participants’ most recent lumbar puncture (median 1.7 years, standard deviation 3.0
years, maximum 16.6 years, minimum 24 days), within 3.6 years of participants’ most recent blood
draw (median 3.3 years, standard deviation 1.7 years, maximum 10.0 years, minimum 1.3 years),
and within 5 months of participants’ most recent CDR assessment (median 4.6 months, standard
deviation 100 days, maximum 1.4 years, minimum 2 days). Processing of stool samples was done
blind to AD status. All participants underwent identical procedures, so no group randomization
was carried out. Sample sizes were not determined in advance.
Participants
Participants were recruited for this study from the Adult Children Study [19] at the Knight
ADRC at WUSM, St. Louis from July 2019 to September 2020. Participants ranged from 67 to 93
years of age. All participants were asymptomatic, with their most recent (within 5 months on
average) CDR equal to 0. Preclinical AD was defined as CDR = 0 and PiB standardized uptake
value ratio (SUVR) > 1.2, while healthy was defined as CDR = 0 and PiB SUVR <= 1.2. CDR
rating was performed by qualified clinicians in accordance to established scoring rules [10];
dementia diagnostic criteria conformed to National Institute on Aging-Alzheimer’s Association
Work Group recommendations [73]. Other than CDR = 0, there were no additional exclusion
criteria.
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Study protocols were approved by the Washington University School of Medicine Institutional
Review Board, and all participants provided written informed consent to the use of clinical and
genetic information for research purposes. Clinical, biomarker, and genetic data were extracted on
January 26, 2021. Data were analyzed from April 1, 2020 to October 5, 2021.
Clinical Assessment
All CDR scores were obtained from assessments by experienced clinicians trained in the
use of the CDR. The CDR is used to determine whether dementia is present and, if so, to stage its
severity. When using global scores, a CDR of 0 indicates that the individual is “cognitively
normal,” whereas CDR 0.5 and CDR 1 indicate very mild and mild AD, respectively [74]. For this
study all participants had a CDR of 0.
Apolipoprotein ε4 Status and Polygenic Risk Scores
DNA samples were collected at enrollment and genotyped using either an Illumina 610 or
Omniexpress chip. Genotyping methods were previously published [75]. To control for effects of
apolipoprotein ε4 (APOE ε4) on individuals in this analysis, APOE status was converted from a
genotype to a binary variable. Participants either had at least one copy of the APOE ε4 allele
(“APOE ε4 positive”) or had no copies of the allele (“APOE ε4 negative”). For the polygenic risk
score (PRS) for AD, weighted scores were calculated by using a logarithm of base 2 transformation
on single nucleotide polymorphisms (SNPs), as reported in the International Genomics of
Alzheimer's Project (IGAP) study [76] and as previously described [77]. SNPs utilized for the
score had either a high genotyping rate (> 90%) or were reasonable proxies to the IGAP hits.
Magnetic Resonance Imaging (MRI) Acquisition
Imaging was performed using a 3.0 Tesla Trio Siemens or Siemens Biograph 3.0 Tesla
MRI scanner equipped with a 12-channel head coil. For atlas registration, high-resolution 3-
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dimensional sagittal T1 MP-RAGE anatomical images were acquired using the Alzheimer Disease
Neuroimaging Initiative (ADNI) protocol. T1-weighted scans were segmented with FreeSurfer
5.3. Previous work has identified the temporal (inferior, middle, and superior), parietal (inferior
and superior), entorhinal cortex, precuneus, and hippocampus as the regions that are most affected
by disease and change the earliest [78]. We converted volumes to Z scores separately in the left
and right hemispheres relative to the entire cohort, and then averaged them to obtain an “AD
Signature Region.” The AD Signature Region creates a summary metric that succinctly describes
brain volume atrophy due to AD [78].
PET Imaging of Amyloid and Tau
Imaging studies were obtained at baseline and then every 3 years thereafter in the ACS
study. PET images were acquired within 2 years (mean = 0.6 ± 1.2 years) of MRI using
methodology previously described. PET data were processed using the PET Unified Pipeline
(github.com/ysu001/PUP), which uses regions of interest (ROI) defined using the FreeSurfer
version 5.3 (Martinos Center for Biomedical Imaging, Charlestown, Massachusetts, USA)
Desikan-Killiany atlas. Data were transformed into standardized uptake ratios (SUVRs) using
cerebellar gray as a reference and partial volume corrected by calculating regional spread functions
as part of a geometric transfer matrix framework. PET amyloid imaging was performed with either
11

C Pittsburgh compound B (PiB) or 18F-florbetapir (AV45). The time window for quantification

was 30 to 60 minutes post-injection for PiB and 50 to 70 minutes for AV45. Centiloids were used
to harmonize measures from these two different tracers.
PET tau imaging was performed using 18F-flortaucipir (AV1451) with SUVRs calculated
for the 80 to 100-minute post-injection window. A summary measure of tauopathy, previously
defined as the arithmetic mean of the amygdala, entorhinal cortex, inferior temporal region, and
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lateral occipital regions based on FreeSurfer version 5.3 segmentation, was calculated for each
participant.
CSF Collection and Analysis
CSF (10-20 mL) was collected by lumbar puncture using a 22-gauge Sprotte spinal needle
(Geisingen, Germany). Lumbar punctures were performed in the morning after overnight fasting
by a trained neurologist. CSF was aliquoted (500 µl) into polypropylene tubes and was free of
visible blood contamination. After collection, samples were gently inverted and frozen at -80℃.
CSF amyloid-β-42 (Aβ42), t-tau, and phosphorylated tau 181 (p-tau-181) were measured as
previously described using an automated electrochemiluminescence immunoassay (Elecsys on the
cobas e 601 analyzer, Roche) [79].
Plasma NfL
Plasma NfL samples were analyzed using Single Molecule Array (Simoa) technology
(Simoa; Quanterix, Lexington, MA, USA). Tests were performed to optimize dilution factors and
centrifugation. After thawing, samples were vortexed and spun at 10,000g for 5 minutes; the
supernatant was directly transferred to a 96 well plate (90µL for singlet). A recombinant calibration
curve was constructed and transferred to the 96 well plate (334ul). Calibration range was 0-500
pg/mL with the dynamic range of 0-2000 pg/mL. Analog 200 pg/mL and digital controls 10 pg/mL
were transferred to the 96 well plate (90 µL for singlet).
Stool Collection
Stool samples were collected from Dec 20, 2019 to July 22, 2020 under an established
community sample acquisition protocol [80, 81]; samples were produced at participants’ homes
with standardized instructions and collection materials, and transported same-day to WUSM in
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insulated packages by a commercial courier, at which point samples were frozen (-80°C) and
aliquoted under barcode provenance until processing for bacterial DNA extraction.
Metagenomic Sequencing
100-200mg frozen stool was used as input to the DNeasy PowerSoil Pro Kit (QIAGEN,
Germantown, MD, USA) to extract genomic DNA. DNA yields were measured using the QuantiT PicoGreen dsDNA Assay Kit (ThermoFisher, Waltham, MA, USA). 0.5ng genomic DNA per
sample was used to create sequencing libraries with the Nextera Kit (Illumina, San Diego, CA,
USA) [82]. The libraries were pooled in equimolar concentrations and sequenced on a NovaSeq
6000 (2 x 150bp) to obtain an average of 20.2M reads per sample (standard deviation 10.6M;
minimum 7.0M, maximum 58.0M). The reads were demultiplexed by sequencing barcode.
Illumina (Nextera-PE) adaptors were removed, and reads were quality filtered and trimmed using
Trimmomatic v0.38 [83], with parameters ILLUMINACLIP: Nextera-PE.fa:2:30:10:1:TRUE,
LEADING:10, TRAILING:10, SLIDINGWINDOW:4:20, MINLEN:60. Contaminating human
reads were removed using Deconseq v0.4.3 against hsref38 [84], and paired ends repaired using
repair.sh from bbtools v38.26 (sourceforge.net/projects/bbmap/).
Processed reads were used as input to MetaPhlAn2 v2.6.0 [21] to determine per-sample
taxonomic relative abundances using clade-specific marker genes, and HUMAnN 2.0 v2.8.1 [22]
to functionally profile the metagenomes. For rarefaction analysis, reads from a subset of samples
(20%) were subsampled to counts of 100, 1000, 10000, 100000, 500000, 1M…15M (in steps of
1M) and 20M, and reanalyzed with MetaPhlAn2. The R package phyloseq v1.32.0 [85] was then
used to estimate sample alpha diversities with the richness metric, or number of unique observed
taxa, based on the count-transformed taxonomic abundance data. Pairwise Wilcoxon tests between
all subsampling depths for differences in alpha diversity were then carried out, with Benjamini-
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Hochberg adjustment for multiple hypothesis testing. The read threshold was defined as the lowest
read depth at which there was no significant difference in sample alpha diversities compared to
any higher read depth. Samples that passed the empirically determined read threshold (5M reads)
were retained in downstream analyses (n = 93).
Processed reads were additionally used as input to SPAdes v3.14.0 (Python v2.7.15) [86]
with the --meta parameter (metaSPAdes) to assemble contigs. Contigs assembled by metaSPAdes
were used as input to the snakemake pipeline ATLAS-metagenome v2.6a2 [23] for binning,
quality assessment, dereplication, quantification, and taxonomic assignment of metagenome
assembled genomes (MAGs). Specifically, individually for each sample metaSPAdes-assembled
contigs were binned by MetaBAT 2 [87] and MaxBin 2.0 [88], and the bins were dereplicated,
aggregated, and scored by DAS tool [89] to yield MAGs for each sample. The completeness and
contamination of each MAG was assessed with CheckM [90], and used to inform dRep [91] which
uses ANI-based clustering approaches (Mash [92], MUMmer [93]) to obtain a non-redundant set
of MAGs across all samples. MAG abundances within samples were then estimated by mapping
reads to the non-redundant set of MAGs, and calculating the median coverage of each MAG within
each sample. Taxonomic annotation was carried out through the genome taxonomy database tool
kit (GTDB-tk [94]). MAG phylogenetic trees were built based on markers from GTDB and
CheckM. The ATLAS-metagenome snakemake pipeline described was executed on a local cluster
computing

environment

using

the

cluster

configuration

profile

available

at

https://github.com/metagenome-atlas/clusterprofile.git. All workflows for the generation of
quality-filtered, taxonomically annotated, and quantified MAGs were executed using default
parameters in the config.yaml file generated by the ATLAS-metagenome command atlas init.
Statistical Analyses
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Statistical analyses were conducted in R v4.0.3 [95] and visualizations generated with
ggplot2 v3.3.3 [96] unless otherwise specified. Output from MetaPhlAn2 (taxonomic relative
abundances), HUMAnN 2.0 (functional pathway relative abundances), and ATLAS-metagenome
(MAG median genome coverages) along with sample metadata were used to generate phyloseq
objects using phyloseq v1.32.0 [85]. The phylogenetic tree for the MetaPhlAn2 taxonomic
database was obtained from curatedMetagenomicData v1.20.0 [97], and incorporated into the
MetaPhlAn2 phyloseq object in order to visualize the phylogenetic tree encompassing the taxa
observed in the samples in this study and to calculate between-sample UniFrac distances [24].
Similarly, the phylogenetic tree output from ATLAS-metagenome was incorporated into the MAG
phyloseq object. MAGs were filtered to exclude those with < 90% completeness and > 10%
contamination. HUMAnN 2.0 output was filtered to exclude unmapped or unintegrated read
contributions.
The phyloseq estimate_richness function was used to calculate sample alpha diversities
(richness and the Shannon Diversity Index) from count-transformed taxonomic and pathway
abundances (MetaPhlAn2 and HUMAnN 2.0 output, respectively), or MAG median genome
coverages. Lowly abundant MetaPhlAn2 taxa (with mean relative abundance across samples < =
0.1%), and HUMAnN 2.0 pathways (with mean relative abundance across samples < = 0.01%)
were filtered out prior to downstream analyses. Vegan v2.5.7 [98], as called in phyloseq, was used
for principal coordinates analysis (PCoA) and canonical analysis of principal coordinates (CAP)
[25] using unweighted UniFrac distances for MetaPhlAn2 data, or Bray-Curtis dissimilarities [99]
for HUMAnN 2.0 pathway data and MAGs. Significant group differences were tested by
permutational ANOVA (PERMANOVA) using between-sample distances or dissimilarities as
implemented in vegan v2.5.7 (adonis function). Significance of the constraint in the CAP analysis
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was tested by ANOVA as implemented in vegan v2.5.7 (anova function). Group differences in
principal coordinates were assessed by Student’s t-test. All p-values were adjusted for multiple
hypothesis testing using the Benjamini-Hochberg method.
Gut enterotypes were identified through an unsupervised, probabilistic clustering approach
involving the fitting of Dirichlet multinomial mixture models [26] to MetaPhlAn2 taxonomic
abundance data. This was implemented with DirichletMultinomial v1.26.0 [100] using scripts
available from D’Souza et al. [27], with seed = 9904 and maximum Dirichlet components
(effectively, clusters) k = 20. The model with the most evidence (as identified by Laplace
approximations for each k) contained two Dirichlet components; samples were assigned to the
component, or cluster, for which they had the most probabilistic support. In this study we define
enterotype as equivalent to these cluster assignations.
Pairwise Pearson correlations of AD biomarkers and GM features were visualized using
the R package corrplot v0.84 [101], filtered to show only correlations with Benjamini-Hochberg
adjusted P < 0.05. Fixed effects linear regression analyses of AD biomarkers (PET Centiloid, CSF
Aβ42/40, PET tau, cortical signature) against PCoA axes from ordinations of taxonomic
(MetaPhlAn2) or pathway (HUMAnN 2.0) abundance data were carried out using the lm and aov
functions (stats v4.0.3). Model summaries are provided in Tables S1-4. All p-values were adjusted
for multiple hypothesis testing using the Benjamini-Hochberg method.
To identify specific taxa, pathways, or MAGs (MetaPhlAn2, HUMAnN 2.0, and ATLASmetagenome output, respectively) significantly associated with AD preclinical status, MaAsLin2
v1.2.0 [102] was used to fit negative binomial models to count-transformed abundance data
individually for each of the three data types. As relative abundances of taxa and pathway data were
preserved after count transformation, the normalization parameter was set to ‘NONE’ for these

181

data types, whereas it was set to ‘TMM’ (weighted trimmed mean of log2 ratios, or M values)
[103] for the MAGs median genome coverage data. The min_abundance parameter was set such
that taxa that did not achieve at least 0.01% relative abundance or pathways that did not achieve
at least 0.001% relative abundance within a sample were excluded, while MAGs were not filtered
by abundance. Remaining parameters were identical for all three MaAsLin2 analyses:
min_prevalence = 0, transform = ‘NONE’ (as count transformation occurred outside of the
MaAsLin2 model executions), analysis_method = ‘NEGBIN’, fixed_effects set to AD status
(‘healthy’ or ‘preclinical’), and max_significance = 0.05. That is, significant features were required
to have Benjamini-Hochberg adjusted p-values < 0.05. For visualization, significant features were
additionally filtered to include only those observed in at least 25/93 samples (~27% of the cohort),
and with magnitude of the fitted coefficient > 0.15 (for taxa and pathways) or > 0.5 (for MAGs).
Training and testing of Random Forest classifiers for AD preclinical status was
implemented through caret v6.0.86 [104]. Categorical variables sex, race, enterotype, and APOE
e4 status were numerically encoded. The data was imputed using VIM v6.1.0 [105], using the knearest neighbor method with k = 5. Variables with missing data included plasma NfL (31%
missing), PRS (22%), tau-PET (15%), CSF p-tau (13%), CSF t-tau (13%), CSF Aβ42/40 (13%),
and WMH volume (1%). Data was then combinatorially subsetted by AT(N) + genetic biomarker
categories (see model definitions for Alpha through Pi, Figure 5.4a) and optionally merged with the
GM features: alpha diversity (Shannon Diversity Index) and enterotype, and either taxonomic
relative abundances (MetaPhlAn2) or MAG median genome coverages. Demographic variables
age, sex, race, and education (years) were included as predictors in every model. Continuous
variables were z-scored (‘center’ and ‘scale’ methods in the caret preProcess function). For each
model, class-balanced partitions of the data were generated with 80% samples used for training
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and 20% reserved for testing. Random Forest classifiers were trained (seed = 42) on the training
sets using 10-fold cross-validation and the ‘Accuracy’ test metric, with default parameters ntree =
500 and search = ‘grid’ for mtry (the number of variables to be randomly sampled at each tree
node). Trained classifiers were then tested on their respective test sets, with accuracy, negative
predictive value, positive predictive value, sensitivity, and specificity retained as performance
metrics. To compare the performance of the different models, a nested cross-validation approach
was used in which the random train/test data partitioning was repeated 100 times for each model
(using seed = 1:100). For each partition, training and testing was repeated as described and
performance metrics on the test sets were collated. Cases in which inclusion of GM features (alpha
diversity and enterotype, and either taxonomic relative abundances or MAG median genome
coverages) improved the performance of the trained classifier were identified via ANOVA with
Tukey’s HSD comparing the data sets (no microbiome data, microbiome data including
MetaPhlAn2 taxa, or microbiome data including MAGs), for each performance metric and for
each model definition Alpha through Pi (aov and TukeyHSD functions from stats v4.0.3).
Significant ANOVA and Tukey HSD p-values after Benjamini-Hochberg adjustment for multiple
hypothesis testing are reported. The varImp function from caret v6.0.86 was used to rank features
by importance.
Data and software availability
Shotgun metagenomic reads and assembled MAGs will be deposited and released to NCBI
SRA; these, and source data for all figures are currently available from the lead author upon
request. The software packages used in the study are free and open source. Scripts used for
Dirichlet multinomial mixture model analyses are available from D’Souza et al. [27].
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Chapter 6 : General Conclusions and Future Directions
Appreciation of the gut microbiome as a correlate and in some cases driver of disease [13] has grown in the last 15-20 years with the advent of accessible high-throughput DNA
sequencing technologies [4]. Translation of microbiome correlates of disease to clinically relevant
gut-directed therapeutics remains a goal of many research efforts, necessitating investigation of
causality and mechanism [5]. However, there are additional important ways in which insights
about the gut microbiome may be applied with clinical ramifications. First, efforts to develop gutdirected therapeutics have increased concomitantly with our understanding of the gut microbiome,
including the development of engineered commensal microbes for applications in infectious
disease [6, 7], cancers [8], and metabolic disorders [9] some of which have even reached early
phase clinical trials [10]. While such living therapeutics can be developed independent of any
knowledge of the recipient gut microbiome, their safe and efficacious application requires an
understanding of their behavior in complex gut environments, and means by which to control their
activity and viability [11]. Second, improvements in resolution of microbiome-wide association
studies may identify candidate biomarkers of disease in stool, with potential for clinical utility and
expansion of community testing programs [12, 13]. This is attractive when acquisition of canonical
disease biomarkers is challenging, or not typically indicated in asymptomatic persons despite the
high value of early risk identification to research efforts.
To the first point, during my thesis work I took both investigative and engineering
approaches towards the safety and efficacy of microbial therapies. Development of microbial
therapies should account for the interactions that will inevitably occur between the therapeutic
organism and native members of recipient microbiomes. For example, colonization resistance to
probiotics (and, potentially, benefit from their properties) is person-dependent and can be
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attributed to the prior occupation of metabolic and physical niches by closely related native strains
[14]. On the other hand, in dysbiotic guts (e.g. antibiotic-treated) probiotics can delay recovery of
microbiomes to pre-intervention states [15], suggesting that the beneficial nature of probiotics is
context-dependent. Probiotics can participate in horizontal gene transfer of antibiotic resistance
genes [16, 17]. Fecal matter transplants, while highly promising for applications such as protection
against recurrent Clostridioides difficile infection, can also contribute novel antibiotic resistance
genes to a recipient microbiome [18]. Importantly, unlike traditional therapeutics, engineered
microbes are subject to selection potentially at the cost of their intended function.
Using gnotobiotic and conventional mouse models of probiotic colonization, wherein diet
and background microbiome diversity were systematically altered, I carried out functional
metagenomic selections as well as whole genome sequencing of hundreds of isolates to identify
the major selective forces acting on the probiotic Escherichia coli Nissle 1917 in the dysbiotic
mammalian gut (Chapter 2) [19]. In low-diversity gut microbiomes the main selective pressure on
E. coli Nissle was access to preferred carbon sources. When E. coli Nissle had access to a large
and diverse repertoire of heterologous genes, as in the functional metagenomic selections,
populations encoding glycosyl hydrolases enabling consumption of dietary polysaccharides were
strongly enriched. In the absence of this asset, wild-type Nissle mutated to better consume host
mucins. While these gnotobiotic models of colonization are extreme examples of low-diversity gut
microbiomes, adaptations with putative effects on utilization of host or diet-derived carbon sources
have also been reported in studies of commensal evolution in healthy humans [20]. Future work
will determine if such adaptations affect mucosal barrier integrity and enteric inflammation of the
host, and if adapted probiotic strains prohibit subsequent colonization by naïve type strains. In
addition, E. coli Nissle isolates recovered from conventional mice 5 weeks after a single
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streptomycin exposure exhibited mutations known to confer aminoglycoside resistance, with no
apparent fitness cost. This may carry clinical implications with respect to probiotic administration
adjacent to antibiotic exposures, as probiotic species should not be excluded when considering
reservoirs of antibiotic resistance genes in the gut. Other future directions include the inverse
approach of characterizing, instead of functions that enhance E. coli Nissle fitness, the functions
necessary for E. coli Nissle colonization of diverse gut environments through selection of
transposon mutagenesis libraries [21]. To better characterize the safety profile of E. coli Nissle as
a chassis for engineered therapies, future work should also involve a systematic characterization
of its propensity for horizontal gene transfer with other commensals, e.g. carbapenem-resistant
Enterobacteriaceae, in situ [22]. In light of the context-dependence of probiotic behavior and
adaptation, and the variability of gut microbiomes in commercially-sourced mice [23], future
investigations will benefit from greater utilization of gnotobiotic models of colonization wherein
germ-free animals can be pre-colonized with specific donor human microbiomes or defined
communities, improving reproducibility of hypothesis testing and characterization of microbemicrobe and microbe-host interactions [24]. A major caveat is that germ-free animals exhibit
impaired immune function [25], which may confound experimental observations.
Biocontainment systems are thus a critical element of engineered microbial therapeutics.
Such engineering controls mitigate risk of competitive exclusion of native microbes, pathogenic
potential against the host, or environmental contamination [26]. Biocontainment often refers to
restriction of microbial viability, but also includes restriction of engineered function to sites or
conditions of interest via biosensors that respond to specific metabolites, proteins, or
environmental signals. In contrast to constitutive expression of therapeutic deliverables, designs
that implement this parsimony can minimize off-target effects and metabolic burden (and thus
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selective pressure) on the engineered microbes. However, developing synthetic constructs in
microbes is a labor-intensive process requiring multiple design-test cycles; if the intended site of
application is the gut, the number of subjects (e.g. mice) required to assess engineered strain
activity with appropriate statistical power rapidly becomes unfeasible [27]. In my thesis work I
validated a transcript-barcoding approach designed to enable the parallel measurement of activity
of many synthetic constructs in vivo (Chapter 3) [27]. Using the ratio of construct-specific barcode
counts from high-throughput sequencing of DNA and corresponding RNA species extracted from
intestinal contents of mice administered a pool of engineered E. coli Nissle strains, I was able to
rank the relative activities of 30 synthetic constructs in discrete gut sites, and identify in vitro
growth conditions that were predictive of in vivo construct activities. This work informed the
development of Nissle strains engineered to express phenylalanine ammonia lyase for the
treatment of phenylketonuria, the efficacy of which I validated in a mouse model of the disease
(Pahenu2) [19]. Future work for the continued development of Nissle as a chassis for engineered
therapeutics includes the identification and optimization of gut- and disease-relevant biosensors,
including sensors for bile acids, short chain fatty acids, and in the case of phenylketonuria,
phenylalanine; tools such as the transcript barcoding method will facilitate the design and testing
of these biosensing constructs in vivo.
Biocontainment of microbes themselves provides a different set of challenges. In general,
there are two genetic engineering approaches to biocontainment: a loss of essential function that
must be complemented to retain viability (e.g. engineered auxotrophy [28]), or insertion of an
inducible lethal function (kill switch circuits [29]). Genetic circuits that initiate cell death in
response to a chemical inducer or environmental signal are attractive due the level of control they
offer over viability of engineered microbes. However, due to the intense selective pressure
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imposed by a kill switch such designs are prone to mutational inactivation. An important design
criterion for kill switch systems is thus genetic stability.
In my thesis work I helped implement and optimize kill switch strategies in E. coli Nissle
using conventional mouse models of gut colonization (Chapter 4); the kill switch system was
CRISPR-Cas9 based, and inducible by either a small molecule (anhydrotetracycline, aTc), or both
aTc and temperatures below 33°C. With this design, engineered populations of Nissle can be
removed selectively from the gut in response to aTc and are additionally subject to kill switch
induction upon excretion from the gut. To achieve genetic stability, we applied parallel approaches
of engineering control, including multiple genomic integrations of Cas9 expression cassettes,
multiple plasmid-borne guide RNAs which in turn direct Cas9 to multicopy genes (total 11 target
cleavage sites), an antibiotic-free plasmid retention system, and knockouts of SOS response genes
to mitigate incidence of escape mutants. We characterized in vitro and in vivo kill switch stability
including types and frequencies of inactivating mutations throughout the iterative design process,
and used this to inform optimization decisions. Importantly, we observed a higher frequency of
escape mutants in in vivo or in vivo-like growth conditions, where nutrient availability is sparser
and growth is slower than in rich media conditions; in keeping with a theme of my thesis, kill
switch design efforts should account for the additional selective pressures imposed by the
environment in which they will be applied. Innovatively, we also applied environmental control in
the form of intra-niche competition; inspired by the competitive inter-strain exclusion behavior
observed in gut pathogens and commensals alike [14, 30, 31], we co-administered kill switch
Nissle with control non-kill switch Nissle. Kill switch induction in tandem with competitive strain
exclusion enabled virtually complete eradication of the kill switch population from the guts of
mice. This is approach is attractive when the goal is to remove an engineered subpopulation of
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engineered microbes, and not a probiotic species itself, from the gut. Co- or pre-administration of
wild-type probiotic in clinical applications of engineered probiotics could help prime the gut for
induced elimination of the engineered strain. Future work will characterize the in situ stability of
co-administered populations in the absence of kill switch induction. Additionally, the efficacy of
the kill switch can be further optimized by inclusion of an orthogonal kill switch mechanism [29];
while our design is inducible by two inputs, both feed into the same kill switch construct and thus
dual induction did not result in a synergistic increase in efficacy. Finally, in future work we will
integrate the kill switch with a therapeutic delivery construct (e.g. a closed-loop design where
phenylalanine ammonia lyase is induced by a phenylalanine biosensor) to demonstrate both
treatment efficacy and robust inducible biocontainment in the same strain.
As resolution of microbiome-wide association studies reaches the strain level [32], there is
growing opportunity to identify candidate microbial biomarkers of disease in stool. In my thesis
work I considered the gut microbiome in association with preclinical stage Alzheimer Disease
(Chapter 5). While global and specific gut microbiomes differences have been previously reported
in cohorts comparing healthy individuals to those with symptomatic Alzheimer Disease [33, 34],
identification of microbiome correlates at the preclinical stage has the potential for clinical
significance in that current biomarkers of preclinical Alzheimer Disease require access, often
limited, to PET-CT scanners or invasive CSF lumbar puncture [35], whereas stool is a cheaply
acquired analyte. I found that summary gut microbiome metrics were correlated with amyloid
biomarkers, but not markers of tau or neurodegeneration. As asymptomatic amyloidosis without
neurodegeneration is considered the most antecedent signature within the AT(N) staging
framework of Alzheimer Disease progression [36], with elevations in PET amyloid associated with
greater risk of developing symptomatic AD [37], this result highlights the potential utility of gut
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microbiome correlates in early screening measures for preclinical Alzheimer Disease. In support,
I found that in the absence of amyloid biomarkers addition of microbiome features to machine
learning classifiers for preclinical Alzheimer Disease improved sensitivity of the predictions.
Notably, this was most often the case when metagenome-assembled genomes were included as
features, rather than taxa identified through clade-specific marker sequences. This suggests that
taxonomic associations with Alzheimer Disease status may be strain-specific, and encourages the
pursuit of strain-level resolution in future gut microbiome-wide association studies for any disease,
not least because associations at the strain level can narrow the gap between association and
etiology.
As such, an important future direction beyond the validation of these microbiome correlates
in broader preclinical cohorts, is consideration of markers of gut dysfunction and inflammation in
addition to gut microbiome dysbiosis. Loss of barrier integrity and mucosal inflammation
characterize gut dysfunction, and are associated with increased intestinal permeability and
systemic inflammation [38]. Notably, it has been reported that symptomatic AD patients have
increased circulating lipopolysaccharide (endotoxin), presumably of gut origin [39], and in animal
models manipulation of gut microbes decreases amyloid deposition and improves neurologic
function [40]. The role of gut dysfunction and inflammation secondary to a dysbiotic microbiome
in Alzheimer Disease progression is a plausible hypothesis [41, 42], but warrants further
investigation. In addition, future studies will benefit from longitudinal sampling of participants in
order to account for intra-subject variation in microbiome composition and markers of gut
dysfunction, and also to identify individuals that indeed progress to mild cognitive impairment or
symptomatic Alzheimer Disease. Corresponding analyses may identify gut features predictive of
this transition, inform hypotheses about potential etiologic roles of the gut in Alzheimer Disease,
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and may enable development of strategies to interdict this progression early on. Pipelines for
assembling genomes from metagenomes, optionally complemented with long-read sequencing,
will enable strain tracking within individuals over time. Finally, adoption of a broader ‘omics
approach in future investigations, including metatranscriptomics and metabolomics in addition to
metagenomics, will bolster mechanistic hypotheses about the role of the gut microbiome and
specific gut taxa in Alzheimer Disease.
Overall, I conclude that the gut microbiome and the selective pressures it imposes must
guide design and implementation of engineered microbial therapeutics (Chapters 2 and 3). On the
other hand, the selective pressures present in the gut can be leveraged to reach design goals, as was
the case with the co-administration of control and kill switch probiotic populations to mitigate
escape (Chapter 4). As we work to translate observations about the gut microbiome to actionable
clinical interventions, high-resolution characterization of microbiomes at early disease stages can
identify candidate microbial biomarkers in stool (Chapter 5), and ultimately feed back into the
design of novel gut-directed therapies.
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Chapter 7 : Appendix I – Supplementary Figures

Figure 7.1: Phylogeny of Escherichia strains. Maximum likelihood phylogeny of representative Escherichia

strains annotated by clade (inner track, branches) and by strain type (outer track).
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Experimental design and
sampling timelines for (A) functional metagenomic selections in germ-free mice, (B) functional
metagenomic selections in mice pre-colonized with a defined community, (C) genomic adaptation
experiments in mice fed different diets, (D) genomic adaptation experiments in mice with different gut
microbiota complexities, (E) longitudinal analysis of genomic adaptation in conventional, streptomycin
treated mice, (F) analysis of adaptations specific to gut sites, and (G) genomic adaptation experiments in
Pahenu2 mutant mice (PKU model) that were treated with EcN harboring either empty vector or the PAL2
gene. Mice were gavaged with EcN on day 0. N: number of replicate mice, n: total number of sequenced
isolates. Pink bars: sampling time point from which EcN isolates were harvested. Mice with a defined
community were pre-colonized 7 days before EcN Gavage. Related to Table 2.1.
Figure 7.2: Schematic of in vivo functional metagenomic selections and adaptation experiments.
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Figure 7.3: Assessment of in vivo plasmid loss. CFUs/mg of EcN recovered from mouse fecal samples over 5 weeks

when plated either on MacConkey agar (selects for all EcN) or LB agar with Kanamycin (selects for EcN
containing pZE21). Shaded regions represent 95% confidence intervals of LOESS regressions on the data.
10 mice from two different cages were sampled. Related to Figure 2.2.
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In vitro growth of EcN on minimal media
supplemented with the monosaccharides glucose or lactulose, or with various polysaccharides under
aerobic (A) and anaerobic (B) conditions. Shown are means of 3 replicates. Error bars are one standard
deviation above and below the mean. Related to Figure 2.2, Figure 2.3, and Figure 2.4.
Figure 7.4: Growth of wild-type EcN on mono- and polysaccharides.
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gDNA
from longitudinal fecal samples was analyzed by 16S rRNA sequencing. Mice were fed a Human Diet, and
in some arms were supplemented with prebiotic in the drinking water. One week after humanization with
the 13-member community, mice were gavaged with EcN containing either empty pZE21 vector ( - Library)
or the functional metagenomic library ( + Library). Related to Figure 2.4.
Figure 7.5: Relative taxonomic abundances from gnotobiotic mice humanized with a defined 13-member community.
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Figure 7.6: Estimation of in vivo mutation rate and comparison of functions mutated in EcN after passage through mice with a
range of gut microbiome complexities and fed different diets. A) Regression of SNP accumulation on number of

bacterial generations. New unique SNPs detected in EcN isolates from fecal samples collected weeks 2-5
after gavage from two streptomycin treated mice are plotted against number of generations, where the
in vivo generation time is assumed to be 100 minutes (Rang et al., 1999), and the number of SNPs at time
0 is assumed to be 0. 10 isolates per mouse per timepoint were whole-genome sequenced for SNP
detection. The shaded area represents the 95% confidence interval of a linear regression of new unique
SNPs/genome on generation. The estimated mutation rate of 0.007 (± 0.002) mutations per genome per
generation is on the same order of magnitude as the previously published rate of 0.001 new SNPs per
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genome per generation (Lee et al., 2012). B) Heatmap of the cumulative number of nonsynonymous SNPs
detected in genes grouped by their GO terms. Inclusion criteria for the heatmap was any function with at
least two cumulative mutations identified across isolates from at least two mice. Dendrograms represent
the clustering applied to group similar rows/columns of the heatmap. With 168 mutations, the GO
pathway for Cell Division was the most commonly-mutated, but it should be noted that this GO pathway
was almost entirely (165/168 mutations) composed of the ribosomal genes mutated during streptomycin
treatment. The next most abundant pathways were transcription (57 mutations), regulation of
transcription (23 genes), and gluconate transmembrane transport (22 mutations). Related to Figure 2.5.
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A) Diauxic growth curves of nagC
mutants on glucose and porcine gastric mucin minimal media. B) Growth curves of gntT mutants on
porcine gastric mucin minimal media supplemented with either 0.5, 1, 2, 4, or 8 mM gluconate. The gray
panel summarizes the growth via the areas under the curves (AUC) for each gluconate concentration. N =
3, * P < 0.05, Welch’s t-tests, Benjamini-Hochberg correction for multiple comparisons. Black stars indicate
that both Isolate 3 and Isolate 21 had a significantly greater AUC at a given gluconate concentration; red
– only Isolate 21. Areas under the curves were calculated using the growthcurver R package. Related to
Figure 2.6.
Figure 7.7: Growth of nagC and gntT mutants on mucin-containing minimal medias.
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Figure 7.8: Environmental context alters the EcN transcriptome. A) Principal

components analysis ordination of the
EcN transcriptome in the four different in vitro culture conditions (three biological replicates per
condition). B) Heatmap of hierarchically clustered transcriptomic data from the in vitro culturing
conditions. Rows correspond to significantly differentially expressed genes, and the regularized logarithm
of transcript counts for each gene is plotted. C) Average fraction of total transcriptomic reads mapping
to the native pMut1 and pMut2 plasmids, with shaded regions indicating the standard deviation across
three biological replicates per condition. Corresponding schematics of the annotated plasmid features are
below each read density plot. Related to Figure 3.2.
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Figure 7.9: Correlation between fluorescence values for the promoter library and previously-measured promoter activities. A)

Relationship between fluorescence levels in EcN (vertical axis) and reported promoter activities for the
synthetic promoter library in E. coli strain TG1. Error bars indicate the standard deviation observed among
three biological replicates. B) Relationship between fluorescence levels in EcN (vertical axis) and reported
promoter activities for native E. coli promoters in the human fecal metatranscriptome. To compute the
x-axis, the proportion of RNA-derived reads that were reported to map to each E. coli gene was divided
by the gene length. Vertical error bars indicate the standard deviation observed among three biological
replicates. Horizontal error bars indicate the standard deviation observed among fecal samples from 8
subjects. Related to Figure 3.2.
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A) Relationship between
GFP fluorescence values (vertical axis) and DNA/RNA ratio (horizontal axis). Vertical error bars indicate
the standard deviation in mean per-cell fluorescence values observed among 3 biological replicates.
Horizontal error bars indicate the standard deviation in DNA/RNA ratio observed among 3 independent
culture experiments. Data for the culture condition LB/Aerobic/Exponential Phase is plotted, as only this
condition had paired data. B) Relationship between gene expression values observed in transcriptomic
analysis (vertical axis) and RNA/DNA ratio observed via barcode sequencing (horizontal axis). Vertical
error bars indicate the standard deviation in gene expression levels (2^regularized logarithm) observed
among three biological replicates. Horizontal error bars indicate the standard deviation in DNA/RNA ratio
observed among 3 independent culture experiments. Data for all four LB culture conditions is plotted, as
these conditions had paired data. rlog – regularized logarithm of read counts from rlog transformation in
DESEQ2 package. Related to Figure 3.2.
Figure 7.10: Relationship between RNA/DNA ratio and protein levels or transcriptomic data.
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Quantile-quantile plot of the in vivo log2ratios against the
normal distribution (p = 0.33, Shapiro-Wilk normality test). Related to Figure 3.4 and Figure 3.5.
Figure 7.11: In vivo log2ratios are normally distributed.
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Heatmap indicating
significant differences in mean log2ratios in vitro when comparing different culture conditions (p < 0.05).
For each of the 30 cloned promoters, log2ratios were compared across each pair of culture conditions
using Student’s t-test. N = 3 biological replicates per condition. All p-values were Bonferroni corrected for
multiple comparisons. Related to Figure 3.3.
Figure 7.12: Pairwise comparisons of promoter activities between in vitro culture conditions.
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Figure 7.13: Pairwise comparisons between promoters in the gut. Heatmap indicating significant differences in mean

log2ratios in the gut. Log2ratios of each promoter was compared to every other promoter using Student’s
t-test in the (A) stomach, (B) small intestine, or (C) large intestine. N = 4 mice. All p-values were Bonferroni
corrected for multiple comparisons. Related to Figure 3.4.
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Figure 7.14: Coefficients and summary statistics of linear models for predicting in vivo promoter activities from in vitro
promoter activities. Model summaries for the stomach, small intestine, and large intestine, where the

predictor for each gut site was the in vitro condition in which promoter activities exhibited the highest
Pearson correlation to the activities in that gut site. Mouse ID was included as a random effect in all
models. These models were used to generate the predicted values presented in Figure 3.5a-c.
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Figure 7.15: Distributions of log2ratios and their standard deviations differ by gut site. Density plots of (A) the log2ratios

(ANOVA p < 0.05) and (B) the standard deviations of the log2ratios (ANOVA p < 0.001) in the large
intestine, small intestine, and stomach. Log2ratios of 30 promoters from 4 mice represented. Related to
Figure 3.4.
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A) Log10 fraction viable time course for
ile-2 gRNA expression plasmid in wild-type EcN with the Ptet-cas9 expression plasmid. B) Log10 CFUs for
the no gRNA control and six gRNA expression plasmids in EcN with four genome-integrated Ptet-cas9
expression cassettes. C and D) Ptet promoter library (C) design and (D) screening results for optimizing the
2-gRNA kill switch plasmid. D) Number of library variants that demonstrated insignificant killing in
response to 0 ng/mL aTc, complete killing in response 500 ng/mL aTc, both, or neither. One variant was
obtained that displayed insignificant uninduced killing and complete induced killing. E) aTc-inducible
killing transfer curve for the ile-2 single gRNA, initial 2-gRNA, and optimized 2-gRNA kill switches after 1.5
h of induction in LB. Points represent experimental data while lines represent the fitted curves. For all kill
switch assays, exponential phase cells for each strain were induced with the specified aTc concentrations
or 0 and 100 ng/mL aTc for 1.5 h or the specified amount of time. Values and error bars are the average
and standard deviation of biological triplicate, respectively. Related to Figure 4.1.
Figure 7.16: Characterization of single-gRNA and 2-gRNA kill switch strains.
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(A-F) System
schematics and log10 CFU values for the following kill switch strains: (A) initial 2-gRNA circuit, which has
four genome-integrated Ptet-cas9 expression cassettes (X4) and unoptimized groL-2 and ile-2 Ptet-gRNA
expression cassettes. (B) ABX-independent initial 2-gRNA circuit, which has four genome-integrated Ptetcas9 expression cassettes (X4), unoptimized groL-2 and ile-2 Ptet-gRNA expression cassettes, and an
unoptimized constitutive infA expression cassette to complement a genomic infA knockout. (C) ABXindependent infA optimized initial 2-gRNA circuit, which has four genome-integrated Ptet-cas9 expression
cassettes (X4), unoptimized groL-2 and ile-2 Ptet-gRNA expression cassettes, and an optimized constitutive
infA expression cassette to complement a genomic infA knockout. (D) ABX-independent single gRNA
Figure 7.17: Multi-method approach to developing an optimized antibiotic-independent CRISPRks.
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optimized initial 2-gRNA circuit, which has four genome-integrated Ptet-cas9 expression cassettes (X4),
unoptimized groL-2 and ile-2 Ptet-gRNA expression cassettes and an optimized rrs-2 Ptet-gRNA expression
cassette, and an unoptimized constitutive infA expression cassette to complement a genomic infA
knockout. (E) ABX-independent infA optimized, optimized 2-gRNA circuit, which has four genomeintegrated Ptet-cas9 expression cassettes (X4), unoptimized groL-2 and ile-2 Ptet-gRNA expression
cassettes, and an optimized constitutive infA expression cassette to complement a genomic infA
knockout. (F) ABX-independent gRNA optimized, optimized 2-gRNA circuit, which has four genomeintegrated Ptet-cas9 expression cassettes (X4), optimized groL-2, ile-2, and rrs-2 Ptet-gRNA expression
cassettes, and an unoptimized constitutive infA expression cassette to complement a genomic infA
knockout. Exponential phase cells for each strain were induced with 0 and 500 ng/mL aTc for 1.5 h (A and
B) or 5 h (C-F) in LB with and without spectinomycin. CFUs were determined by plating onto LB agar with
and without spectinomycin. Key differences between the circuits are in red. gRNA, tetR, and infA cassettes
are located on the same plasmid (connected lines), while cas9 is located exclusively in the genome. Values
and error bars are the average and standard deviation of biological triplicate, respectively. Related to
Figure 4.2.
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(A and B) Library schematic and screening
results for incorporating a rrs-2 gRNA expression cassette into the optimized antibiotic (ABX)-independent
2-gRNA kill switch. (B) Number of library variants that demonstrated insignificant killing in response to 0
ng/mL aTc, complete killing in response 500 ng/mL aTc, both, or neither. Two kill switches were obtained
that displayed insignificant uninduced killing and complete induced killing (Mut14 and Mut32). (C) Log10
CFU values for the Mut32 CRISPRks, which has four genome-integrated Ptet-cas9 expression cassettes,
optimized groL-2, ile-2, and rrs-2 Ptet-gRNA expression cassettes, and an optimized constitutive infA
expression cassette to complement a genomic infA knockout. Exponential phase cells for each strain were
induced with 0 and 500 ng/mL aTc in LB with and without spectinomycin. CFUs were determined by plating
onto LB agar with or without spectinomycin. (D) aTc-inducible killing transfer curves for the Mut14 and
Mut32 CRISPRks strains after 3 h of induction in LB without antibiotics. Points represent experimental
data while lines represent the fitted curves. (E) Long-term stability assessment of the Mut14 and Mut32
CRISPRks strains. Each day for 28 days, three replicates of each strain were diluted 250X into fresh LB
without antibiotics and grown for 24 h. Every 3-4 days, exponential phase cells were induced with 0 and
500 ng/mL aTc for 3 h and plated on LB agar without antibiotics for CFU quantification. (F) Percent of
Figure 7.18: Selecting a final optimized antibiotic-independent CRISPRks.
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Mut14 and Mut32 CRISPRks cells that survived aTc induction with non-functional kill switches. To assay
for kill switch functionality, exponential phase cells were induced with 0 and 500 ng/mL aTc for 3 h and
the absorbance at 600nm quantified. Induced to uninduced absorbance ratios within three standard
deviations of the no gRNA control strain were deemed non-functional. 24 colonies (8 from each replicate)
at selected timepoints from Figure S3E were tested for functionality. (G) Mut14 was selected for further
characterization due to its superior aTc response time, aTc sensitivity, and efficiency after long-term
growth. Fraction viable values of <-8 or <-9 had no colonies obtained from cultures receiving aTc. Values
and error bars are the average and standard deviation of biological triplicate, respectively. Statistical
comparisons were performed using mixed model ANOVA (**, P < 0.01). Related to Figure 4.2.
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Figure 7.19: Knocking out key components of the SOS response does not impact the log-term stability of the CRISPRks and
minimally affects the growth and aTc-response of no gRNA control strains. (A) Log10 Fraction Viable of the no gRNA

control strain with and without the Δrpdu knockouts when incubated in a 1:1 ratio mixture with the
CRISPRks or CRISPRks Δrpdu strains, respectively. Cells were cultured anaerobically at 37°C without
shaking in M9+0.4% glucose and induced with 0 or 500 ng/mL aTc. Values and error bars are the average
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and standard deviation of biological triplicates, respectively. (B) Log10 CFU values for the no gRNA control
( ̶ CRISPRks) and CRISPRks strain with and without knockouts (Δrpdu). Exponential phase cells for each
strain were induced with 0 and 500 ng/mL aTc for 3 h in LB without antibiotics. CFUs were determined by
plating onto LB agar without antibiotics. (C) Log10 Fraction Viable of CRISPRks Δrpdu when incubated with
the no gRNA control strain at different ratios. Cells were cultured anaerobically at 37°C without shaking
in M9+0.4% glucose and induced with 0 or 500 ng/mL aTc. Values and error bars are the average and
standard deviation of biological triplicates, respectively. (D) Long-term stability assessment of CRISPRks
and CRISPRks Δrpdu. Each day for 28 days, three replicates of each strain were diluted 250X into fresh LB
without antibiotics and grown for 24 h. Every 7 days, exponential phase cells were induced with 0 and 500
ng/mL aTc for 3 h and plated on LB agar without antibiotics for CFU quantification. Fraction viable values
of <-8 had no colonies obtained from cultures receiving aTc. (E) Percent of CRISPRks and CRISPRks Δrpdu
cells that survived aTc induction with non-functional kill switches. To assay for kill switch functionality,
exponential phase cells were induced with 0 and 500 ng/mL aTc for 3 h and the absorbance at 600nm
quantified. Induced to uninduced absorbance ratios within three standard deviations of the no gRNA
control strain were deemed non-functional. 24 colonies (8 from each replicate) of each strain at each
timepoint in Figure S4C were tested for functionality. (F) Sequencing results from 24 CRISPRks and 24
CRISPRks Δrpdu survivors (8 from each replicate) from Figure S4C with non-functional kill switches. The
fraction mutated is the fraction of total sequenced cassettes that contained a mutation. (G and H) Log10
CFUs/mg feces of the no gRNA control strain (G) without or (H) with the Δrpdu knockouts from mice
receiving control water or aTc treatment water. Points are the average of two technical replicates. Lines
and error bars are the average and standard error from 6 (G) or 4 (H) mice across two cages, respectively.
Statistical comparisons were performed using mixed model ANOVA (**, P < 0.01). Related to Figure 4.3.
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Figure 7.20: Optimization of the antibiotic knockdown and EcN gavage protocol as well as in vivo results for single gavage of
the no gRNA control and CRISPRks Δrpdu strains. (A) Schematic for testing different antibiotic knockdown and EcN

gavage protocols. 24 (B only), 48 (B only), and 72 h after antibiotic treatment, 108 CFUs of
chloramphenicol- or spectinomycin-resistant no gRNA control strains were gavaged into C57BL/6 mice.
Fecal samples were collected 24, 48, and 168 (B only) h after gavage for CFU quantification. (B-D) Log10
CFUs/mg feces of the chloramphenicol- and spectinomycin-resistant no gRNA control strains from mice
receiving (B) a streptomycin knockdown, (C) no antibiotics, or (D) a carbenicillin knockdown. (E and F)
Log10 CFUs/mg feces of the (E) no gRNA control or (F) CRISPRks Δrpdu strain from mice receiving each
strain alone and control water or aTc treatment water. Points are the average of two technical replicates.
Lines and error bars are the average and standard error from 4 mice across two cages, respectively.
Statistical comparisons were performed using mixed model ANOVA (F) or mixed model ANOVA with
Sidak's multiple comparisons (B) (*, P < 0.05; **, P < 0.01). Related to Figure 4.3.
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(A and B) Temperature
sensing schematics and transfer curves for the (A) wild-type TlpA and (B) modified TlpA* temperature
sensors. The TlpA/TlpA* temperature sensors and gfpmut3 are expressed in an operon from the PtlpA
promoter. At low temperatures, TlpA/TlpA* proteins form homodimers and repress transcription from
Figure 7.21: Development and selection of an optimized 2-input CRISPRks Δrpdu kill switch.
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the PtlpA promoter. TlpA was previously engineered to have a half-maximal expression at ~36°C in E. coli
NEB10β, resulting in TlpA*. EcN with the temperature sensing plasmids was grown at (A) 31.5, 32.7, 34.6,
37, 40.2, 42.7, 44.4, and 45.5°C or (B) 31, 31.5, 32.5, 33.6, 35.1, 36.2, 37, and 37.5°C for 24 h, and the
fluorescence was quantified by flow cytometry. Points represent experimental data while lines represent
the fitted curves. (C) Log10 Fraction Viable for the initial 2-input CRISPRks when incubated at different fold
dilutions. Exponential phase cells were diluted 25, 100, 1000, and 2500X into fresh LB without antibiotics
and incubated for 3 h at 30 and 37°C. Cultures were then plated on LB agar without antibiotics and
incubated overnight at 37°C for CFU quantification. (D) Log10 CFUs for the no gRNA control, initial 2-input
CRISPRks, and optimized 2-input CRISPRks. Exponential phase cells for each strain were induced with 0
and 500 ng/mL aTc at 37°C for 3 h. Cultures were then plated on LB agar without antibiotics and incubated
overnight at 37°C (both 0 and 500 n/mL aTc cultures) or for seven days at 30°C (0 ng/mL cultures) for CFU
quantification. The 2AA-81, 2AA-333, 3AA-208, 3AA-271, and 3AA-359 variants were selected for further
characterization. (E) Long-term stability of the five 2-input CRISPRks strain selected from Figure S6D. Each
day for 28 days, three replicates of each strain were diluted 250X into fresh LB without antibiotics and
grown for 24 h. Every 3-4 days, exponential phase cells were plated on LB agar without antibiotics and
incubated overnight at 37°C and for 7 days at 30°C for CFU quantification. Fraction viable values of <-7
had no colonies obtained from cultures receiving aTc. The 2AA-81, 3AA-271, and 3AA-359 variants were
selected for further characterization. (F) Cell death transfer curve with respect to temperature for the no
gRNA control and the three 2-input CRISPRks variants selected from Figure S6E. Exponential phase cells
were incubated in a thermocycler for 5 h at a range of temperatures: 30, 30.6, 31.6, 32.8, 34.4, 35.6, 36.4,
and 37°C. Points represent experimental data while lines represent the fitted curves. Control values were
not fit due to a lack of response. The 2AA-81 2-input CRISPRks variant was selected for further
characterization. Values and error bars are the average and standard deviation of biological triplicate,
respectively. Related to Figure 4.4.
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(A-C) Log10
CFUs/mg feces (A and B) or cecal contents (C) of no gRNA control (A and C) or 2-input CRISPRks (B and C)
cells from mice receiving the no gRNA control strain alone or the 2-input CRISPRks strain alone. CFUs were
quantified at 37°C (top) or RT (bottom). Points are the average of two technical replicates. Lines and error
bars are the average and standard error from 6 mice across two cages, respectively. (D) RT growth assays
for no gRNA control and 2-input CRISPRks cells obtained from fecal or cecal samples at different
timepoints in A-C. (E) CFUs of no gRNA control and 2-input CRISPRks cells from (D) following 24 h of RT
growth. Points are the average of two technical replicates. Values and error bars are the average and
Figure 7.22: Temperature and aTc response of the 2-input CRISPRks in the absence of intra-niche competition.
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standard error from 6 mice across two cages, respectively. Statistical comparisons were performed using
mixed model ANOVA with Sidak's multiple comparisons, (*, P < 0.05; **, P < 0.01; ***, P < 0.001, ****, P
< 0.0001). Related to Figure 4.5.
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Figure 7.23: The CRISPRks Δrpdu and 2-input CRISPRksΔ rpdu strains can express heterologous proteins from the genome and
on plasmids at levels equivalent to wild-type EcN. (A-C) Fluorescence of constitutively expressed GFP in wild-type,

control, CRISPRks Δrpdu, and 2-input CRISPRks Δrpdu EcN strains. GFP was expressed from (A and B) a
genome-integrated cassette, or (C) a medium-copy plasmid-based cassette and genome-integrated
cassette. Stationary phase cultures were diluted 100X into (A) M9+0.4% glucose (poor) or (B and C) LB
medium (rich) and incubated for 6 h before fluorescence quantification. Values and error bars are the
average and standard deviation of biological triplicate, respectively.
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Figure 7.24: Time elapsed between neuroimaging, biofluid, or neurocognitive assessments and stool sampling. PET: Positron

Emission Tomography. CSF: Cerebrospinal fluid. CDR: Clinical Dementia Rating. Related to Figure 5.1
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Figure 7.25: Gut microbiome characteristics of the study cohort. A-B) Phylogenetic trees of the (A) MetaPhlAn2 taxa

and (B) MAGs observed in the cohort. Shown are species with with mean relative abundance > 0.1% (A)
or MAGs with median(median genome coverage) > 0.1 (B). Filled circles at leaf tips enumerate the number
of healthy (green) or AD preclinical (orange) samples in which each taxon was observed. Node labels
indicate bootstrap values: > 95 (filled black circle), 50-95 (numeric), < 50 (no label). C) Stacked taxonomic
(MAGs) bar plots at the order level by AD preclinical status, with color grouping at the phylum level (inset
legend). D) Alpha diversities (richness, or number of unique observed features, and Shannon Diversity
Index) for MetaPhlAn2 taxa, HUMAnN 2.0 functional pathways, and MAGs. Alpha diversities were not
significantly different by AD preclinical status. Related to Figure 5.2.
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Figure 7.26: Fitting Dirichlet multinomial mixture models to taxonomic (MetaPhlAn2) profiles identifies two gut enterotypes in
the cohort. A) PCoA on unweighted UniFrac distances calculated from MetaPhlAn2 taxonomic profiles,

colored by enterotype. Global microbiome composition is significantly different between enterotypes (P
= 0.001, PERMANOVA). In addition, sample coordinates are significantly different along PCoA Axis 1 (P <
1E-10, Student’s t-test). Ellipses are 95% confidence bounds around group centroids. B) MetaPhlAn2 taxa
alpha diversities (richness, or number of unique observed features, and Shannon Diversity Index) are
significantly different between enterotypes (P < 0.001 [richness], P < 1E-5 [Shannon], Student’s t-tests).
C) Stacked taxonomic (MetaPhlAn2) bar plots at the genus level by enterotype, with color grouping at the
phylum level (inset legend). ***P < 0.001. Benjamini-Hochberg adjusted p-values are reported. Related to
Figure 5.3 and Figure 5.5.
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Figure 7.27: Abundances of taxa, pathways, and MAGs significantly associated with AD preclinical status according to negative
binomial regressions. Shown are the top 10 (A) MetaPhlAn2 taxa, (B) MAGs, and (C) HUMAnN 2.0 functional

pathways identified as significantly associated with AD preclinical status after fitting negative binomial
models to each data type. Top panels in A-C show the 5 features most associated with healthy status,
while the bottom panels in each show the 5 features most associated with AD preclinical status (by
magnitude of the coefficient). Related to Figure 5.4.
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Chapter 8 : Appendix II – Supplementary Tables
Table 8.1: Comparison of mouse diet nutrient compositions. Mouse Chow (Laboratory Rodent Diet 5001*, Lab Diet);

High-fat ‘Human’ Diet (TD.88137, Teklad). Related to Table 2.1.
High-fat (‘Human’) Diet

Mouse Chow
% By Weight

% kcal from

% By Weight

% kcal from

Protein

24.1

28.7

17.3

15.2

Fat

11.4

13.4

21.2

42

Carbohydrates

48.7

57.9

48.5

42.7

kcal/gm

2.89

4.50
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Mouse Chow (Laboratory Rodent Diet 5001*, Lab
Diet); High-fat ‘Human’ Diet (TD.88137, Teklad). Ingredients are listed in order of most to least abundant
by weight. Related to Table 2.1.
Table 8.2: Comparison of mouse diet formulaic compositions.

Mouse Chow

High-fat (‘Human’) Diet

Ground Corn

Sucrose

Dehulled Soybean Meal

Anhydrous Milk Fat

Dried Plain Beet Pulp

Casein

Fish Meal

Corn Starch

Ground Oats

Cellulose

Dehydrated Alfalfa Meal

Mineral Mix

Brewers Dried Yeast

Vitamin Mix

Cane Molasses

Calcium Carbonate

Wheat Germ

DL-Methionine

Dried Whey

Cholesterol

Porcine Animal Fat

Ethoxyquin

Porcine Meat and Bone Meal
Wheat Middlings
Salt
Calcium Carbonate
Vitamin Mix
Mineral Mix
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Table 8.3: Summary of in vivo adapted EcN isolates. Related to Figure 2.5.

Microbiome
None
None
None
None
None
13-member
Mouse+strep
Mouse+strep
Mouse+strep
Mouse+strep
Mouse+strep
Mouse+strep
Mouse+strep
Mouse+strep
Mouse+strep
Mouse+strep
Mouse+strep
Mouse
Mouse
PKU Mouse
PKU Mouse

pZE21 Plasmid Insert
Metagenomic
Metagenomic
Metagenomic
Metagenomic
No insert
No insert
No insert
No insert
No insert
No insert
No insert
No insert
No insert
No insert
No insert
No insert
No insert
No insert
No insert
No insert
PAL2

Diet
Human
Human
Human+Dextrin
Mouse
Human
Human+Dextrin
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human+Dextrin
Human
Human+Dextrin
Mouse
Mouse
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Organ
Cecum
Cecum
Cecum
Cecum
Feces
Feces
Prox. SI
Med. SI
Dist. SI
Cecum
Colon
Feces
Feces
Feces
Feces
Feces
Feces
Feces
Feces
Feces
Feces

#
#
Day Isolates Mice
35
20
2
35
20
2
35
20
2
21
20
2
35
20
2
35
20
2
35
2
2
35
22
3
35
25
3
35
20
2
35
30
3
5
5
1
12
20
2
19
20
2
26
20
2
33
20
2
35
20
2
35
20
2
35
20
2
35
17
2
35
20
2

Table 8.4: Taxonomic composition of the 13-member defined bacterial community.

Community from Goodman et al.,

2011. Related to Table 2.1.
Species

ATCC/DSMZ

Bacteroides caccae

ATCC 43185T

Parabacteroides distasonis

ATCC 8503

Bacteroides novel WH2

A. Salyers strain collection

Bacteroides ovatus

ATCC 8483T

Bacteroides uniformis

ATCC 8492

Bacteroides vulgatus

ATCC 8482

Clostridium scindens

ATCC 35704

Clostridium symbiosum

ATCC 14940

Dorea longicatena

DSM 13814

Eubacterium rectale

ATCC 33656

Ruminococcus obeum

ATCC 29174

Collinsella aerofaciens

ATCC 25986

Ruminococcus torques

ATCC 27756
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Related to Figure 2.5.
REGION_LENGTH SPECIFIC_KEYWORD
18.8Kb
transposase,terminase
45.5Kb
transposase,lysis,head,capsid,tail
59Kb
tail,head,portal,terminase,lysin,integrase
12.5Kb
integrase,capsid,head
38.8Kb
integrase,transposase,tail

Table 8.5: Putative phage regions in the EcN genome.
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REGION_POSITION
276890-295730
1325775-1371307
2011601-2070656
2535374-2547895
3318001-3356837

Table 8.6: Primers (Chapter 2). Related to Figure 2.2, Figure 2.3, Figure 2.4, and Figure 2.5.

Primer
#
1
2
3
4
5
6
7
8
9

Primer Name

Primer Sequence

pZE21_79_102For
pZE21_80_103For
pZE21_81_106For
pZE21_126_149rc
Rev
pZE21_128_150rc
Rev
pZE21_129_151rc
Rev
Barcode1
Barcode2
IlluminaPEAmpF

CCGAATTCATTAAAGAGGAGAAAG
CGAATTCATTAAAGAGGAGAAAGG
GAATTCATTAAAGAGGAGAAAGGTAC
GATATCAAGCTTATCGATACCGTC

10 IlluminaPEAmpR

CGATATCAAGCTTATCGATACCG
TCGATATCAAGCTTATCGATACC
/5Phos/ANNNNNNNGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNNNN*T
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCC
GATCT
CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAACCGCTC
TTCCGATCT
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The kanR mutations could have been accumulated during growth in selective
media prior to delivery. As all kanamycin was removed from the gavage bolus by 3 washes in PBS, no
antibiotic selection was present during growth in vivo. Further, these isolates were from mice never
treated with streptomycin, eliminating cross-resistance as a possible explanation. No inactivating
mutations in kanR were observed, potentially limited by the fact that kanamycin was used to recover EcN
from fecal and intestinal contents. Related to Figure 2.5.
Position Type of mutation
Mutation
# isolates # mice # cages
74
intergenic (in ori)
G→T
1
1
1
295
intergenic (between kanR and ori) G→T
1
1
1
313
intergenic (between kanR and ori) G→T
3
2
1
386
intergenic (between kanR and ori) G→T
1
1
1
480
intergenic (between kanR and ori) C→A
1
1
1
532
intragenic (in kanR)
P249P (CCC→CCA)
7
3
2
648
intragenic (in kanR)
R211R (CGG→AGG) 1
1
1
742
intragenic (in kanR)
P179P (CCC→CCA)
3
1
1
802
intragenic (in kanR)
D159E (GAC→GAA) 1
1
1
805
intragenic (in kanR)
L158L (CTG→CTT)
1
1
1
890
intragenic (in kanR)
T130N (ACC→AAC) 3
2
1
963
intragenic (in kanR)
H106N (CAC→AAC) 1
1
1
1,019
intragenic (in kanR)
A87E (GCG→GAG)
1
1
1
1,085
intragenic (in kanR)
A65V (GCG→GTG)
1
1
1
1,372
intergenic (upstream of promoter) G→T
1
1
1
1,440
intergenic (upstream of promoter) T→C
1
1
1
1,482
intergenic (upstream of promoter) G→T
1
1
1
1,558
intergenic (in promoter)
G→T
1
1
1
1,681
intergenic (in terminator)
G→T
1
1
1
1,717
intergenic (in terminator)
G→T
1
1
1
Table 8.7: Mutations in pZE21.
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Table 8.8: P-values of pairwise Student's t-test comparing mean expression (log2ratios) between gut sites for each promoter.

Bold values are comparisons that resulted in significant differences (p < 0.05) after Benjamini-Hochberg
adjustment for multiple comparisons. Related to Figure 3.4.
Comparison
Large Intestine
Large Intestine
Small Intestine
vs
vs
vs
Promoter
Small Intestine
Stomach
Stomach
p00
0.97
0.30
0.58
p01
0.07
0.59
0.06
p02
0.89
0.59
0.79
p03
0.03
0.79
0.39
p04
0.11
0.60
0.11
p05
0.22
0.65
0.79
p06
0.94
0.48
0.41
p07
0.71
0.94
0.79
p08
0.94
0.57
0.79
p09
0.02
0.86
0.15
p10
0.03
0.22
0.58
p11
0.15
0.59
0.11
p12
0.79
0.94
0.79
p14
0.06
0.94
0.04
p16
0.04
0.79
0.22
p17
0.14
0.94
0.48
p18
0.74
0.89
0.94
p19
0.03
0.86
0.04
phoE
0.07
0.79
0.27
plsC
0.04
0.94
0.35
polA
0.20
0.86
0.24
purC
0.06
0.58
0.58
rhtA
0.02
0.45
0.02
rnhA
0.11
0.94
0.51
yihA
0.79
0.89
0.79
acnA
0.74
0.79
0.60
glnA
0.04
0.79
0.79
grpE
0.46
0.46
0.74
lipA
0.23
0.48
0.94
mocA
0.11
0.79
0.30
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The Hill equation, described in the Methods, was fit to each set of
normalized fluorescence (au) values by minimizing the root mean square error (RMSE). Fmax and Fmin
represent the fitted maximum and minimum normalized fluorescence (au) values, CFUs/mL, or Fraction
Viable, respectively. The half-maximal constant (KA) is in mM of the respective ligand or oC. The fitted Hill
coefficient (n) and RMSE are also reported. FV, Fraction Viable. Related to Figure 4.2 and Figure 4.4.
Table 8.9: Fitted Hill equation parameters.

Figure

Strain

Plasmid

Fmax

Fmin

n

KA

RMSE

2D and S3D
4E and S6F
S1E
S1E
S1E
S3D
S6A
S6B
S6F
S6F

sAGR514
sAGR596
sAGR039
sAGR514
sAGR514
sAGR514
sAGR039
sAGR039
sAGR596
sAGR596

pAGR401
pAGR510
pAGR318
pAGR378
pAGR384
pAGR402
pAGR414
pAGR415
pAGR513
pAGR514

1 FV
108.86 CFUs/mL
107.79 CFUs/mL
107.19 CFUs/mL
108.31 CFUs/mL
1 FV
6.10 au
50.0 au
109.67 CFUs/mL
109.14 CFUs/mL

10-9.00 FV
102.91 CFUs/mL
103.07 CFUs/mL
0 CFUs/mL
0 CFUs/mL
10-8.81 FV
1.31 au
1.10 au
103.02 CFUs/mL
104.93 CFUs/mL

0.76
123
8.33
4.27
1.37
0.98
185
109
33.4
86.3

21.0 ng/mL
32.1°C
81.9 ng/mL
3.09 ng/mL
18.7 ng/mL
37.5 ng/mL
43.4°C
35.6°C
33.2°C
32.3°C

1.08
0.06
0.28
0.02
0.45
1.47
11.0
2.30
0.28
0.32
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Table 8.10: Model summaries for linear regressions of Centiloid and Axis2 from the PCoA ordination of MetaPhlAn2 taxonomic
abundances (PCOA2). Observations: 90. Dependent variable: Centiloid. Standard errors: Ordinary Least

Squares. Related to Figure 5.3b (top panel).
Estimate
2.50%
97.50%
t-value
2
2
Model 1 Fit: F(1, 88) = 6.79, p = 0.01, R = 0.07, Adj. R = 0.06
(Intercept)
20.04
13.74
26.35
6.32
PCOA2
70.55
16.73
124.37
2.61
2
2
Model 2 Fit: F(3, 86) = 33.28, p = 0.00, R = 0.54, Adj.R = 0.52
(Intercept)
1.21
-4.95
7.38
0.39
PCOA2
2
-50.67
54.67
0.08
ADstatus(preclinical)
39.33
30.28
48.39
8.64
PCOA2:ADstatus(preclinical)
120.58
43.27
197.89
3.1
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p-value
0
0.01
0.7
0.94
0
0

Table 8.11: Analysis of variance corresponding to models summarized in Table 8.10. Related to Figure 5.3b (top panel).

Model Ø: Centiloid ~ 1
Model 1: Centiloid ~ PCOA2

Residual
RSS
DF
DF
Null Model v. Model 1
89
85734
88
79596 1
Model 1 v. Model 2
88
79596
86
39677 2

Sum of
Squares

F

Pr(>F)

6138.1

6.7862

0.01078†

Model 1: Centiloid ~ PCOA2
Model 2: Centiloid ~
39919
43.262
PCOA2*ADstatus
†
Remains significant after Benjamini-Hochberg correction for multiple hypothesis testing.
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9.97E-14†

Table 8.12: Model summary for linear regression of CSF Aβ42/40 and Axis2 from the PCoA ordination of HUMAnN 2.0 functional
pathway abundances (Fun.PCOA2). Observations: 78. Dependent variable: CSF Aβ42/40. Standard errors:

Ordinary Least Squares. Related to Figure 5.3b (bottom panel).
Estimate
2.50%
97.50%
t-value
Model 3 Fit: F(1, 76) = 9.56, p = 0.00, R2 = 0.11, Adj. R2 = 0.10
(Intercept)
0.08
0.07
0.08
33.2
Fun.PCOA2
-0.12
-0.2
-0.04
-3.09
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p-value
0
0

Table 8.13: Analysis of variance corresponding to model summarized in Table 8.12. Related to Figure 5.3b (bottom

panel).
Residual
RSS
DF
DF
Null Model v. Model 3
77
0.034253
76
0.030426 1

Sum of
Squares

F

Pr(>F)

Model Ǿ: CSF Aβ42/40 ~ 1
Model 3: CSF Aβ42/40 ~
0.003826 9.5578 0.002783†
Fun.PCOA2
†
Remains significant after Benjamini-Hochberg correction for multiple hypothesis testing.
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